-
Posted: December 11th, 2023, 3:00am GMT
Conditions: Melanoma Brain Metastases
Interventions: Drug: Bevacizumab; Drug: Ipilimumab; Drug: Nivolumab; Radiation: Hypofractionated stereotactic radiotherapy
Sponsors: Melanoma and Skin Cancer Trials Limited
Not yet recruiting
-
Posted: December 8th, 2023, 3:00am GMT
Conditions: Small Cell Carcinoma of the Bladder; Small Cell Carcinoma of the Urinary Tract; Squamous Cell Carcinoma of the Bladder; Squamous Cell Carcinoma of the Urinary Tract; Primary Adenocarcinoma of the Bladder; Primary Adenocarcinoma of the Urinary Tract; Renal Medullary Carcinoma; Squamous Cell Carcinoma of the Penis
Interventions: Drug: Sacituzumab govitecan; Drug: Atezolizumab
Sponsors: National Cancer Institute (NCI)
Not yet recruiting
-
Posted: December 8th, 2023, 3:00am GMT
Conditions: Melanoma
Interventions: Drug: Nivolumab +/- ipilimumab; Drug: Nivolumab
Sponsors: Bristol-Myers Squibb
Completed
-
Posted: December 7th, 2023, 3:00am GMT
Conditions: Neuroendocrine Tumors
Interventions: Diagnostic Test: diagnostic accuracy
Sponsors: IRCCS San Raffaele
Recruiting
-
Posted: December 7th, 2023, 3:00am GMT
Conditions: Pancreas Adenocarcinoma; Small-cell Lung Cancer; Glioblastoma, IDH-wildtype
Interventions: Genetic: Long term survival multimodal analysis
Sponsors: Cure 51; Gustave Roussy, Cancer Campus, Grand Paris; Centre Leon Berard; Vall d'Hebron Institute of Oncology; Istituto Europeo di Oncologia; Charite University, Berlin, Germany
Recruiting
-
Posted: December 6th, 2023, 3:00am GMT
Conditions: Advanced Neuroendocrine Carcinoma
Interventions: Drug: LBL-024 for Injection; Drug: Etoposide Injection; Drug: Cisplatin for Injection; Drug: Carboplatin Injection
Sponsors: Nanjing Leads Biolabs Co.,Ltd
Recruiting
-
Posted: December 6th, 2023, 3:00am GMT
Conditions: Pancreatic Neuroendocrine Tumor
Interventions: Drug: Surufatinib; Drug: Placebo
Sponsors: Changhai Hospital
Not yet recruiting
-
Posted: December 5th, 2023, 3:00am GMT
Conditions: Neuroendocrine Tumors
Interventions: Drug: 68Ga-DOTA-MGS5
Sponsors: Medical University Innsbruck; Novartis
Completed
-
Posted: December 5th, 2023, 3:00am GMT
Conditions: Advanced Solid Tumors With Neuroendocrine Differentiation
Interventions: Drug: surufatinib、serplulimab
Sponsors: Shanghai Changzheng Hospital
Not yet recruiting
-
Posted: December 5th, 2023, 3:00am GMT
Conditions: Clinical Stage IIA Cutaneous Melanoma AJCC v8
Interventions: Drug: Atorvastatin; Drug: Placebo Administration; Procedure: Computed Tomography; Procedure: Magnetic Resonance Imaging; Other: Electronic Health Record Review
Sponsors: OHSU Knight Cancer Institute; Oregon Health and Science University; Kuni Foundation
Recruiting
-
Posted: December 4th, 2023, 3:00am GMT
Conditions: Melanoma
Sponsors: University Hospital, Grenoble; Etablissement Français du Sang
Recruiting
-
Posted: December 4th, 2023, 3:00am GMT
Conditions: Gastroenteropancreatic Neuroendocrine Tumor
Interventions: Diagnostic Test: 68Ga-DOTATOC PET as a part of their clinical diagnostic work-up will be included
Sponsors: IRCCS San Raffaele
Recruiting
-
Posted: December 4th, 2023, 3:00am GMT
Conditions: Paraganglioma
Interventions: Drug: Fluorescence guided identification using indocyanine green
Sponsors: Leiden University Medical Center
Recruiting
-
Posted: December 1st, 2023, 3:00am GMT
Conditions: Melanoma
Interventions: Drug: GME751; Drug: Keytruda - EU; Drug: Keytruda - US
Sponsors: Sandoz
Not yet recruiting
-
Posted: November 30th, 2023, 3:00am GMT
Conditions: Stage III Malignant Melanoma of Skin AJCC V6; Stage IV Malignant Melanoma of Skin
Interventions: Biological: TAPCells vaccine
Sponsors: University of Chile
Completed
-
Posted: November 30th, 2023, 3:00am GMT
Conditions: Clinical Stage IV Cutaneous Melanoma AJCC v8; Metastatic Melanoma; Pathologic Stage IIIC Cutaneous Melanoma AJCC v8; Unresectable Melanoma
Interventions: Procedure: Biospecimen Collection; Drug: Cyclophosphamide; Procedure: Echocardiography; Drug: Fludarabine; Biological: Interleukin-2; Biological: Lifileucel; Procedure: Magnetic Resonance Imaging; Procedure: Multigated Acquisition Scan; Procedure: Tumor Resection
Sponsors: University of Kansas Medical Center; National Cancer Institute (NCI); Iovance Biotherapeutics, Inc.
Recruiting
-
Posted: November 30th, 2023, 3:00am GMT
Conditions: Merkel Cell Carcinoma
Interventions: Drug: Nivolumab 240 mg / Relatlimab 80 mg in a fixed dose combination
Sponsors: Melanoma Institute Australia; Bristol-Myers Squibb
Recruiting
-
Posted: November 29th, 2023, 3:00am GMT
Conditions: Non Small Cell Lung Cancer; Triple Negative Breast Cancer; Hodgkin Lymphoma; Head and Neck Squamous Cell Carcinoma; Malignant Melanoma
Interventions: Drug: CTX-8371
Sponsors: Compass Therapeutics
Recruiting
-
Posted: November 28th, 2023, 3:00am GMT
Conditions: Neuroendocrine Tumors; Neuroendocrine Tumor of the Lung; Neuroendocrine Tumor Grade 1; Neuroendocrine Tumor Grade 2; Neuroendocrine Tumor of Pancreas
Interventions: Drug: [212Pb] VMT-α-NET; Diagnostic Test: [203Pb] VMT-α-NET SPECT/CT
Sponsors: David Bushnell; Holden Comprehensive Cancer Center; National Cancer Institute (NCI); Perspective Therapeutics
Recruiting
-
Posted: November 22nd, 2023, 3:00am GMT
Conditions: Rectal Neoplasms; Neuroendocrine Tumors
Interventions: Procedure: salvage treatment
Sponsors: Yanhong Deng
Completed
-
Posted: November 21st, 2023, 3:00am GMT
Conditions: Adrenal Cortical Carcinoma; Medullary Thyroid Cancer; Thymic Neuroendocrine Carcinoma; Pancreatic Neuroendocrine Tumor
Interventions: Biological: individualized mRNA neoantigen vaccine (mRNA-0523-L001)
Sponsors: Shanghai Jiao Tong University School of Medicine
Recruiting
-
Posted: November 15th, 2023, 3:00am GMT
Conditions: Neuroendocrine Neoplasms
Interventions: Drug: BI 764532; Drug: Carboplatin; Drug: Etoposide; Drug: Cisplatin
Sponsors: Boehringer Ingelheim
Recruiting
-
Posted: November 14th, 2023, 3:00am GMT
Conditions: Cardiac Sarcoidosis
Interventions: Diagnostic Test: 64Cu-DOTATATE PET/CT scan
Sponsors: Rigshospitalet, Denmark
Recruiting
-
Posted: November 8th, 2023, 3:00am GMT
Conditions: Pancreatic Neuroendocrine Tumor
Sponsors: IRCCS San Raffaele
Recruiting
-
Posted: November 1st, 2023, 2:00am GMT
Conditions: Advanced Melanoma
Interventions: Biological: IMC-F106C; Biological: Nivolumab; Biological: Nivolumab + Relatlimab
Sponsors: Immunocore Ltd
Recruiting
-
Posted: October 10th, 2023, 2:00am GMT
Conditions: Uveal Melanoma
Interventions: Behavioral: Education for Intervention; Behavioral: Best Practice
Sponsors: Jonsson Comprehensive Cancer Center
Recruiting
-
Posted: October 6th, 2023, 2:00am GMT
Conditions: Uveal Melanoma
Interventions: Drug: Tebentafusp
Sponsors: Diwakar Davar; Immunocore Ltd
Not yet recruiting
-
Posted: October 3rd, 2023, 2:00am GMT
Conditions: adrenalDisease
Interventions: Procedure: laparoscopic adrenalectomy
Sponsors: Zagazig University
Completed
-
Posted: September 26th, 2023, 2:00am GMT
Conditions: Neuroendocrine Tumors; Colorectal Cancer; Gastric Cancer
Interventions: Biological: CHM-2101 CAR-T cells
Sponsors: Chimeric Therapeutics
Not yet recruiting
-
Posted: September 21st, 2023, 2:00am GMT
Conditions: Metastatic Neuroendocrine Tumour
Sponsors: Hospices Civils de Lyon
Recruiting
-
Posted: September 8th, 2023, 2:00am GMT
Conditions: PD-1 Refractory Advanced Melanoma
Interventions: Biological: Responder-Derived Fecal microbiota transplantation (R-FMT; Drug: Pembrolizumab; Drug: Lenvatinib
Sponsors: Diwakar Davar; Merck Sharp & Dohme LLC; Gateway for Cancer Research
Not yet recruiting
-
Posted: September 1st, 2023, 2:00am GMT
Conditions: Triple Negative Breast Cancer; Diffuse Large B Cell Lymphoma; Follicular Lymphoma; Lymphoma, Non-Hodgkin; Mantle Cell Lymphoma; Bladder Cancer; Uveal Melanoma, Recurrent; Cervix Cancer; Carcinoma in Situ; Head and Neck Squamous Cell Carcinoma; Skin Cancer; Metastatic Cancer; Tumor, Solid; Tumor Recurrence
Interventions: Drug: ONM-501; Drug: Cemiplimab
Sponsors: OncoNano Medicine, Inc.
Recruiting
-
Posted: August 30th, 2023, 2:00am GMT
Conditions: Digestive System Neuroendocrine Tumor G1; Digestive System Neuroendocrine Tumor G2; Metastatic Digestive System Neuroendocrine Neoplasm; Metastatic Malignant Neoplasm in the Liver; Pancreatic Neuroendocrine Tumor G1; Pancreatic Neuroendocrine Tumor G2
Interventions: Procedure: Tumor Debulking; Drug: Lutetium Lu 177 Dotatate; Procedure: Computed Tomography; Procedure: Magnetic Resonance Imaging; Drug: Copper Cu 64 Dotatate; Procedure: Positron Emission Tomography
Sponsors: Vanderbilt-Ingram Cancer Center
Recruiting
-
Posted: August 28th, 2023, 2:00am GMT
Conditions: Squamous Cell Carcinoma of the Skin; Malignant Melanoma of Skin; Merkel Cell Carcinoma of Skin
Interventions: Drug: PH-762
Sponsors: Phio Pharmaceuticals Inc.
Recruiting
-
Posted: August 23rd, 2023, 2:00am GMT
Conditions: Choroidal Melanoma; Indeterminate Lesions; Uveal Melanoma; Ocular Melanoma
Interventions: Drug: Belzupacap Sarotalocan; Device: Suprachoroidal Microinjector; Device: Infrared Laser; Device: Sham Infrared Laser; Device: Sham Microinjector; Drug: Sham Treatment
Sponsors: Aura Biosciences
Recruiting
-
Posted: August 1st, 2023, 2:00am GMT
Conditions: Advanced Anal Carcinoma; Advanced Biliary Tract Carcinoma; Advanced Bladder Carcinoma; Advanced Breast Carcinoma; Advanced Carcinoid Tumor; Advanced Cervical Carcinoma; Advanced Colorectal Carcinoma; Advanced Gastric Carcinoma; Advanced Glioblastoma; Advanced Head and Neck Carcinoma; Advanced HER2 Positive Breast Carcinoma; Advanced Lung Carcinoma; Advanced Lung Small Cell Carcinoma; Advanced Malignant Germ Cell Tumor; Advanced Malignant Solid Neoplasm; Advanced Neuroendocrine Carcinoma; Advanced Ovarian Carcinoma; Advanced Pancreatic Carcinoma; Advanced Prostate Small Cell Neuroendocrine Carcinoma; Advanced Prostate Carcinoma; Hematopoietic and Lymphoid System Neoplasm; Multiple Myeloma; Myelodysplastic Syndrome
Interventions: Procedure: Clinical Encounter; Other: Home Health Encounter; Other: Quality-of-Life Assessment; Other: Questionnaire Administration
Sponsors: Mayo Clinic
Recruiting
-
Posted: August 1st, 2023, 2:00am GMT
Conditions: Cancer; Melanoma Stage III; Melanoma Stage IV; Cutaneous Melanoma; Osteosarcoma; Carcinoma, Squamous Cell; Carcinoma, Basal Cell
Interventions: Biological: KB707
Sponsors: Krystal Biotech, Inc.
Recruiting
-
Posted: July 20th, 2023, 2:00am GMT
Conditions: Metastatic Melanoma
Interventions: Drug: Enco+bini
Sponsors: Pfizer
Active, not recruiting
-
Posted: July 18th, 2023, 2:00am GMT
Conditions: Advanced Solid Tumors
Interventions: Drug: INCB099280; Drug: axitinib
Sponsors: Incyte Corporation
Recruiting
-
Posted: July 13th, 2023, 2:00am GMT
Conditions: Neoplasms; Prostatic Neoplasms, Castration-Resistant; Stomach Neoplasms; Esophageal Neoplasms; Head and Neck Neoplasms; Colorectal Neoplasms; Pancreatic Neoplasms; Lung Neoplasms; Urinary Bladder Neoplasms; Mesothelioma, Malignant; Uterine Cervical Neoplasms; Kidney Neoplasms; Sarcoma; Pheochromocytomas
Interventions: Drug: HTL0039732 Capsules; Drug: HTL0039732 Capsules and atezolizumab infusion
Sponsors: Cancer Research UK; Heptares Therapeutics Limited
Recruiting
-
Posted: June 26th, 2023, 2:00am GMT
Conditions: Lung Cancer
Interventions: Drug: Pioglitazone 45 mg; Drug: Placebo
Sponsors: Pennington Biomedical Research Center
Recruiting
-
Posted: June 22nd, 2023, 2:00am GMT
Conditions: Melanoma
Interventions: Drug: IO102/IO103; Drug: Nivolumab-Relatlimab
Sponsors: Memorial Sloan Kettering Cancer Center; IO Biotech
Recruiting
-
Posted: June 18th, 2023, 2:00am GMT
Conditions: Carcinoma; Cervix Carcinoma
Interventions: Drug: Karelizumab combined with etoposide and cisplatin
Sponsors: Fujian Cancer Hospital
Recruiting
-
Posted: June 9th, 2023, 2:00am GMT
Conditions: Clinical Stage III Cutaneous Melanoma AJCC v8; Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8; Clinical Stage IV Cutaneous Melanoma AJCC v8; Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8; Metastatic Basal Cell Carcinoma; Metastatic Carcinoma in the Skin; Metastatic Melanoma; Metastatic Merkel Cell Carcinoma; Metastatic Skin Squamous Cell Carcinoma; Unresectable Basal Cell Carcinoma; Unresectable Melanoma; Unresectable Merkel Cell Carcinoma; Unresectable Skin Squamous Cell Carcinoma
Interventions: Procedure: Biopsy; Procedure: Biospecimen Collection; Procedure: Computed Tomography; Biological: Ipilimumab; Procedure: Kidney Biopsy; Procedure: Magnetic Resonance Imaging; Biological: Nivolumab; Drug: Prednisone; Drug: Sirolimus
Sponsors: National Cancer Institute (NCI)
Recruiting
-
Posted: May 31st, 2023, 2:00am GMT
Conditions: Small Cell Lung Carcinoma; Neuroendocrine Neoplasms
Interventions: Drug: BI 764532, formulation 1; Drug: BI 764532, formulation 2
Sponsors: Boehringer Ingelheim
Recruiting
-
Posted: May 30th, 2023, 2:00am GMT
Conditions: Small Cell Lung Carcinoma (SCLC); Neuroendocrine Neoplasms
Interventions: Drug: BI 764532; Drug: Ezabenlimab
Sponsors: Boehringer Ingelheim
Recruiting
-
Posted: May 22nd, 2023, 2:00am GMT
Conditions: Melanoma
Interventions: Drug: OH2; Drug: Salvage chemotherapy or best supportive care
Sponsors: Binhui Biopharmaceutical Co., Ltd.
Recruiting
-
Posted: May 15th, 2023, 2:00am GMT
Conditions: Cutaneous Squamous Cell Carcinoma; SCC - Squamous Cell Carcinoma; Basal Cell Carcinoma; BCC; BCC - Basal Cell Carcinoma; Melanoma; Merkel Cell Carcinoma; Sebaceous Carcinoma; Extramammary Paget Disease; Kaposi Sarcoma; Head and Neck Squamous Cell Carcinoma; HNSCC; Adnexal Carcinoma; Angiosarcoma; Cutaneous Neoplasm; Advanced Cancer; Metastatic Cancer; Refractory Cancer; Solid Tumor
Interventions: Biological: MQ719; Drug: Pembrolizumab
Sponsors: Memorial Sloan Kettering Cancer Center
Recruiting
-
Posted: May 6th, 2023, 2:00am GMT
Conditions: Somatostatin Receptor-positive Neuroendocrine Tumor
Interventions: Other: LUTATHERA
Sponsors: Novartis Pharmaceuticals
Active, not recruiting
-
Posted: May 3rd, 2023, 2:00am GMT
Conditions: Melanoma
Interventions: Procedure: Excision of clinically detected lymph node metastasis before any systemic therapy; Procedure: Excision of clinically detected lymph node metastasis after neoadjuvant systemic therapy
Sponsors: Craig L Slingluff, Jr
Recruiting
-
Posted: May 1st, 2023, 2:00am GMT
Conditions: Invasive Ductal Breast Carcinoma; Invasive Ductal Breast Carcinoma Stage IV; Lobular Breast Carcinoma; Lobular Breast Carcinoma Stage IV; Non Small Cell Lung Cancer; NSCLC; Gastrointestinal Cancer; Gastrointestinal Squamous Cell Cancer; Gastrointestinal Adenocarcinoma; Pancreatic Cancer; Bladder Cancer; Renal Cell Carcinoma; Melanoma; Sarcoma; Metastatic Solid Tumor
Interventions: Radiation: Stereotactic body radiotherapy; Radiation: Lattice Radiation Therapy
Sponsors: Memorial Sloan Kettering Cancer Center; Varian Medical Systems
Recruiting
-
Posted: April 26th, 2023, 2:00am GMT
Conditions: Lung Non-Small Cell Carcinoma; Malignant Solid Neoplasm; Melanoma; Renal Cell Carcinoma
Interventions: Procedure: Biospecimen Collection; Procedure: Computed Tomography; Procedure: Positron Emission Tomography; Other: Questionnaire Administration; Radiation: Stereotactic Body Radiation Therapy
Sponsors: City of Hope Medical Center; National Cancer Institute (NCI)
Recruiting
-
Posted: March 31st, 2023, 2:00am GMT
Conditions: Hepatocarcinoma; Pancreatic Tumor
Interventions: Biological: Hepatocellular carcinoma; Biological: Pancreatic adenocarcinoma; Biological: Pancreatic neuroendocrine tumor
Sponsors: Assistance Publique - Hôpitaux de Paris
Recruiting
-
Posted: March 28th, 2023, 2:00am GMT
Conditions: Non-small Cell Lung Cancer; Histiocytic Neoplasm; Histiocytosis; Melanoma; Melanoma (Skin); BRAF Gene Mutation; BRAF V600E; BRAF V600 Mutation; BRAF Mutation-Related Tumors; BRAF; Metastatic Lung Non-Small Cell Carcinoma; Metastatic Melanoma; Metastatic Lung Cancer; Recurrent Melanoma; Recurrent Lung Cancer; Recurrent Lung Non-Small Cell Carcinoma; NSCLC; Solid Tumor; Solid Carcinoma; KRAS G12D; KRAS G12V; KRAS Mutation-Related Tumors; NRAS Gene Mutation; Thyroid Cancer; Thyroid Carcinoma; Colorectal Cancer; Colorectal Carcinoma; Recurrent Histiocytic and Dendritic Cell Neoplasm; Brain Metastases; Recurrent NSCLC; KRAS G13C
Interventions: Drug: BDTX-4933
Sponsors: Black Diamond Therapeutics, Inc.
Recruiting
-
Posted: March 27th, 2023, 2:00am GMT
Conditions: Vestibular Schwannoma
Sponsors: Maastricht Radiation Oncology; Maastricht University Medical Center
Recruiting
-
Posted: March 22nd, 2023, 2:00am GMT
Conditions: Metastatic Melanoma; Skin Cancer
Interventions: Drug: Ipilimumab; Drug: Nivolumab; Procedure: Cryoablation
Sponsors: Massachusetts General Hospital
Recruiting
-
Posted: March 17th, 2023, 2:00am GMT
Conditions: Metastatic Midgut Neuroendocrine Tumor; Metastatic Midgut Neuroendocrine Tumor G1; Metastatic Midgut Neuroendocrine Tumor G2; Unresectable Midgut Neuroendocrine Tumor
Interventions: Procedure: Biospecimen Collection; Procedure: Computed Tomography; Drug: Everolimus; Drug: Lutetium Lu 177 Dotatate; Other: Quality-of-Life Assessment; Other: Questionnaire Administration
Sponsors: National Cancer Institute (NCI)
Recruiting
-
Posted: March 6th, 2023, 3:00am GMT
Conditions: Melanoma; Malignant Melanoma
Interventions: Combination Product: T3011 + Cobimetinib
Sponsors: ImmVira Pharma Co. Ltd
Suspended
-
Posted: March 1st, 2023, 3:00am GMT
Conditions: Neuroendocrine Tumor
Interventions: Drug: Al18F-octreotide
Sponsors: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Recruiting
-
Posted: February 27th, 2023, 3:00am GMT
Conditions: Neuroendocrine Tumors; Well-Differentiated Neuroendocrine Carcinoma; High Grade Neuroendocrine Carcinoma, Any Site
Interventions: Drug: Lenvatinib; Drug: Pembrolizumab; Drug: Hyperpolarized 13C-Pyruvate
Sponsors: University of California, San Francisco; Merck Sharp & Dohme LLC
Recruiting
-
Posted: February 13th, 2023, 3:00am GMT
Conditions: Metastatic Neuroendocrine Tumor
Interventions: Procedure: Biospecimen Collection; Procedure: Computed Tomography; Drug: Lutetium Lu 177 Dotatate; Procedure: Magnetic Resonance Imaging; Drug: Triapine
Sponsors: National Cancer Institute (NCI)
Recruiting
-
Posted: February 8th, 2023, 3:00am GMT
Conditions: Clinical Stage IV Cutaneous Melanoma AJCC v8; Metastatic Malignant Neoplasm in the Lung; Metastatic Melanoma; Recurrent Melanoma; Unresectable Melanoma
Interventions: Biological: Aerosol Sargramostim; Procedure: Biospecimen Collection; Procedure: Computed Tomography; Procedure: Magnetic Resonance Imaging; Other: Medical Device Usage and Evaluation; Biological: Nivolumab
Sponsors: Mayo Clinic
Not yet recruiting
-
Posted: February 6th, 2023, 3:00am GMT
Conditions: Colorectal Neuroendocrine Carcinomas (CRNEC); Genomic Landscape; Genetic Landscape; Prognosis; CCL5; PAX5
Sponsors: Zhejiang University
Completed
-
Posted: January 30th, 2023, 3:00am GMT
Conditions: Melanoma (Skin)
Interventions: Drug: BMS-986213 (Relatlimab-Nivolumab FDC); Drug: Nivolumab; Drug: Relatlimab
Sponsors: M.D. Anderson Cancer Center
Active, not recruiting
-
Posted: January 27th, 2023, 3:00am GMT
Conditions: Advanced Solid Tumours
Interventions: Drug: EBC-129; Drug: Pembrolizumab
Sponsors: EDDC (Experimental Drug Development Centre), A*STAR Research Entities; Parexel
Recruiting
-
Posted: January 27th, 2023, 3:00am GMT
Conditions: Vestibular Schwannoma
Interventions: Procedure: Microsurgical resection of VS; Radiation: Stereotactic radiosurgery; Other: PREHAB
Sponsors: Medical College of Wisconsin
Recruiting
-
Posted: January 27th, 2023, 3:00am GMT
Conditions: Pheochromocytoma; Paraganglioma; Adrenalectomy; Status; Adrenergics Causing Adverse Effects in Therapeutic Use
Interventions: Drug: Phenoxybenzamine
Sponsors: Seoul National University Hospital
Recruiting
-
Posted: January 25th, 2023, 3:00am GMT
Conditions: Metastatic Melanoma; Advanced Melanoma
Interventions: Drug: XmAb22841; Drug: XmAb23104
Sponsors: University of California, San Francisco; Xencor, Inc.
Active, not recruiting
-
Posted: January 20th, 2023, 3:00am GMT
Conditions: Metastatic Prostate Adenocarcinoma With Neuroendocrine Differentiation; Metastatic Prostate Neuroendocrine Carcinoma; Metastatic Prostate Small Cell Neuroendocrine Carcinoma; Stage IV Prostate Cancer AJCC v8
Interventions: Procedure: Biospecimen Collection; Procedure: Computed Tomography; Radiation: Gallium Ga 68-DOTATATE; Drug: Lutetium Lu 177 Dotatate; Procedure: Positron Emission Tomography
Sponsors: National Cancer Institute (NCI)
Recruiting
-
Posted: January 18th, 2023, 3:00am GMT
Conditions: Metastatic Pancreatic Neuroendocrine Tumor; Pancreatic Neoplasm; Stage III Pancreatic Neuroendocrine Tumor AJCC v8; Stage IV Pancreatic Neuroendocrine Tumor AJCC v8; Unresectable Pancreatic Neuroendocrine Tumor
Interventions: Procedure: Biospecimen Collection; Procedure: Computed Tomography; Drug: Lutetium Lu 177 Dotatate; Procedure: Magnetic Resonance Imaging; Procedure: Positron Emission Tomography; Drug: Sunitinib Malate
Sponsors: National Cancer Institute (NCI)
Recruiting
-
Posted: January 17th, 2023, 3:00am GMT
Conditions: Neurofibromatosis 2
Interventions: Drug: Bevacizumab Zirconium Zr-89
Sponsors: Leiden University Medical Center
Recruiting
-
Posted: January 13th, 2023, 3:00am GMT
Conditions: Schwannomatosis; Schwannomas; Pain, Chronic
Interventions: Drug: Siltuximab; Drug: Erenumab-Aooe; Drug: Siltuximab Matching Placebo; Drug: Erenumab-Aooe Matching Placebo
Sponsors: Massachusetts General Hospital; United States Department of Defense; Recordati Rare Diseases
Recruiting
-
Posted: January 11th, 2023, 3:00am GMT
Conditions: Small Cell Lung Cancer Extensive Stage; Large Cell Neuroendocrine Carcinoma of the Lung
Interventions: Biological: LB2102
Sponsors: Legend Biotech USA Inc
Recruiting
-
Posted: December 30th, 2022, 3:00am GMT
Conditions: Solid Tumors; Melanoma; NSCLC; CRC; ATC
Interventions: Drug: CFT1946; Drug: Trametinib
Sponsors: C4 Therapeutics, Inc.
Recruiting
-
Posted: December 19th, 2022, 3:00am GMT
Conditions: Melanoma (Skin); Metastatic Melanoma; Melanoma Stage IV; Melanoma, Uveal; Mucosal Melanoma; Melanoma Stage III
Interventions: Drug: [203Pb]VMT01; Drug: [212Pb]VMT01; Drug: [212Pb]VMT01
Sponsors: Perspective Therapeutics
Recruiting
-
Posted: December 15th, 2022, 3:00am GMT
Conditions: Small Cell Lung Cancer (SCLC); Large Cell Neuroendocrine Cancer (LCNEC); Neuroendocrine Prostate Cancer (NEPC); Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)
Interventions: Drug: PT217
Sponsors: Phanes Therapeutics
Recruiting
-
Posted: December 7th, 2022, 3:00am GMT
Conditions: Metastatic Melanoma
Interventions: Biological: Lifileucel (LN-144)
Sponsors: Memorial Sloan Kettering Cancer Center; Iovance Biotherapeutics, Inc.
Active, not recruiting
-
Posted: December 5th, 2022, 3:00am GMT
Conditions: Neuroendocrine Tumors; Neuroendocrine Tumor of the Lung; Neuroendocrine Tumor of Pancreas; Neuroendocrine Carcinoma Metastatic; Neuroendocrine Tumor Carcinoid; Carcinoid Tumor of GI System; Carcinoid Tumor; Paraganglioma; Pheochromocytoma
Interventions: Drug: [212Pb]VMT-α-NET; Drug: [212Pb]VMT-α-NET
Sponsors: Perspective Therapeutics
Recruiting
-
Posted: November 29th, 2022, 3:00am GMT
Conditions: Metastatic Melanoma; Unresectable Melanoma; Acral Melanoma; Mucosal Melanoma; Cutaneous Melanoma; Ocular Melanoma; Uveal Melanoma; Iris Melanoma; Conjunctival Melanoma; Non-Cutaneous Melanoma
Interventions: Biological: TBio-4101; Drug: Cyclophosphamide; Drug: Fludarabine; Drug: Interleukin-2
Sponsors: H. Lee Moffitt Cancer Center and Research Institute; Turnstone Biologics, Corp.
Recruiting
-
Posted: November 17th, 2022, 3:00am GMT
Conditions: Small Cell Lung Cancer; Neuroendocrine Carcinoma
Interventions: Drug: RO7616789; Drug: Tocilizumab
Sponsors: Hoffmann-La Roche
Recruiting
-
Posted: November 17th, 2022, 3:00am GMT
Conditions: Melanoma
Interventions: Drug: Definity; Device: Sonalleve Focused Ultrasound Device
Sponsors: Sunnybrook Health Sciences Centre; Terry Fox Research Institute
Recruiting
-
Posted: November 9th, 2022, 3:00am GMT
Conditions: Pancreatic Neuroendocrine Tumor; Pancreas Cancer
Interventions: Procedure: cytoreductive surgery; Drug: Lutathera - a small molecule used in Peptide Receptor Radionuclide Therapy (PRRT); Procedure: Peptide receptor radionuclide therapy (PRRT)
Sponsors: University of Chicago
Recruiting
-
Posted: November 7th, 2022, 3:00am GMT
Conditions: Uveal Melanoma; Melanoma; Metastatic Uveal Melanoma; Metastatic Melanoma
Interventions: Biological: Lifileucel (LN-144)
Sponsors: Memorial Sloan Kettering Cancer Center; Iovance Biotherapeutics, Inc.
Recruiting
-
Posted: November 4th, 2022, 2:00am GMT
Conditions: Pancreatic Ductal Adenocarcinoma (PDAC); Squamous Cell Carcinoma of Head and Neck; Colorectal Cancer; Gastric Cancer; Ewing Sarcoma; NTSR1 Expressing Solid Tumours; Neuroendocrine Differentiated (NED) Prostate Cancer
Interventions: Drug: [225]-FPI-2059; Drug: [111In]-FPI-2058
Sponsors: Fusion Pharmaceuticals Inc.
Recruiting
-
Posted: October 31st, 2022, 2:00am GMT
Conditions: Advanced Solid Tumors
Interventions: Drug: ABBV-706; Drug: Cisplatin; Drug: Budigalimab; Drug: Carboplatin
Sponsors: AbbVie
Recruiting
-
Posted: October 28th, 2022, 2:00am GMT
Conditions: Leptomeningeal Metastasis; Non-small Cell Lung Cancer Stage IV; Melanoma Stage IV
Interventions: Drug: intrathecal nivolumab and intrathecal ipilimumab
Sponsors: University of Zurich
Recruiting
-
Posted: October 18th, 2022, 2:00am GMT
Conditions: Advanced Solid Tumor; Pancreatic Adenocarcinoma; Malignant Melanoma (Cutaneous); Non-small Cell Lung Cancer (NSCLC)
Interventions: Drug: IMM-1-104 Monotherapy (Treatment Group A); Drug: IMM-1-104 + modified Gemcitabine/nab-Paclitaxel (Treatment Group B); Drug: IMM-1-104 + modified FOLFIRINOX (Treatment Group C)
Sponsors: Immuneering Corporation
Recruiting
-
Posted: October 18th, 2022, 2:00am GMT
Conditions: Merkel Cell Carcinoma
Interventions: Drug: Pembrolizumab; Drug: Lutetium Lu 177 dotatate
Sponsors: Weill Medical College of Cornell University
Recruiting
-
Posted: October 13th, 2022, 2:00am GMT
Conditions: Melanoma (Skin); Cutaneous Melanoma; Adult Disease; Advanced Solid Tumor; Metastatic Melanoma
Interventions: Drug: ANV419; Drug: Pembrolizumab; Drug: Ipilimumab
Sponsors: Anaveon AG
Recruiting
-
Posted: October 13th, 2022, 2:00am GMT
Conditions: Acute Peripheral Vestibulopathy Following Surgical Procedure
Interventions: Procedure: Prehabituation; Procedure: 3D optokinetic stimulation in virtual reality space; Procedure: Vestibular training
Sponsors: Charles University, Czech Republic
Recruiting
-
Posted: October 12th, 2022, 2:00am GMT
Conditions: Breast Cancer; Colorectal Cancer; Uveal Melanoma; Cutaneous Melanoma; Non-Small Cell Lung Cancer; Head and Neck Squamous Cell Carcinoma
Interventions: Biological: TBio-4101; Drug: Pembrolizumab
Sponsors: Turnstone Biologics, Corp.
Recruiting
-
Posted: October 10th, 2022, 2:00am GMT
Conditions: Melanoma; Non-small Cell Lung Cancer; Colorectal Cancer
Interventions: Biological: LYL845
Sponsors: Lyell Immunopharma, Inc.
Recruiting
-
Posted: October 7th, 2022, 2:00am GMT
Conditions: Cutaneous Melanoma; Non-small Cell Lung Cancer; Colorectal Neoplasms; Pancreatic Neoplasms; Mesothelioma
Interventions: Drug: SGN-BB228
Sponsors: Seagen Inc.
Recruiting
-
Posted: September 27th, 2022, 2:00am GMT
Conditions: Intracranial Glioma; Metastatic Brain Tumor; Breast Cancer; Neuroendocrine Tumors; Rectal Cancer
Interventions: Drug: 1-(2-[18F]FLUOROETHYL)-L-Tryptophan
Sponsors: Barbara Ann Karmanos Cancer Institute; Washington University School of Medicine
Recruiting
-
Posted: September 22nd, 2022, 2:00am GMT
Conditions: Advanced Melanoma
Interventions: Drug: Tebentafusp; Drug: Tebentafusp with Pembrolizumab; Drug: Investigators Choice
Sponsors: Immunocore Ltd
Recruiting
-
Posted: September 22nd, 2022, 2:00am GMT
Conditions: Castration-Resistant Prostatic Cancer; Androgen-Independent Prostatic Cancer; Androgen-Insensitive Prostatic Cancer; Androgen-Resistant Prostatic Cancer; Hormone Refractory Prostatic Cancer; Anal Cancer; Anal Neoplasm; Carcinoma, Squamous Cell of Head and Neck; Head and Neck Squamous Cell Carcinoma; Laryngeal Squamous Cell Carcinoma; Oral Squamous Cell Carcinoma; Malignant Melanoma; Melanoma; Non-small Cell Lung Cancer; Non-small Cell Carcinoma; Small-cell Lung Cancer; Small Cell Carcinoma
Interventions: Biological: vobramitamab duocarmazine 2.0 mg (Arm A); Biological: vobramitamab duocarmazine 2.7 mg (Arm B); Biological: vobramitamab duocarmazine
Sponsors: MacroGenics
Active, not recruiting
-
Posted: September 21st, 2022, 2:00am GMT
Conditions: Sinonasal Melanoma
Interventions: Procedure: Surgical resection
Sponsors: M.D. Anderson Cancer Center
Recruiting
-
Posted: September 19th, 2022, 2:00am GMT
Conditions: NSCLC; SCLC; High Grade Neuroendocrine Cancer; DLBCL; L-MYC and N-MYC Amplified Solid Tumors; NSCLC With High or Low L-MYC or N-MYC Expression
Interventions: Drug: Oral MRT-2359; Drug: Oral MRT-2359; Drug: Oral MRT-2359; Drug: Oral MRT-2359
Sponsors: Monte Rosa Therapeutics, Inc
Recruiting
-
Posted: September 19th, 2022, 2:00am GMT
Conditions: Carcinoma, Non-Small-Cell Lung; Cutaneous Melanoma; Carcinoma, Renal Cell; Carcinoma, Ovarian Epithelial; Nasopharyngeal Carcinoma; Carcinoma, Thymic; Anal Cancer; Mesothelioma; Esophagogastric Cancer; High Microsatellite Instability Colorectal Carcinoma; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms
Interventions: Drug: KFA115; Drug: pembrolizumab
Sponsors: Novartis Pharmaceuticals
Recruiting
-
Posted: September 15th, 2022, 2:00am GMT
Conditions: Uveal Melanoma
Interventions: Drug: Tislelizumab; Drug: Sitravatinib Malate
Sponsors: Grupo Español Multidisciplinar de Melanoma; Mirati Therapeutics Inc.; BeiGene
Active, not recruiting
-
Posted: February 17th, 2020, 3:00am GMT
Conditions: Advanced Solid Tumors; MSI-H/dMMR Tumors; Cutaneous Squamous Cell Carcinoma; Urothelial Carcinoma, HCC; Cervical Cancer; Esophageal Squamous Cell Carcinoma; Merkel Cell Carcinoma; Small-cell Lung Cancer; Mesothelioma; PD-L1 Amplified Tumor (9p24.1); Nasopharyngeal Carcinoma; Cyclin-dependent Kinase 12 Mutated Tumors; Basal Cell Carcinoma (Unresectable or Metastatic); Sarcomatoid Renal Cell Carcinoma; Clear Cell Ovarian or Endometrial Carcinoma; Anal Carcinoma; Squamous Cell Penile Carcinoma; DNA Polymerase Epsilon Mutated Tumors (P286R and V411L)
Interventions: Drug: INCB099318
Sponsors: Incyte Corporation
Active, not recruiting
-
Posted: February 10th, 2020, 3:00am GMT
Conditions: Faecal Incontinence; Prostate Cancer
Interventions: Radiation: hypofractionated radiotherapy
Sponsors: Consorci Sanitari de Terrassa
Active, not recruiting
-
Posted: January 21st, 2020, 3:00am GMT
Conditions: Thyroid; Renal Cell Carcinoma; Non Small Cell Lung Cancer; Small-cell Lung Cancer; Bladder Cancer; Melanoma; Merkel Cell Carcinoma; Skin Squamous Cell Carcinoma; Microsatellite Instability High; Triple Negative Breast Cancer; Mesothelioma; Thymic Cancer; Cervical Cancer; Biliary Tract Cancer; Hepatocellular Carcinoma; Ovarian Cancer; Gastric Cancer; Head and Neck Squamous Cell Carcinoma; Anal Cancer
Interventions: Drug: SO-C101; Drug: pembrolizumab
Sponsors: SOTIO Biotech AG; SOTIO Biotech a.s.
Active, not recruiting
-
Posted: November 8th, 2019, 3:00am GMT
Conditions: Advanced Solid Tumors; NSCLC; Bladder Cancer; HNSCC; Renal Cancer; Melanoma; Anal Cancer; Colorectal Cancer; Cholangiocarcinoma; Gastric Cancer; Hepatocellular Carcinoma; Merkel Cell Carcinoma; Cervical Cancer
Interventions: Drug: Continue PD-1/PD-L1 Inhibitors treatment; Other: Discontinue PD-1/PD-L1-1 inhibitor
Sponsors: Jason J. Luke, MD
Recruiting
-
Posted: October 29th, 2019, 2:00am GMT
Conditions: HIV Infection
Interventions: Other: Cytology Specimen Collection Procedure; Other: Laboratory Biomarker Analysis; Procedure: Medical Examination; Procedure: Physical Examination; Procedure: Proctoscopy with Biopsy; Other: Questionnaire Administration
Sponsors: AIDS Malignancy Consortium; National Cancer Institute (NCI); Tata Memorial Hospital; Udaan Trust; University of Arkansas
Not yet recruiting
-
Posted: October 29th, 2019, 2:00am GMT
Conditions: HIV Infection; Human Papillomavirus Infection; Human Papillomavirus-Related Carcinoma
Interventions: Other: Cytology Specimen Collection Procedure; Procedure: High Resolution Anoscopy with Biopsy; Other: Laboratory Biomarker Analysis; Procedure: Medical Examination; Procedure: Physical Examination; Other: Questionnaire Administration
Sponsors: AIDS Malignancy Consortium; National Cancer Institute (NCI)
Not yet recruiting
-
Posted: September 19th, 2019, 2:00am GMT
Conditions: Anal Cancer
Interventions: Device: special tampon with a diameter of 28mm; Device: standard tampon with a diameter of 12-13mm
Sponsors: Juergen Debus
Recruiting
-
Posted: September 16th, 2019, 2:00am GMT
Conditions: Anal Cancer
Interventions: Behavioral: Practice Self-/Companion Exams; Behavioral: Control Arm
Sponsors: Medical College of Wisconsin; University of Chicago; M.D. Anderson Cancer Center; The University of Texas Health Science Center, Houston; Gordon Crofoot MD PA; National Cancer Institute (NCI)
Completed
-
Posted: September 3rd, 2019, 2:00am GMT
Conditions: Crohn's Disease; Complex Perianal Fistula
Interventions: Biological: Darvadstrocel
Sponsors: Takeda
Active, not recruiting
-
Posted: May 20th, 2019, 2:00am GMT
Conditions: Colorectal Cancer
Interventions: Other: Right time eating; Other: Delayed time eating; Procedure: Sigmoidoscopy; Procedure: Optional 24h circadian assessment in the Biological Rhythms lab; Other: Alcohol
Sponsors: Rush University Medical Center
Active, not recruiting
-
Posted: March 15th, 2019, 2:00am GMT
Conditions: Rectal Cancer; Advanced Cancer
Interventions: Drug: Chemotherapy; Drug: Radiochemotherapy
Sponsors: Assistance Publique - Hôpitaux de Paris
Recruiting
-
Posted: February 27th, 2019, 3:00am GMT
Conditions: Cervical Cancer; Anal Cancer; Penile Cancer
Interventions: Behavioral: HPV vaccination messages
Sponsors: University of Maryland, College Park; National Cancer Institute (NCI)
Completed
-
Posted: November 14th, 2018, 3:00am GMT
Conditions: HPV Positive Pelvic Cancer
Interventions: Procedure: Blood sampling
Sponsors: Institut Curie
Recruiting
-
Posted: October 19th, 2018, 2:00am GMT
Conditions: Cancer; Esophagus Squamous Cell Carcinoma; Squamous Cell Carcinoma of the Head and Neck; Anal Canal Squamous Cell Carcinoma; Metastatic Cancer
Sponsors: University Health Network, Toronto
Active, not recruiting
-
Posted: July 27th, 2018, 2:00am GMT
Conditions: Anal Intraepithelial Neoplasia; High Grade Squamous Intraepithelial Neoplasia; HIV Positivity; Human Papillomavirus-16 Positive; Human Papillomavirus-18 Positive
Interventions: Device: Electroporation; Biological: HPV DNA Plasmids Therapeutic Vaccine VGX-3100; Other: Laboratory Biomarker Analysis
Sponsors: AIDS Malignancy Consortium; National Cancer Institute (NCI); The Emmes Company, LLC; Inovio Pharmaceuticals
Active, not recruiting
-
Posted: July 2nd, 2018, 2:00am GMT
Conditions: Rectal Cancer
Interventions: Procedure: TME with LAR
Sponsors: Institut du Cancer de Montpellier - Val d'Aurelle; Intuitive Surgical
Active, not recruiting
-
Posted: May 8th, 2018, 2:00am GMT
Conditions: Anal Cancer
Interventions: Drug: MPDL3280A; Drug: mDCF
Sponsors: GERCOR - Multidisciplinary Oncology Cooperative Group; Roche Pharma AG
Active, not recruiting
-
Posted: April 5th, 2018, 2:00am GMT
Conditions: Anal Cancer
Interventions: Behavioral: Home-based human papillomavirus (HPV) DNA screening; Behavioral: Clinic-based human papillomavirus (HPV) DNA screening
Sponsors: Medical College of Wisconsin; National Cancer Institute (NCI); The University of Texas Health Science Center, Houston; M.D. Anderson Cancer Center
Completed
-
Posted: December 29th, 2017, 3:00am GMT
Conditions: Anal Cancer, Squamous Cell Carcinoma; Radiation Exposure
Interventions: Drug: BMX-001
Sponsors: University of Nebraska; BioMimetix JV, LLC
Recruiting
-
Posted: September 15th, 2017, 2:00am GMT
Conditions: AIDS-Related Human Papillomavirus Infection; High Grade Cervical Squamous Intraepithelial Neoplasia; HIV Infection
Interventions: Other: Laboratory Biomarker Analysis; Biological: Recombinant Human Papillomavirus Nonavalent Vaccine; Other: Saline
Sponsors: AIDS Malignancy Consortium; National Cancer Institute (NCI); University of Arkansas; AIDS and Cancer Specimen Resource; Merck Sharp & Dohme LLC; The Emmes Company, LLC; University of California, Los Angeles
Active, not recruiting
-
Posted: September 14th, 2017, 2:00am GMT
Conditions: Rectal Cancer
Interventions: Procedure: TaTME; Procedure: TME
Sponsors: Case Comprehensive Cancer Center
Recruiting
-
Posted: August 24th, 2017, 2:00am GMT
Conditions: HPV-Related Carcinoma; HPV-Related Cervical Carcinoma; HPV-Related Anal Squamous Cell Carcinoma; HPV-Related Penile Squamous Cell Carcinoma; HPV-Related Vulvar Squamous Cell Carcinoma
Interventions: Biological: TG4001; Drug: Avelumab
Sponsors: Transgene; Merck KGaA, Darmstadt, Germany; EMD Serono Research & Development Institute, Inc.; Pfizer
Active, not recruiting
-
Posted: July 11th, 2017, 2:00am GMT
Conditions: Head and Neck Squamous Cell Carcinoma; Lung Cancer; Oesophageal Cancer
Interventions: Drug: Durvalumab; Drug: Tremelimumab; Radiation: SBRT
Sponsors: Gustave Roussy, Cancer Campus, Grand Paris
Active, not recruiting
-
Posted: July 5th, 2017, 2:00am GMT
Conditions: Colorectal Cancer Screening
Interventions: Diagnostic Test: Water method group; Diagnostic Test: Air insufflation group
Sponsors: Chinese University of Hong Kong
Completed
-
Posted: February 23rd, 2017, 3:00am GMT
Conditions: Vulvar Cancer; Cervical Cancer; Vulvar Dysplasia; Cervical Dysplasia; Anal Cancer; Anal Dysplasia; HPV-Related Anal Squamous Cell Carcinoma
Interventions: Procedure: Screening anal Pap smear - No high-resolution anoscopy; Procedure: Screening anal Pap smear - High-resolution anoscopy
Sponsors: Dr. Danielle Vicus
Recruiting
-
Posted: February 13th, 2017, 3:00am GMT
Conditions: High Grade Anal Canal Intraepithelial Neoplasia; High Grade Vulvar Squamous Intraepithelial Lesion
Interventions: Other: Laboratory Biomarker Analysis; Other: Placebo Administration; Other: Questionnaire Administration; Biological: Recombinant Human Papillomavirus Nonavalent Vaccine
Sponsors: Fred Hutchinson Cancer Center; National Cancer Institute (NCI)
Terminated
-
Posted: January 16th, 2017, 3:00am GMT
Conditions: Pelvic Tumor
Interventions: Radiation: Repeat CT scan
Sponsors: University Medical Center Groningen
Completed
-
Posted: August 12th, 2016, 2:00am GMT
Conditions: Cancer of Head and Neck; Cancer of Cervix; Cancer of Anus
Interventions: Drug: DPX-E7 vaccine; Drug: Cyclophosphamide
Sponsors: Dana-Farber Cancer Institute; Stand Up To Cancer
Completed
-
Posted: August 8th, 2016, 2:00am GMT
Conditions: Papillomavirus Infections; Cervical Intraepithelial Neoplasia; Carcinoma In Situ; Vulvar Neoplasms; Vulvar Diseases
Interventions: Biological: E7 TCR cells; Drug: Aldesleukin; Drug: Fludarabine; Drug: Cyclophosphamide
Sponsors: National Cancer Institute (NCI)
Recruiting
-
Posted: December 11th, 2015, 3:00am GMT
Conditions: Advanced Cancer; Anal Carcinoma; Anal Cancer; Biliary Cancer; Cholangiocarcinoma; Bile Duct Cancer; Neuroendocrine Tumor; Carcinoid Tumor; Endometrial Carcinoma; Endometrial Cancer; Cervical Carcinoma; Cervical Cancer; Vulvar Carcinoma; Vulvar Cancer; Small Cell Lung Carcinoma; Small Cell Lung Cancer (SCLC); Mesothelioma; Thyroid Carcinoma; Thyroid Cancer; Salivary Gland Carcinoma; Salivary Gland Cancer; Salivary Cancer; Parotid Gland Cancer; Advanced Solid Tumors; Colorectal Carcinoma
Interventions: Biological: pembrolizumab; Biological: pembrolizumab
Sponsors: Merck Sharp & Dohme LLC
Recruiting
-
Posted: October 6th, 2015, 2:00am GMT
Conditions: Human Papillomavirus-Related Carcinoma
Interventions: Other: Laboratory Biomarker Analysis; Biological: Recombinant Human Papillomavirus Nonavalent Vaccine
Sponsors: National Cancer Institute (NCI)
Active, not recruiting
-
Posted: May 8th, 2015, 2:00am GMT
Conditions: Anal Squamous Cell Carcinoma; HIV Infection; Stage 0 Anal Canal Cancer; Stage I Anal Canal Cancer
Interventions: Procedure: Therapeutic Conventional Surgery
Sponsors: AIDS Malignancy Consortium; National Cancer Institute (NCI); The Emmes Company, LLC; AIDS and Cancer Specimen Resource; University of Arkansas
Active, not recruiting
-
Posted: April 6th, 2015, 2:00am GMT
Conditions: Advanced Malignant Solid Neoplasm; Anal Carcinoma; HIV Infection; Kaposi Sarcoma; Lung Carcinoma; Metastatic Malignant Solid Neoplasm; Recurrent Classic Hodgkin Lymphoma; Refractory Classic Hodgkin Lymphoma; Unresectable Solid Neoplasm
Interventions: Procedure: Biospecimen Collection; Procedure: Bone Marrow Biopsy; Procedure: Computed Tomography; Biological: Ipilimumab; Biological: Nivolumab; Procedure: Positron Emission Tomography
Sponsors: National Cancer Institute (NCI)
Recruiting
-
Posted: March 5th, 2015, 3:00am GMT
Conditions: Human Papillomavirus-Related Carcinoma; Human Papillomavirus Positive Oropharyngeal Carcinoma; Human Papillomavirus Positive Cervical Carcinoma; Human Papillomavirus Positive Anal Carcinoma; Human Papillomavirus Positive Vulvar Carcinoma; Human Papillomavirus Positive Penile Carcinoma
Interventions: Genetic: HPV Specific T Cells; Drug: Cytoxan; Drug: Fludarabine; Biological: Nivolumab
Sponsors: Baylor College of Medicine; Center for Cell and Gene Therapy, Baylor College of Medicine; The Methodist Hospital Research Institute
Active, not recruiting
-
Posted: March 4th, 2015, 3:00am GMT
Conditions: Squamous Carcinoma; Head and Neck Cancer; Anal Cancer; Lung Cancer; Esophageal Cancer; Cervix Cancer
Sponsors: Umeå University; Lund University
Completed
-
Posted: May 16th, 2014, 2:00am GMT
Conditions: Cervical Adenocarcinoma; Cervical Adenocarcinoma In Situ; Cervical Intraepithelial Neoplasia; Cervical Squamous Cell Carcinoma, Not Otherwise Specified; Cervical Squamous Intraepithelial Neoplasia; Early Invasive Cervical Adenocarcinoma; Early Invasive Cervical Squamous Cell Carcinoma; High Grade Cervical Squamous Intraepithelial Neoplasia; High Grade Vaginal Intraepithelial Neoplasia; Low Grade Vaginal Intraepithelial Neoplasia; Stage I Cervical Cancer AJCC v8; Stage I Vaginal Cancer AJCC v8; Stage I Vulvar Cancer AJCC v8; Stage IA Cervical Cancer AJCC v8; Stage IA Vaginal Cancer AJCC v8; Stage IA Vulvar Cancer AJCC v8; Stage IA1 Cervical Cancer AJCC v8; Stage IA2 Cervical Cancer AJCC v8; Stage IB Cervical Cancer AJCC v8; Stage IB Vaginal Cancer AJCC v8; Stage IB Vulvar Cancer AJCC v8; Stage IB1 Cervical Cancer AJCC v8; Stage IB2 Cervical Cancer AJCC v8; Stage II Cervical Cancer AJCC v8; Stage II Vaginal Cancer AJCC v8; Stage II Vulvar Cancer AJCC v8; Stage IIA Cervical Cancer AJCC v8; Stage IIA Vaginal Cancer AJCC v8; Stage IIA1 Cervical Cancer AJCC v8; Stage IIA2 Cervical Cancer AJCC v8; Stage IIB Cervical Cancer AJCC v8; Stage IIB Vaginal Cancer AJCC v8; Stage III Cervical Cancer AJCC v8; Stage III Vaginal Cancer AJCC v8; Stage III Vulvar Cancer AJCC v8; Stage IIIA Cervical Cancer AJCC v8; Stage IIIA Vulvar Cancer AJCC v8; Stage IIIB Cervical Cancer AJCC v8; Stage IIIB Vulvar Cancer AJCC v8; Stage IIIC Vulvar Cancer AJCC v8; Stage IV Cervical Cancer AJCC v8; Stage IV Vaginal Cancer AJCC v8; Stage IV Vulvar Cancer AJCC v8; Stage IVA Cervical Cancer AJCC v8; Stage IVA Vaginal Cancer AJCC v8; Stage IVA Vulvar Cancer AJCC v8; Stage IVB Cervical Cancer AJCC v8; Stage IVB Vaginal Cancer AJCC v8; Stage IVB Vulvar Cancer AJCC v8; Vaginal Adenocarcinoma; Vulvar Adenocarcinoma; Vulvar High Grade Squamous Intraepithelial Lesion; Vulvar Intraepithelial Neoplasia; Vulvar Squamous Cell Carcinoma; Vulvar Squamous Intraepithelial Lesion
Interventions: Procedure: Biospecimen Collection; Other: Laboratory Biomarker Analysis
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Active, not recruiting
-
Posted: May 12th, 2014, 2:00am GMT
Conditions: Anal Cancer; High-grade Squamous Intraepithelial Lesion; HIV Infection; Human Papilloma Virus Infection
Interventions: Drug: imiquimod; Drug: fluorouracil; Device: infrared photocoagulation therapy; Device: thermal ablation therapy; Device: laser therapy; Other: clinical observation; Other: laboratory biomarker analysis
Sponsors: AIDS Malignancy Consortium; National Cancer Institute (NCI); The Emmes Company, LLC; University of Arkansas; University of California, San Francisco; University of Arizona
Active, not recruiting
-
Posted: February 25th, 2014, 3:00am GMT
Conditions: Colorectal Cancer
Sponsors: Dutch Colorectal Cancer Group
Recruiting
-
Posted: February 11th, 2014, 3:00am GMT
Conditions: Anal Intraepithelial Neoplasia; High-grade Squamous Intraepithelial Lesion; HIV Infection
Interventions: Drug: imiquimod; Drug: fluorouracil; Other: questionnaire administration; Other: laboratory biomarker analysis
Sponsors: AIDS Malignancy Consortium; National Cancer Institute (NCI); The Emmes Company, LLC; University of Arkansas
Active, not recruiting
-
Posted: December 16th, 2013, 3:00am GMT
Conditions: Pancreatic Cancer; Thyroid Cancer; Lung Cancer; Esophageal Cancer; Thymus Cancer; Colon Cancer; Rectal Cancer; Gastrointestinal Stromal Tumors; Anal Cancer; Bile Duct Cancer; Duodenal Cancer; Gallbladder Cancer; Gastric Cancer; Liver Cancer; Small Intestine Cancer; Peritoneal Surface Malignancies; Familial Adenomatous Polyposis; Lynch Syndrome; Bladder Cancer; Kidney Cancer; Penile Cancer; Prostate Cancer; Testicular Cancer; Ureter Cancer; Urethral Cancer; Hypopharyngeal Cancer; Laryngeal Cancer; Lip Cancer; Oral Cavity Cancer; Nasopharyngeal Cancer; Oropharyngeal Cancer; Paranasal Sinus Cancer; Nasal Cavity Cancer; Salivary Gland Cancer; Skin Cancer; Central Nervous System Tumor; Central Nervous System Cancer; Mesothelioma; Breast Cancer; Leukemia; Melanoma; Sarcoma; Unknown Primary Tumor; Multiple Myeloma; Ovarian Cancer; Endometrial Cancer; Vaginal Cancer; Neuroendocrine Tumors; Plasma Cell Dyscrasia; Healthy Control
Sponsors: University of Nebraska
Recruiting
-
Posted: September 30th, 2013, 2:00am GMT
Conditions: High Grade Cervical Dysplasia; Cervical Cancer
Interventions: Procedure: Screening Anal Pap Smear - No High Resolution Anoscopy; Procedure: Screening Anal Pap Smear - With High Resolution Anoscopy
Sponsors: Sunnybrook Health Sciences Centre
Completed
-
Posted: September 10th, 2013, 2:00am GMT
Conditions: Anal Cancer
Sponsors: Oslo University Hospital
Active, not recruiting
-
Posted: February 15th, 2013, 3:00am GMT
Conditions: Rare Disorders; Undiagnosed Disorders; Disorders of Unknown Prevalence; Cornelia De Lange Syndrome; Prenatal Benign Hypophosphatasia; Perinatal Lethal Hypophosphatasia; Odontohypophosphatasia; Adult Hypophosphatasia; Childhood-onset Hypophosphatasia; Infantile Hypophosphatasia; Hypophosphatasia; Kabuki Syndrome; Bohring-Opitz Syndrome; Narcolepsy Without Cataplexy; Narcolepsy-cataplexy; Hypersomnolence Disorder; Idiopathic Hypersomnia Without Long Sleep Time; Idiopathic Hypersomnia With Long Sleep Time; Idiopathic Hypersomnia; Kleine-Levin Syndrome; Kawasaki Disease; Leiomyosarcoma; Leiomyosarcoma of the Corpus Uteri; Leiomyosarcoma of the Cervix Uteri; Leiomyosarcoma of Small Intestine; Acquired Myasthenia Gravis; Addison Disease; Hyperacusis (Hyperacousis); Juvenile Myasthenia Gravis; Transient Neonatal Myasthenia Gravis; Williams Syndrome; Lyme Disease; Myasthenia Gravis; Marinesco Sjogren Syndrome(Marinesco-Sjogren Syndrome); Isolated Klippel-Feil Syndrome; Frasier Syndrome; Denys-Drash Syndrome; Beckwith-Wiedemann Syndrome; Emanuel Syndrome; Isolated Aniridia; Axenfeld-Rieger Syndrome; Aniridia-intellectual Disability Syndrome; Aniridia - Renal Agenesis - Psychomotor Retardation; Aniridia - Ptosis - Intellectual Disability - Familial Obesity; Aniridia - Cerebellar Ataxia - Intellectual Disability; Aniridia - Absent Patella; Aniridia; Peters Anomaly - Cataract; Peters Anomaly; Potocki-Shaffer Syndrome; Silver-Russell Syndrome Due to Maternal Uniparental Disomy of Chromosome 11; Silver-Russell Syndrome Due to Imprinting Defect of 11p15; Silver-Russell Syndrome Due to 11p15 Microduplication; Syndromic Aniridia; WAGR Syndrome; Wolf-Hirschhorn Syndrome; 4p16.3 Microduplication Syndrome; 4p Deletion Syndrome, Non-Wolf-Hirschhorn Syndrome; Autosomal Recessive Stickler Syndrome; Stickler Syndrome Type 2; Stickler Syndrome Type 1; Stickler Syndrome; Mucolipidosis Type 4; X-linked Spinocerebellar Ataxia Type 4; X-linked Spinocerebellar Ataxia Type 3; X-linked Intellectual Disability - Ataxia - Apraxia; X-linked Progressive Cerebellar Ataxia; X-linked Non Progressive Cerebellar Ataxia; X-linked Cerebellar Ataxia; Vitamin B12 Deficiency Ataxia; Toxic Exposure Ataxia; Unclassified Autosomal Dominant Spinocerebellar Ataxia; Thyroid Antibody Ataxia; Sporadic Adult-onset Ataxia of Unknown Etiology; Spinocerebellar Ataxia With Oculomotor Anomaly; Spinocerebellar Ataxia With Epilepsy; Spinocerebellar Ataxia With Axonal Neuropathy Type 2; Spinocerebellar Ataxia Type 8; Spinocerebellar Ataxia Type 7; Spinocerebellar Ataxia Type 6; Spinocerebellar Ataxia Type 5; Spinocerebellar Ataxia Type 4; Spinocerebellar Ataxia Type 37; Spinocerebellar Ataxia Type 36; Spinocerebellar Ataxia Type 35; Spinocerebellar Ataxia Type 34; Spinocerebellar Ataxia Type 32; Spinocerebellar Ataxia Type 31; Spinocerebellar Ataxia Type 30; Spinocerebellar Ataxia Type 3; Spinocerebellar Ataxia Type 29; Spinocerebellar Ataxia Type 28; Spinocerebellar Ataxia Type 27; Spinocerebellar Ataxia Type 26; Spinocerebellar Ataxia Type 25; Spinocerebellar Ataxia Type 23; Spinocerebellar Ataxia Type 22; Spinocerebellar Ataxia Type 21; Spinocerebellar Ataxia Type 20; Spinocerebellar Ataxia Type 2; Spinocerebellar Ataxia Type 19/22; Spinocerebellar Ataxia Type 18; Spinocerebellar Ataxia Type 17; Spinocerebellar Ataxia Type 16; Spinocerebellar Ataxia Type 15/16; Spinocerebellar Ataxia Type 14; Spinocerebellar Ataxia Type 13; Spinocerebellar Ataxia Type 12; Spinocerebellar Ataxia Type 11; Spinocerebellar Ataxia Type 10; Spinocerebellar Ataxia Type 1 With Axonal Neuropathy; Spinocerebellar Ataxia Type 1; Spinocerebellar Ataxia - Unknown; Spinocerebellar Ataxia - Dysmorphism; Non Progressive Epilepsy and/or Ataxia With Myoclonus as a Major Feature; Spasticity-ataxia-gait Anomalies Syndrome; Spastic Ataxia With Congenital Miosis; Spastic Ataxia - Corneal Dystrophy; Spastic Ataxia; Rare Hereditary Ataxia; Rare Ataxia; Recessive Mitochondrial Ataxia Syndrome; Progressive Epilepsy and/or Ataxia With Myoclonus as a Major Feature; Posterior Column Ataxia - Retinitis Pigmentosa; Post-Stroke Ataxia; Post-Head Injury Ataxia; Post Vaccination Ataxia; Polyneuropathy - Hearing Loss - Ataxia - Retinitis Pigmentosa - Cataract; Muscular Atrophy - Ataxia - Retinitis Pigmentosa - Diabetes Mellitus; Non-hereditary Degenerative Ataxia; Paroxysmal Dystonic Choreathetosis With Episodic Ataxia and Spasticity; Olivopontocerebellar Atrophy - Deafness; NARP Syndrome; Myoclonus - Cerebellar Ataxia - Deafness; Multiple System Atrophy, Parkinsonian Type; Multiple System Atrophy, Cerebellar Type; Multiple System Atrophy; Maternally-inherited Leigh Syndrome; Machado-Joseph Disease Type 3; Machado-Joseph Disease Type 2; Machado-Joseph Disease Type 1; Leigh Syndrome; Late-onset Ataxia With Dementia; Infection or Post Infection Ataxia; GAD Ataxia; Hereditary Episodic Ataxia; Gliadin/Gluten Ataxia; Friedreich Ataxia; Fragile X-associated Tremor/Ataxia Syndrome; Familial Paroxysmal Ataxia; Exposure to Medications Ataxia; Episodic Ataxia With Slurred Speech; Episodic Ataxia Unknown Type; Episodic Ataxia Type 7; Episodic Ataxia Type 6; Episodic Ataxia Type 5; Episodic Ataxia Type 4; Episodic Ataxia Type 3; Episodic Ataxia Type 1; Epilepsy and/or Ataxia With Myoclonus as Major Feature; Early-onset Spastic Ataxia-neuropathy Syndrome; Early-onset Progressive Neurodegeneration - Blindness - Ataxia - Spasticity; Early-onset Cerebellar Ataxia With Retained Tendon Reflexes; Early-onset Ataxia With Dementia; Childhood-onset Autosomal Recessive Slowly Progressive Spinocerebellar Ataxia; Dilated Cardiomyopathy With Ataxia; Cataract - Ataxia - Deafness; Cerebellar Ataxia, Cayman Type; Cerebellar Ataxia With Peripheral Neuropathy; Cerebellar Ataxia - Hypogonadism; Cerebellar Ataxia - Ectodermal Dysplasia; Cerebellar Ataxia - Areflexia - Pes Cavus - Optic Atrophy - Sensorineural Hearing Loss; Brain Tumor Ataxia; Brachydactyly - Nystagmus - Cerebellar Ataxia; Benign Paroxysmal Tonic Upgaze of Childhood With Ataxia; Autosomal Recessive Syndromic Cerebellar Ataxia; Autosomal Recessive Spastic Ataxia With Leukoencephalopathy; Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay; Autosomal Recessive Spastic Ataxia - Optic Atrophy - Dysarthria; Autosomal Recessive Spastic Ataxia; Autosomal Recessive Metabolic Cerebellar Ataxia; Autosomal Dominant Spinocerebellar Ataxia Due to Repeat Expansions That do Not Encode Polyglutamine; Autosomal Recessive Ataxia, Beauce Type; Autosomal Recessive Ataxia Due to Ubiquinone Deficiency; Autosomal Recessive Ataxia Due to PEX10 Deficiency; Autosomal Recessive Degenerative and Progressive Cerebellar Ataxia; Autosomal Recessive Congenital Cerebellar Ataxia Due to MGLUR1 Deficiency; Autosomal Recessive Congenital Cerebellar Ataxia Due to GRID2 Deficiency; Autosomal Recessive Congenital Cerebellar Ataxia; Autosomal Recessive Cerebellar Ataxia-pyramidal Signs-nystagmus-oculomotor Apraxia Syndrome; Autosomal Recessive Cerebellar Ataxia-epilepsy-intellectual Disability Syndrome Due to WWOX Deficiency; Autosomal Recessive Cerebellar Ataxia-epilepsy-intellectual Disability Syndrome Due to TUD Deficiency; Autosomal Recessive Cerebellar Ataxia-epilepsy-intellectual Disability Syndrome Due to KIAA0226 Deficiency; Autosomal Recessive Cerebellar Ataxia-epilepsy-intellectual Disability Syndrome; Autosomal Recessive Cerebellar Ataxia With Late-onset Spasticity; Autosomal Recessive Cerebellar Ataxia Due to STUB1 Deficiency; Autosomal Recessive Cerebellar Ataxia Due to a DNA Repair Defect; Autosomal Recessive Cerebellar Ataxia - Saccadic Intrusion; Autosomal Recessive Cerebellar Ataxia - Psychomotor Retardation; Autosomal Recessive Cerebellar Ataxia - Blindness - Deafness; Autosomal Recessive Cerebellar Ataxia; Autosomal Dominant Spinocerebellar Ataxia Due to a Polyglutamine Anomaly; Autosomal Dominant Spinocerebellar Ataxia Due to a Point Mutation; Autosomal Dominant Spinocerebellar Ataxia Due to a Channelopathy; Autosomal Dominant Spastic Ataxia Type 1; Autosomal Dominant Spastic Ataxia; Autosomal Dominant Optic Atrophy; Ataxia-telangiectasia Variant; Ataxia-telangiectasia; Autosomal Dominant Cerebellar Ataxia, Deafness and Narcolepsy; Autosomal Dominant Cerebellar Ataxia Type 4; Autosomal Dominant Cerebellar Ataxia Type 3; Autosomal Dominant Cerebellar Ataxia Type 2; Autosomal Dominant Cerebellar Ataxia Type 1; Autosomal Dominant Cerebellar Ataxia; Ataxia-telangiectasia-like Disorder; Ataxia With Vitamin E Deficiency; Ataxia With Dementia; Ataxia - Oculomotor Apraxia Type 1; Ataxia - Other; Ataxia - Genetic Diagnosis - Unknown; Acquired Ataxia; Adult-onset Autosomal Recessive Cerebellar Ataxia; Alcohol Related Ataxia; Multiple Endocrine Neoplasia; Multiple Endocrine Neoplasia Type II; Multiple Endocrine Neoplasia Type 1; Multiple Endocrine Neoplasia Type 2; Multiple Endocrine Neoplasia, Type IV; Multiple Endocrine Neoplasia, Type 3; Multiple Endocrine Neoplasia (MEN) Syndrome; Multiple Endocrine Neoplasia Type 2B; Multiple Endocrine Neoplasia Type 2A; Atypical Hemolytic Uremic Syndrome; Atypical HUS; Wiedemann-Steiner Syndrome; Breast Implant-Associated Anaplastic Large Cell Lymphoma; Autoimmune/Inflammatory Syndrome Induced by Adjuvants (ASIA); Hemophagocytic Lymphohistiocytosis; Behcet's Disease; Alagille Syndrome; Inclusion Body Myopathy With Early-onset Paget Disease and Frontotemporal Dementia (IBMPFD); Lowe Syndrome; Pitt Hopkins Syndrome; 1p36 Deletion Syndrome; Jansen Type Metaphyseal Chondrodysplasia; Cockayne Syndrome; Chronic Recurrent Multifocal Osteomyelitis; CRMO; Malan Syndrome; Hereditary Sensory and Autonomic Neuropathy Type Ie; VCP Disease; Hypnic Jerking; Sleep Myoclonus; Mollaret Meningitis; Recurrent Viral Meningitis; CRB1; Leber Congenital Amaurosis; Retinitis Pigmentosa; Rare Retinal Disorder; KCNMA1-Channelopathy; Primary Biliary Cirrhosis; ZMYND11; Transient Global Amnesia; Glycogen Storage Disease; Alstrom Syndrome; White Sutton Syndrome; DNM1; EIEE31; Myhre Syndrome; Recurrent Respiratory Papillomatosis; Laryngeal Papillomatosis; Tracheal Papillomatosis; Refsum Disease; Nicolaides Baraitser Syndrome; Leukodystrophy; Tango2; Cauda Equina Syndrome; Rare Gastrointestinal Disorders; Achalasia-Addisonian Syndrome; Achalasia Cardia; Achalasia Icrocephaly Syndrome; Anal Fistula; Congenital Sucrase-Isomaltase Deficiency; Eosinophilic Gastroenteritis; Idiopathic Gastroparesis; Hirschsprung Disease; Rare Inflammatory Bowel Disease; Intestinal Pseudo-Obstruction; Scleroderma; Short Bowel Syndrome; Sacral Agenesis; Sacral Agenesis Syndrome; Caudal Regression; Scheuermann Disease; SMC1A Truncated Mutations (Causing Loss of Gene Function); Cystinosis; Juvenile Nephropathic Cystinosis; Nephropathic Cystinosis; Kennedy Disease; Spinal Bulbar Muscular Atrophy; Warburg Micro Syndrome; Mucolipidoses; Mitochondrial Diseases; Mitochondrial Aminoacyl-tRNA Synthetases; Mt-aaRS Disorders; Hypertrophic Olivary Degeneration; Non-Ketotic Hyperglycinemia; Fish Odor Syndrome; Halitosis; Isolated Congenital Asplenia; Lambert Eaton (LEMS); Biliary Atresia; STAG1 Gene Mutation; Coffin Lowry Syndrome; Borjeson-Forssman-Lehman Syndrome; Blau Syndrome; Arginase 1 Deficiency; HSPB8 Myopathy; Beta-Mannosidosis; TBX4 Syndrome; DHDDS Gene Mutations; MAND-MBD5-Associated Neurodevelopmental Disorder; Constitutional Mismatch Repair Deficiency (CMMRD); SPATA5 Disorder; SPATA5L1 Related Disorder
Sponsors: Sanford Health; National Ataxia Foundation; International WAGR Syndrome Association; 4p- Support Group; ML4 Foundation; Cornelia de Lange Syndrome Foundation; Stickler Involved People; Kawasaki Disease Foundation; Klippel-Feil Syndrome Alliance; Klippel-Feil Syndrome Freedom; Hyperacusis Research Limited; Hypersomnia Foundation; Kabuki Syndrome Network; Kleine-Levin Syndrome Foundation; Leiomyosarcoma Direct Research Foundation; Marinesco-Sjogren Syndrome Support Group - NORD; Mucolipidosis Type IV (ML4) Foundation; People with Narcolepsy 4 People with Narcolepsy (PWN4PWN); Soft Bones Incorporated; American Multiple Endocrine Neoplasia Support; Atypical Hemolytic Uremic Syndrome Foundation; All Things Kabuki; Wiedemann-Steiner Syndrome Foundation; Breast Implant Victim Advocates; PROS Foundation; American Behcet's Disease Association; Alstrom United Kingdom; Athymia; Curing Retinal Blindness Foundation; HSAN1E Society; 1p36 Deletion Support and Awareness; The Alagille Syndrome Alliance; Autoinflammatory Alliance; Beyond Batten Disease Foundation; Bohring-Opitz Syndrome Foundation, INC; Cockayne Syndrome Network (Share and Care); CRMO Foundation; Cure VCP Disease,INC; FOD Support; Cystinosis Research Foundation; Global DARE Foundation; Hypnic Jerk-Sleep Myoclonus Support Group; Jansen's Foundation; KCNMA1 Channelopathy International Advocacy Foundation; Kawasaki Disease Foundation Australia; Life with LEMS Foundation; Lowe Syndrome Association; The Malan Syndrome Foundation; Maple Syrup Urine Disease Family Support Group; International Association for Muscle Glycogen Storage Disease (IamGSD); Myhre Syndrome Foundation; DNM1 Families; Nicolaides Baraitser Syndrome (NCBRS) Worldwide Foundation; The PBCers Organization; Pitt Hopkins Research Foundation; Recurrent Meningitis Association; Recurrent Respiratory Papillomatosis Foundation; Remember the Girls; Smith-Kingsmore Syndrome Foundation; SPG Research Foundation; Team Telomere; Transient Global Amnesia Project; The Charlotte & Gwenyth Gray Foundation; The Cute Syndrome Foundation; The Maddi Foundation; White Sutton Syndrome Foundation; Zmynd11 Gene Disorder; Cauda Equina Foundation, Inc; Tango2 Research Foundation; Noah's Hope - Hope4Bridget Foundation; Project Sebastian; SMC1A Epilepsy Foundation; International Foundation for Gastrointestinal Disorders; Endosalpingiosis Foundation, Inc; International Sacral Agenesis/Caudal Regression Association (ISACRA); Scheuermann's Disease Fund; Batten Disease Support and Research Association; Kennedy's Disease Association; Cure Mito Foundation; Warburg Micro Research Foundation; Cure Mucolipidosis; Riaan Research Initiative; CureARS A NJ Nonprofit Corporation; CACNA1H Alliance; IMBS Alliance; SHINE-Syndrome Foundaion; Non- Ketotic Hyperglycinemia (NKH) Crusaders; Hypertrophic Olivary Degeneration Association (HODA); National Organization for Disorders of the Corpus Callosum (NODCC); Team4Travis; Taylor's Tale Foundation; Lambert Eaton (LEMS) Family Association; BARE Inc; STAG1 Gene Foundation; Coffin Lowry Syndrome Foundation; BLFS Incorporate; Aniridia North America; Cure Blau Syndrome Foundation; ARG1D Foundation; CURE HSPB8 Myopathy; International Society of Mannosidosis and Related Disorders; TBX4Life; Cure DHDDS; MANDKind Foundation; Krishnan Family Foundation; SPATA Foundation
Recruiting
-
Posted: May 8th, 2009, 2:00am GMT
Conditions: Quality of Life; Sexual Function; Urinary Incontinence; Anal Incontinence
Interventions: Behavioral: Structured Rehabilitation program
Sponsors: University Hospital of North Norway; Helse Nord
Withdrawn
-
Posted: November 23rd, 2000, 3:00am GMT
Conditions: HIV; Kaposi's Sarcoma; Lymphomas; Multicentric Castleman's Disease; Primary Effusion Lymphoma
Sponsors: National Cancer Institute (NCI)
Recruiting
-
Posted: December 12th, 2017, 3:00am GMT
Conditions: Metastatic Carcinoma in the Adrenal Cortex; Stage III Adrenal Cortex Carcinoma AJCC v8; Stage IV Adrenal Cortex Carcinoma AJCC v8; Unresectable Adrenal Cortex Carcinoma
Interventions: Drug: Cabozantinib; Other: Pharmacogenomic Study; Other: Pharmacokinetic Study
Sponsors: M.D. Anderson Cancer Center
Completed
-
Posted: December 8th, 2017, 3:00am GMT
Conditions: Sickle Cell Disease; Thalassemia; High Risk Hematologic Disorders; Cerebral Adrenoleukodystrophy; Inherited Metabolic Disorders
Interventions: Procedure: Blood and Marrow Transplant
Sponsors: Masonic Cancer Center, University of Minnesota
Terminated
-
Posted: November 7th, 2017, 3:00am GMT
Conditions: Genitourinary Cancer; Adrenocortical Carcinoma; Non-urothelial Bladder; Non-urothelial Upper Tract; Penile Cancer; Non-adenocarcinoma Prostate Cancer; Refractory Germ-cell; High Grade Neuroendocrine Carcinoma/Small Cell Carcinoma
Interventions: Drug: Ipilimumab; Drug: Nivolumab
Sponsors: Dana-Farber Cancer Institute; Bristol-Myers Squibb
Active, not recruiting
-
Posted: July 2nd, 2017, 2:00am GMT
Conditions: Pheochromocytoma; Paraganglioma; Neuroendocrine Tumors; Neuroendocrine Neoplasms
Interventions: Drug: Lu-177-DOTATATE; Drug: Ga-68-DOTATATE; Drug: F-18-FDG; Drug: Amino Acid solution
Sponsors: National Cancer Institute (NCI)
Recruiting
-
Posted: June 6th, 2017, 2:00am GMT
Conditions: Traumatic Brain Injury; Trauma, Nervous System; Reperfusion Injury; Ischemia, Brain
Interventions: Device: CellAegis Technologies autoRIC device; Other: Best Practice Management of Traumatic Brain Injury
Sponsors: Unity Health Toronto; Defence Research and Development Canada
Completed
-
Posted: January 9th, 2017, 3:00am GMT
Conditions: Previously Untreated Acute Myeloid Leukemia
Interventions: Biological: Samalizumab (BAML-16-001-S1); Biological: BI 836858 (BAML-16-001-S2); Other: Laboratory Biomarker Analysis; Drug: Daunorubicin (BAML-16-001-S1); Drug: Cytarabine (BAML-16-001-S1); Drug: Azacitidine (BAML-16-001-S2); Drug: AG-221 (BAML-16-001-S3); Drug: Azacitidine (BAML-16-001-S3); Drug: Entospletinib (BAML-16-001-S4); Drug: Azacitidine (BAML-16-001-S4); Drug: Entospletinib (BAML-16-001-S5); Drug: Decitabine (BAML-16-001-S5); Drug: Entospletinib (BAML-16-001-S6); Drug: Daunorubicin (BAML-16-001-S6); Drug: Cytarabine (BAML-16-001-S6); Drug: Pevonedistat (BAML-16-001-S9); Drug: Azacitidine (BAML-16-001-S9); Drug: AG-120 (BAML-16-001-S16); Drug: Azacitidine (BAML-16-001-S16); Drug: Gilteritinib (BAML-16-001-S8 Group 1); Drug: Decitabine (BAML-16-001-S8 Group 1); Drug: AZD5153 (BAML-16-001-S10); Drug: Venetoclax (BAML-16-001-S10); Drug: TP-0903 (BAML-16-001-S14); Drug: Decitabine (BAML-16-001-S14); Drug: Decitabine (BAML-16-001-S8 Group 2); Drug: Venetoclax (BAML-16-001-S8 Group 2); Drug: AZD5991 (BAML-16-001-S18); Drug: Azacitidine (BAML-16-001-S18); Drug: SNDX-5613 (BAML-16-001-S17); Drug: Azacitidine (BAML-16-001-S17); Drug: Venetoclax (BAML-16-001-S17); Drug: Gilteritinib (BAML-16-001-S8 Group 2); Drug: Venetoclax (BAML-16-001-S12 Arm A); Drug: Azacitidine (BAML-16-001-S12 Arm A); Drug: Venetoclax (BAML-16-001-S12 Arm B); Drug: Azacitidine (BAML-16-001-S12 Arm B)
Sponsors: Beat AML, LLC
Recruiting
-
Posted: January 2nd, 2017, 3:00am GMT
Conditions: Malignant Adrenal Gland Pheochromocytoma; Malignant Paraganglioma; Metastatic Adrenal Gland Pheochromocytoma
Interventions: Other: Laboratory Biomarker Analysis; Drug: Lenvatinib; Other: Quality-of-Life Assessment
Sponsors: Mayo Clinic; National Cancer Institute (NCI)
Completed
-
Posted: August 16th, 2016, 2:00am GMT
Conditions: Adrenal Cortical Carcinoma; Alveolar Soft Part Sarcoma; Central Nervous System Neoplasm; Childhood Clear Cell Sarcoma of Soft Tissue; Clear Cell Sarcoma of Soft Tissue; Ewing Sarcoma; Hepatoblastoma; Hepatocellular Carcinoma; Osteosarcoma; Recurrent Adrenal Cortical Carcinoma; Recurrent Alveolar Soft Part Sarcoma; Recurrent Clear Cell Sarcoma of Soft Tissue; Recurrent Ewing Sarcoma; Recurrent Hepatoblastoma; Recurrent Hepatocellular Carcinoma; Recurrent Kidney Wilms Tumor; Recurrent Malignant Solid Neoplasm; Recurrent Osteosarcoma; Recurrent Primary Malignant Central Nervous System Neoplasm; Recurrent Renal Cell Carcinoma; Recurrent Rhabdomyosarcoma; Recurrent Soft Tissue Sarcoma; Recurrent Thyroid Gland Medullary Carcinoma; Refractory Adrenal Cortical Carcinoma; Refractory Alveolar Soft Part Sarcoma; Refractory Clear Cell Sarcoma of Soft Tissue; Refractory Ewing Sarcoma; Refractory Hepatoblastoma; Refractory Hepatocellular Carcinoma; Refractory Malignant Solid Neoplasm; Refractory Osteosarcoma; Refractory Primary Central Nervous System Neoplasm; Refractory Primary Malignant Central Nervous System Neoplasm; Refractory Renal Cell Carcinoma; Refractory Rhabdomyosarcoma; Refractory Soft Tissue Sarcoma; Refractory Thyroid Gland Medullary Carcinoma; Refractory Wilms Tumor; Renal Cell Carcinoma; Rhabdomyosarcoma; Soft Tissue Sarcoma; Solid Neoplasm; Thyroid Gland Medullary Carcinoma; Wilms Tumor
Interventions: Drug: Cabozantinib; Drug: Cabozantinib S-malate; Other: Pharmacological Study
Sponsors: National Cancer Institute (NCI)
Active, not recruiting
-
Posted: July 15th, 2016, 2:00am GMT
Conditions: Acinar Cell Carcinoma; Adenoid Cystic Carcinoma; Adrenal Cortical Carcinoma; Adrenal Gland Pheochromocytoma; Anal Canal Neuroendocrine Carcinoma; Anal Canal Undifferentiated Carcinoma; Angiosarcoma; Apocrine Neoplasm; Appendix Mucinous Adenocarcinoma; Bartholin Gland Transitional Cell Carcinoma; Basal Cell Carcinoma; Bladder Adenocarcinoma; Breast Metaplastic Carcinoma; Cervical Adenocarcinoma; Cholangiocarcinoma; Chordoma; Colorectal Squamous Cell Carcinoma; Desmoid Fibromatosis; Endometrial Transitional Cell Carcinoma; Endometrioid Adenocarcinoma; Esophageal Neuroendocrine Carcinoma; Esophageal Undifferentiated Carcinoma; Extrahepatic Bile Duct Carcinoma; Extramammary Paget Disease; Fallopian Tube Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Fibromyxoid Tumor; Gallbladder Carcinoma; Gastric Neuroendocrine Carcinoma; Gastric Squamous Cell Carcinoma; Gastric Undifferentiated Carcinoma; Gastrointestinal Stromal Tumor; Gestational Trophoblastic Tumor; Giant Cell Carcinoma; Human Papillomavirus-Independent Cervical Adenocarcinoma, Clear Cell-Type; Intestinal Neuroendocrine Carcinoma; Intrahepatic Cholangiocarcinoma; Lung Neuroendocrine Tumor; Lung Sarcomatoid Carcinoma; Major Salivary Gland Carcinoma; Malignant Odontogenic Neoplasm; Malignant Peripheral Nerve Sheath Tumor; Malignant Solid Neoplasm; Malignant Testicular Sex Cord-Stromal Tumor; Metastatic Malignant Neoplasm of Unknown Primary; Metastatic Pituitary Neuroendocrine Tumor; Minimally Invasive Lung Adenocarcinoma; Mixed Mesodermal (Mullerian) Tumor; Mucinous Adenocarcinoma; Mucinous Cystadenocarcinoma; Nasal Cavity Adenocarcinoma; Nasal Cavity Carcinoma; Nasopharyngeal Carcinoma; Nasopharyngeal Low Grade Papillary Adenocarcinoma; Nasopharyngeal Undifferentiated Carcinoma; Oral Cavity Carcinoma; Oropharyngeal Undifferentiated Carcinoma; Ovarian Adenocarcinoma; Ovarian Germ Cell Tumor; Ovarian Mucinous Adenocarcinoma; Ovarian Squamous Cell Carcinoma; Ovarian Transitional Cell Carcinoma; Pancreatic Acinar Cell Carcinoma; Pancreatic Neuroendocrine Carcinoma; Paraganglioma; Paranasal Sinus Adenocarcinoma; Paranasal Sinus Carcinoma; Parathyroid Gland Carcinoma; PEComa; Penile Squamous Cell Carcinoma; Peritoneal Mesothelial Neoplasm; Placental Choriocarcinoma; Primary Peritoneal High Grade Serous Adenocarcinoma; Pseudomyxoma Peritonei; Rare Disorder; Scrotal Squamous Cell Carcinoma; Seminal Vesicle Adenocarcinoma; Seminoma; Serous Cystadenocarcinoma; Small Intestinal Adenocarcinoma; Small Intestinal Squamous Cell Carcinoma; Spindle Cell Neoplasm; Teratoma With Somatic-Type Malignancy; Testicular Non-Seminomatous Germ Cell Tumor; Thyroid Gland Carcinoma; Tracheal Carcinoma; Transitional Cell Carcinoma; Ureter Adenocarcinoma; Ureter Squamous Cell Carcinoma; Urethral Adenocarcinoma; Urethral Squamous Cell Carcinoma; Vaginal Adenocarcinoma; Vaginal Squamous Cell Carcinoma, Not Otherwise Specified; Vulvar Carcinoma
Interventions: Procedure: Biospecimen Collection; Procedure: Computed Tomography; Procedure: Echocardiography; Biological: Ipilimumab; Procedure: Magnetic Resonance Imaging; Biological: Nivolumab
Sponsors: National Cancer Institute (NCI)
Active, not recruiting
-
Posted: March 3rd, 2016, 3:00am GMT
Conditions: Cerebral Adrenoleukodystrophy (CALD); Adrenoleukodystrophy (ALD); X-Linked Adrenoleukodystrophy (X-ALD)
Interventions: Genetic: Lenti-D Drug Product
Sponsors: bluebird bio
Active, not recruiting
-
Posted: February 3rd, 2016, 3:00am GMT
Conditions: Adrenocortical Carcinoma
Interventions: Drug: Pembrolizumab
Sponsors: Memorial Sloan Kettering Cancer Center; Merck Sharp & Dohme LLC
Active, not recruiting
-
Posted: October 30th, 2015, 2:00am GMT
Conditions: Differentiated Thyroid Gland Carcinoma; Malignant Adrenal Gland Pheochromocytoma; Malignant Paraganglioma; Thyroid Gland Medullary Carcinoma
Interventions: Procedure: Computed Tomography; Procedure: Dual X-ray Absorptiometry; Procedure: Physical Examination; Other: Quality-of-Life Assessment; Other: Questionnaire Administration; Drug: Cabozantinib; Drug: Lenvatinib
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Completed
-
Posted: November 27th, 2014, 3:00am GMT
Conditions: Locally Advanced Paraganglioma; Metastatic Adrenal Gland Pheochromocytoma; Metastatic Paraganglioma; Regional Adrenal Gland Pheochromocytoma; Unresectable Adrenal Gland Pheochromocytoma; Unresectable Paraganglioma
Interventions: Drug: Cabozantinib S-malate; Other: Laboratory Biomarker Analysis; Other: Questionnaire Administration
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Active, not recruiting
-
Posted: December 24th, 2013, 3:00am GMT
Conditions: ACTH; Cushing's Syndrome
Interventions: Radiation: DOTATATE PET-CT; Radiation: F-DOPA PET CT; Radiation: CT scan; Diagnostic Test: Routine MRI scan; Diagnostic Test: Gated MRI scan; Drug: 68Ga-DOTATATE; Drug: 18F-DOPA
Sponsors: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting
-
Posted: June 17th, 2013, 2:00am GMT
Conditions: Medulloblastoma
Interventions: Radiation: Craniospinal Irradiation with boost to the primary tumor site; Drug: Cyclophosphamide; Drug: Cisplatin; Drug: Vincristine; Drug: Vismodegib; Drug: Pemetrexed; Drug: Gemcitabine; Other: Aerobic Training; Other: Neurocognitive Remediation
Sponsors: St. Jude Children's Research Hospital; Genentech, Inc.; National Cancer Institute (NCI)
Active, not recruiting
-
Posted: February 15th, 2013, 3:00am GMT
Conditions: Rare Disorders; Undiagnosed Disorders; Disorders of Unknown Prevalence; Cornelia De Lange Syndrome; Prenatal Benign Hypophosphatasia; Perinatal Lethal Hypophosphatasia; Odontohypophosphatasia; Adult Hypophosphatasia; Childhood-onset Hypophosphatasia; Infantile Hypophosphatasia; Hypophosphatasia; Kabuki Syndrome; Bohring-Opitz Syndrome; Narcolepsy Without Cataplexy; Narcolepsy-cataplexy; Hypersomnolence Disorder; Idiopathic Hypersomnia Without Long Sleep Time; Idiopathic Hypersomnia With Long Sleep Time; Idiopathic Hypersomnia; Kleine-Levin Syndrome; Kawasaki Disease; Leiomyosarcoma; Leiomyosarcoma of the Corpus Uteri; Leiomyosarcoma of the Cervix Uteri; Leiomyosarcoma of Small Intestine; Acquired Myasthenia Gravis; Addison Disease; Hyperacusis (Hyperacousis); Juvenile Myasthenia Gravis; Transient Neonatal Myasthenia Gravis; Williams Syndrome; Lyme Disease; Myasthenia Gravis; Marinesco Sjogren Syndrome(Marinesco-Sjogren Syndrome); Isolated Klippel-Feil Syndrome; Frasier Syndrome; Denys-Drash Syndrome; Beckwith-Wiedemann Syndrome; Emanuel Syndrome; Isolated Aniridia; Axenfeld-Rieger Syndrome; Aniridia-intellectual Disability Syndrome; Aniridia - Renal Agenesis - Psychomotor Retardation; Aniridia - Ptosis - Intellectual Disability - Familial Obesity; Aniridia - Cerebellar Ataxia - Intellectual Disability; Aniridia - Absent Patella; Aniridia; Peters Anomaly - Cataract; Peters Anomaly; Potocki-Shaffer Syndrome; Silver-Russell Syndrome Due to Maternal Uniparental Disomy of Chromosome 11; Silver-Russell Syndrome Due to Imprinting Defect of 11p15; Silver-Russell Syndrome Due to 11p15 Microduplication; Syndromic Aniridia; WAGR Syndrome; Wolf-Hirschhorn Syndrome; 4p16.3 Microduplication Syndrome; 4p Deletion Syndrome, Non-Wolf-Hirschhorn Syndrome; Autosomal Recessive Stickler Syndrome; Stickler Syndrome Type 2; Stickler Syndrome Type 1; Stickler Syndrome; Mucolipidosis Type 4; X-linked Spinocerebellar Ataxia Type 4; X-linked Spinocerebellar Ataxia Type 3; X-linked Intellectual Disability - Ataxia - Apraxia; X-linked Progressive Cerebellar Ataxia; X-linked Non Progressive Cerebellar Ataxia; X-linked Cerebellar Ataxia; Vitamin B12 Deficiency Ataxia; Toxic Exposure Ataxia; Unclassified Autosomal Dominant Spinocerebellar Ataxia; Thyroid Antibody Ataxia; Sporadic Adult-onset Ataxia of Unknown Etiology; Spinocerebellar Ataxia With Oculomotor Anomaly; Spinocerebellar Ataxia With Epilepsy; Spinocerebellar Ataxia With Axonal Neuropathy Type 2; Spinocerebellar Ataxia Type 8; Spinocerebellar Ataxia Type 7; Spinocerebellar Ataxia Type 6; Spinocerebellar Ataxia Type 5; Spinocerebellar Ataxia Type 4; Spinocerebellar Ataxia Type 37; Spinocerebellar Ataxia Type 36; Spinocerebellar Ataxia Type 35; Spinocerebellar Ataxia Type 34; Spinocerebellar Ataxia Type 32; Spinocerebellar Ataxia Type 31; Spinocerebellar Ataxia Type 30; Spinocerebellar Ataxia Type 3; Spinocerebellar Ataxia Type 29; Spinocerebellar Ataxia Type 28; Spinocerebellar Ataxia Type 27; Spinocerebellar Ataxia Type 26; Spinocerebellar Ataxia Type 25; Spinocerebellar Ataxia Type 23; Spinocerebellar Ataxia Type 22; Spinocerebellar Ataxia Type 21; Spinocerebellar Ataxia Type 20; Spinocerebellar Ataxia Type 2; Spinocerebellar Ataxia Type 19/22; Spinocerebellar Ataxia Type 18; Spinocerebellar Ataxia Type 17; Spinocerebellar Ataxia Type 16; Spinocerebellar Ataxia Type 15/16; Spinocerebellar Ataxia Type 14; Spinocerebellar Ataxia Type 13; Spinocerebellar Ataxia Type 12; Spinocerebellar Ataxia Type 11; Spinocerebellar Ataxia Type 10; Spinocerebellar Ataxia Type 1 With Axonal Neuropathy; Spinocerebellar Ataxia Type 1; Spinocerebellar Ataxia - Unknown; Spinocerebellar Ataxia - Dysmorphism; Non Progressive Epilepsy and/or Ataxia With Myoclonus as a Major Feature; Spasticity-ataxia-gait Anomalies Syndrome; Spastic Ataxia With Congenital Miosis; Spastic Ataxia - Corneal Dystrophy; Spastic Ataxia; Rare Hereditary Ataxia; Rare Ataxia; Recessive Mitochondrial Ataxia Syndrome; Progressive Epilepsy and/or Ataxia With Myoclonus as a Major Feature; Posterior Column Ataxia - Retinitis Pigmentosa; Post-Stroke Ataxia; Post-Head Injury Ataxia; Post Vaccination Ataxia; Polyneuropathy - Hearing Loss - Ataxia - Retinitis Pigmentosa - Cataract; Muscular Atrophy - Ataxia - Retinitis Pigmentosa - Diabetes Mellitus; Non-hereditary Degenerative Ataxia; Paroxysmal Dystonic Choreathetosis With Episodic Ataxia and Spasticity; Olivopontocerebellar Atrophy - Deafness; NARP Syndrome; Myoclonus - Cerebellar Ataxia - Deafness; Multiple System Atrophy, Parkinsonian Type; Multiple System Atrophy, Cerebellar Type; Multiple System Atrophy; Maternally-inherited Leigh Syndrome; Machado-Joseph Disease Type 3; Machado-Joseph Disease Type 2; Machado-Joseph Disease Type 1; Leigh Syndrome; Late-onset Ataxia With Dementia; Infection or Post Infection Ataxia; GAD Ataxia; Hereditary Episodic Ataxia; Gliadin/Gluten Ataxia; Friedreich Ataxia; Fragile X-associated Tremor/Ataxia Syndrome; Familial Paroxysmal Ataxia; Exposure to Medications Ataxia; Episodic Ataxia With Slurred Speech; Episodic Ataxia Unknown Type; Episodic Ataxia Type 7; Episodic Ataxia Type 6; Episodic Ataxia Type 5; Episodic Ataxia Type 4; Episodic Ataxia Type 3; Episodic Ataxia Type 1; Epilepsy and/or Ataxia With Myoclonus as Major Feature; Early-onset Spastic Ataxia-neuropathy Syndrome; Early-onset Progressive Neurodegeneration - Blindness - Ataxia - Spasticity; Early-onset Cerebellar Ataxia With Retained Tendon Reflexes; Early-onset Ataxia With Dementia; Childhood-onset Autosomal Recessive Slowly Progressive Spinocerebellar Ataxia; Dilated Cardiomyopathy With Ataxia; Cataract - Ataxia - Deafness; Cerebellar Ataxia, Cayman Type; Cerebellar Ataxia With Peripheral Neuropathy; Cerebellar Ataxia - Hypogonadism; Cerebellar Ataxia - Ectodermal Dysplasia; Cerebellar Ataxia - Areflexia - Pes Cavus - Optic Atrophy - Sensorineural Hearing Loss; Brain Tumor Ataxia; Brachydactyly - Nystagmus - Cerebellar Ataxia; Benign Paroxysmal Tonic Upgaze of Childhood With Ataxia; Autosomal Recessive Syndromic Cerebellar Ataxia; Autosomal Recessive Spastic Ataxia With Leukoencephalopathy; Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay; Autosomal Recessive Spastic Ataxia - Optic Atrophy - Dysarthria; Autosomal Recessive Spastic Ataxia; Autosomal Recessive Metabolic Cerebellar Ataxia; Autosomal Dominant Spinocerebellar Ataxia Due to Repeat Expansions That do Not Encode Polyglutamine; Autosomal Recessive Ataxia, Beauce Type; Autosomal Recessive Ataxia Due to Ubiquinone Deficiency; Autosomal Recessive Ataxia Due to PEX10 Deficiency; Autosomal Recessive Degenerative and Progressive Cerebellar Ataxia; Autosomal Recessive Congenital Cerebellar Ataxia Due to MGLUR1 Deficiency; Autosomal Recessive Congenital Cerebellar Ataxia Due to GRID2 Deficiency; Autosomal Recessive Congenital Cerebellar Ataxia; Autosomal Recessive Cerebellar Ataxia-pyramidal Signs-nystagmus-oculomotor Apraxia Syndrome; Autosomal Recessive Cerebellar Ataxia-epilepsy-intellectual Disability Syndrome Due to WWOX Deficiency; Autosomal Recessive Cerebellar Ataxia-epilepsy-intellectual Disability Syndrome Due to TUD Deficiency; Autosomal Recessive Cerebellar Ataxia-epilepsy-intellectual Disability Syndrome Due to KIAA0226 Deficiency; Autosomal Recessive Cerebellar Ataxia-epilepsy-intellectual Disability Syndrome; Autosomal Recessive Cerebellar Ataxia With Late-onset Spasticity; Autosomal Recessive Cerebellar Ataxia Due to STUB1 Deficiency; Autosomal Recessive Cerebellar Ataxia Due to a DNA Repair Defect; Autosomal Recessive Cerebellar Ataxia - Saccadic Intrusion; Autosomal Recessive Cerebellar Ataxia - Psychomotor Retardation; Autosomal Recessive Cerebellar Ataxia - Blindness - Deafness; Autosomal Recessive Cerebellar Ataxia; Autosomal Dominant Spinocerebellar Ataxia Due to a Polyglutamine Anomaly; Autosomal Dominant Spinocerebellar Ataxia Due to a Point Mutation; Autosomal Dominant Spinocerebellar Ataxia Due to a Channelopathy; Autosomal Dominant Spastic Ataxia Type 1; Autosomal Dominant Spastic Ataxia; Autosomal Dominant Optic Atrophy; Ataxia-telangiectasia Variant; Ataxia-telangiectasia; Autosomal Dominant Cerebellar Ataxia, Deafness and Narcolepsy; Autosomal Dominant Cerebellar Ataxia Type 4; Autosomal Dominant Cerebellar Ataxia Type 3; Autosomal Dominant Cerebellar Ataxia Type 2; Autosomal Dominant Cerebellar Ataxia Type 1; Autosomal Dominant Cerebellar Ataxia; Ataxia-telangiectasia-like Disorder; Ataxia With Vitamin E Deficiency; Ataxia With Dementia; Ataxia - Oculomotor Apraxia Type 1; Ataxia - Other; Ataxia - Genetic Diagnosis - Unknown; Acquired Ataxia; Adult-onset Autosomal Recessive Cerebellar Ataxia; Alcohol Related Ataxia; Multiple Endocrine Neoplasia; Multiple Endocrine Neoplasia Type II; Multiple Endocrine Neoplasia Type 1; Multiple Endocrine Neoplasia Type 2; Multiple Endocrine Neoplasia, Type IV; Multiple Endocrine Neoplasia, Type 3; Multiple Endocrine Neoplasia (MEN) Syndrome; Multiple Endocrine Neoplasia Type 2B; Multiple Endocrine Neoplasia Type 2A; Atypical Hemolytic Uremic Syndrome; Atypical HUS; Wiedemann-Steiner Syndrome; Breast Implant-Associated Anaplastic Large Cell Lymphoma; Autoimmune/Inflammatory Syndrome Induced by Adjuvants (ASIA); Hemophagocytic Lymphohistiocytosis; Behcet's Disease; Alagille Syndrome; Inclusion Body Myopathy With Early-onset Paget Disease and Frontotemporal Dementia (IBMPFD); Lowe Syndrome; Pitt Hopkins Syndrome; 1p36 Deletion Syndrome; Jansen Type Metaphyseal Chondrodysplasia; Cockayne Syndrome; Chronic Recurrent Multifocal Osteomyelitis; CRMO; Malan Syndrome; Hereditary Sensory and Autonomic Neuropathy Type Ie; VCP Disease; Hypnic Jerking; Sleep Myoclonus; Mollaret Meningitis; Recurrent Viral Meningitis; CRB1; Leber Congenital Amaurosis; Retinitis Pigmentosa; Rare Retinal Disorder; KCNMA1-Channelopathy; Primary Biliary Cirrhosis; ZMYND11; Transient Global Amnesia; Glycogen Storage Disease; Alstrom Syndrome; White Sutton Syndrome; DNM1; EIEE31; Myhre Syndrome; Recurrent Respiratory Papillomatosis; Laryngeal Papillomatosis; Tracheal Papillomatosis; Refsum Disease; Nicolaides Baraitser Syndrome; Leukodystrophy; Tango2; Cauda Equina Syndrome; Rare Gastrointestinal Disorders; Achalasia-Addisonian Syndrome; Achalasia Cardia; Achalasia Icrocephaly Syndrome; Anal Fistula; Congenital Sucrase-Isomaltase Deficiency; Eosinophilic Gastroenteritis; Idiopathic Gastroparesis; Hirschsprung Disease; Rare Inflammatory Bowel Disease; Intestinal Pseudo-Obstruction; Scleroderma; Short Bowel Syndrome; Sacral Agenesis; Sacral Agenesis Syndrome; Caudal Regression; Scheuermann Disease; SMC1A Truncated Mutations (Causing Loss of Gene Function); Cystinosis; Juvenile Nephropathic Cystinosis; Nephropathic Cystinosis; Kennedy Disease; Spinal Bulbar Muscular Atrophy; Warburg Micro Syndrome; Mucolipidoses; Mitochondrial Diseases; Mitochondrial Aminoacyl-tRNA Synthetases; Mt-aaRS Disorders; Hypertrophic Olivary Degeneration; Non-Ketotic Hyperglycinemia; Fish Odor Syndrome; Halitosis; Isolated Congenital Asplenia; Lambert Eaton (LEMS); Biliary Atresia; STAG1 Gene Mutation; Coffin Lowry Syndrome; Borjeson-Forssman-Lehman Syndrome; Blau Syndrome; Arginase 1 Deficiency; HSPB8 Myopathy; Beta-Mannosidosis; TBX4 Syndrome; DHDDS Gene Mutations; MAND-MBD5-Associated Neurodevelopmental Disorder; Constitutional Mismatch Repair Deficiency (CMMRD); SPATA5 Disorder; SPATA5L1 Related Disorder
Sponsors: Sanford Health; National Ataxia Foundation; International WAGR Syndrome Association; 4p- Support Group; ML4 Foundation; Cornelia de Lange Syndrome Foundation; Stickler Involved People; Kawasaki Disease Foundation; Klippel-Feil Syndrome Alliance; Klippel-Feil Syndrome Freedom; Hyperacusis Research Limited; Hypersomnia Foundation; Kabuki Syndrome Network; Kleine-Levin Syndrome Foundation; Leiomyosarcoma Direct Research Foundation; Marinesco-Sjogren Syndrome Support Group - NORD; Mucolipidosis Type IV (ML4) Foundation; People with Narcolepsy 4 People with Narcolepsy (PWN4PWN); Soft Bones Incorporated; American Multiple Endocrine Neoplasia Support; Atypical Hemolytic Uremic Syndrome Foundation; All Things Kabuki; Wiedemann-Steiner Syndrome Foundation; Breast Implant Victim Advocates; PROS Foundation; American Behcet's Disease Association; Alstrom United Kingdom; Athymia; Curing Retinal Blindness Foundation; HSAN1E Society; 1p36 Deletion Support and Awareness; The Alagille Syndrome Alliance; Autoinflammatory Alliance; Beyond Batten Disease Foundation; Bohring-Opitz Syndrome Foundation, INC; Cockayne Syndrome Network (Share and Care); CRMO Foundation; Cure VCP Disease,INC; FOD Support; Cystinosis Research Foundation; Global DARE Foundation; Hypnic Jerk-Sleep Myoclonus Support Group; Jansen's Foundation; KCNMA1 Channelopathy International Advocacy Foundation; Kawasaki Disease Foundation Australia; Life with LEMS Foundation; Lowe Syndrome Association; The Malan Syndrome Foundation; Maple Syrup Urine Disease Family Support Group; International Association for Muscle Glycogen Storage Disease (IamGSD); Myhre Syndrome Foundation; DNM1 Families; Nicolaides Baraitser Syndrome (NCBRS) Worldwide Foundation; The PBCers Organization; Pitt Hopkins Research Foundation; Recurrent Meningitis Association; Recurrent Respiratory Papillomatosis Foundation; Remember the Girls; Smith-Kingsmore Syndrome Foundation; SPG Research Foundation; Team Telomere; Transient Global Amnesia Project; The Charlotte & Gwenyth Gray Foundation; The Cute Syndrome Foundation; The Maddi Foundation; White Sutton Syndrome Foundation; Zmynd11 Gene Disorder; Cauda Equina Foundation, Inc; Tango2 Research Foundation; Noah's Hope - Hope4Bridget Foundation; Project Sebastian; SMC1A Epilepsy Foundation; International Foundation for Gastrointestinal Disorders; Endosalpingiosis Foundation, Inc; International Sacral Agenesis/Caudal Regression Association (ISACRA); Scheuermann's Disease Fund; Batten Disease Support and Research Association; Kennedy's Disease Association; Cure Mito Foundation; Warburg Micro Research Foundation; Cure Mucolipidosis; Riaan Research Initiative; CureARS A NJ Nonprofit Corporation; CACNA1H Alliance; IMBS Alliance; SHINE-Syndrome Foundaion; Non- Ketotic Hyperglycinemia (NKH) Crusaders; Hypertrophic Olivary Degeneration Association (HODA); National Organization for Disorders of the Corpus Callosum (NODCC); Team4Travis; Taylor's Tale Foundation; Lambert Eaton (LEMS) Family Association; BARE Inc; STAG1 Gene Foundation; Coffin Lowry Syndrome Foundation; BLFS Incorporate; Aniridia North America; Cure Blau Syndrome Foundation; ARG1D Foundation; CURE HSPB8 Myopathy; International Society of Mannosidosis and Related Disorders; TBX4Life; Cure DHDDS; MANDKind Foundation; Krishnan Family Foundation; SPATA Foundation
Recruiting
-
Posted: August 9th, 2012, 2:00am GMT
Conditions: Medullary Thyroid Cancer
Sponsors: National Cancer Institute (NCI)
Recruiting
-
Posted: November 23rd, 2010, 3:00am GMT
Conditions: Adrenal Tumour With Mild Hypercortisolism
Interventions: Procedure: Adrenalectomy
Sponsors: Region Skane
Terminated
-
Posted: November 1st, 2009, 2:00am GMT
Conditions: Endocrine Tumors; Thyroid Neoplasms; Parathyroid Neoplasms; Adrenal Neoplasm; Neuroblastoma
Sponsors: National Cancer Institute (NCI)
Recruiting
-
Posted: April 3rd, 2006, 2:00am GMT
Conditions: Metastatic Hormone-sensitive Prostate Cancer
Interventions: Drug: androgen-deprivation therapy; Drug: docetaxel
Sponsors: ECOG-ACRIN Cancer Research Group; National Cancer Institute (NCI)
Active, not recruiting
-
Posted: March 17th, 2006, 3:00am GMT
Conditions: Stage I Adrenal Cortical Carcinoma AJCC v7; Stage II Adrenal Cortical Carcinoma AJCC v7; Stage III Adrenal Cortical Carcinoma AJCC v7; Stage IV Adrenal Cortical Carcinoma AJCC v7
Interventions: Drug: Cisplatin; Procedure: Conventional Surgery; Drug: Doxorubicin Hydrochloride; Drug: Etoposide; Biological: Filgrastim; Drug: Mitotane; Biological: Pegfilgrastim
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Completed
-
Posted: March 3rd, 2000, 3:00am GMT
Conditions: Pheochromocytoma; Endocrine Disease; Endocrine Diseases
Interventions: Drug: ([18F]-DOPA); Drug: ([18F]-6F-DA)
Sponsors: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting
-
Posted: November 4th, 1999, 3:00am GMT
Conditions: Panhypopituitarism; Gigantism/Acromegaly; Prolactinoma; Cushing Disease
Interventions: Procedure: MRI; Procedure: Tissue specimen collection
Sponsors: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting
-
Posted: February 28th, 2024, 3:00am GMT
Conditions: Amyotrophic Lateral Sclerosis
Interventions: Dietary Supplement: Ultra-high-caloric fatty diet; Other: Placebo
Sponsors: University of Ulm
Not yet recruiting
-
Posted: February 28th, 2024, 3:00am GMT
Conditions: Brain Tumor, Primary; Exercise
Interventions: Other: High-Intensity Interval Training (HIIT)
Sponsors: Amsterdam UMC, location VUmc
Recruiting
-
Posted: February 28th, 2024, 3:00am GMT
Conditions: Carcinoma, Non-Small-Cell Lung; Brain Metastases; Leptomeningeal Metastasis
Interventions: Drug: Lorlatinib
Sponsors: Guangdong Association of Clinical Trials
Not yet recruiting
-
Posted: February 28th, 2024, 3:00am GMT
Conditions: Brain Metastases, Adult
Interventions: Other: health services intervention
Sponsors: University of Vermont Medical Center
Recruiting
-
Posted: February 28th, 2024, 3:00am GMT
Conditions: Pituitary Neoplasms
Interventions: Device: Performing endoscopic transnasal skull base surgery with AR-integrated endoscope
Sponsors: The First Affiliated Hospital of Xiamen University
Not yet recruiting
-
Posted: February 28th, 2024, 3:00am GMT
Conditions: Multiple Sclerosis
Interventions: Combination Product: Wim Hoff method
Sponsors: Comenius University
Active, not recruiting
-
Posted: February 28th, 2024, 3:00am GMT
Conditions: Hematological Diseases
Interventions: Behavioral: AlloCare
Sponsors: Rigshospitalet, Denmark; Danish Cancer Society
Not yet recruiting
-
Posted: February 26th, 2024, 3:00am GMT
Conditions: Meningioma
Sponsors: Central Hospital, Nancy, France
Enrolling by invitation
-
Posted: February 26th, 2024, 3:00am GMT
Conditions: Hematological Diseases
Sponsors: Rigshospitalet, Denmark; Danish Cancer Society
Enrolling by invitation
-
Posted: February 23rd, 2024, 3:00am GMT
Conditions: Intraoral Tumor
Interventions: Drug: Propofol; Drug: Sevoflurane
Sponsors: Clinical Hospital Centre Zagreb
Not yet recruiting
-
Posted: February 23rd, 2024, 3:00am GMT
Conditions: Thyroid Neoplasm; Cough
Interventions: Drug: Total intravenous anesthesia with Byfavo; Drug: Inhalation anesthesia with Sevoflurane
Sponsors: Yonsei University
Completed
-
Posted: February 23rd, 2024, 3:00am GMT
Conditions: Meningioma, Malignant
Interventions: Drug: Regorafenib 40 MG Oral Tablet; Drug: Local Standard of Care
Sponsors: Istituto Oncologico Veneto IRCCS; Bayer
Not yet recruiting
-
Posted: February 23rd, 2024, 3:00am GMT
Conditions: Pain, Acute; Head and Neck Cancer; Cutaneous Tumor
Interventions: Drug: EMLA; Drug: Ethyl chloride; Drug: Aqueous cream BP
Sponsors: University Hospital Waterford
Completed
-
Posted: February 22nd, 2024, 3:00am GMT
Conditions: Esophagectomy; Pneumonectomy; Lobectomy
Interventions: Drug: 0.5% bupivacaine; Other: Saline
Sponsors: University of Minnesota
Not yet recruiting
-
Posted: February 22nd, 2024, 3:00am GMT
Conditions: Colorectal (Colon or Rectal) Cancer; Inflammation
Interventions: Drug: Lidocaine IV; Drug: Ketamine Injectable Solution
Sponsors: University Tunis El Manar
Recruiting
-
Posted: February 22nd, 2024, 3:00am GMT
Conditions: Glioblastoma, IDH-wildtype; Glioblastoma; Glioblastoma Multiforme of Brain; Astrocytoma, Malignant; Brain Neoplasms; Brain Neoplasms, Adult, Malignant; Brain Neoplasms, Adult; Recurrent Adult Brain Tumor; Recurrent Glioblastoma
Interventions: Procedure: Awake mapping under local anesthesia; Procedure: Asleep mapping under general anesthesia; Procedure: Resection under general anesthesia without mapping
Sponsors: Erasmus Medical Center; Haaglanden Medical Centre; Universitaire Ziekenhuizen KU Leuven; University Hospital Heidelberg; Technical University of Munich; Insel Gruppe AG, University Hospital Bern; Massachusetts General Hospital; University of California, San Francisco
Recruiting
-
Posted: February 21st, 2024, 3:00am GMT
Conditions: Giant Cell Arteritis; Aortitis
Sponsors: GMIOFrance
Not yet recruiting
-
Posted: February 20th, 2024, 3:00am GMT
Conditions: Pituitary Tumor; Visual Fields Hemianopsia
Interventions: Diagnostic Test: SONDA
Sponsors: University Medical Center Groningen
Not yet recruiting
-
Posted: February 19th, 2024, 3:00am GMT
Conditions: Dementia; Death
Interventions: Other: There is no intervention. Exposures are predictor variables of mortality.
Sponsors: University of Toronto; Sunnybrook Research Institute; Ottawa Hospital Research Institute; ICES
Completed
-
Posted: February 16th, 2024, 3:00am GMT
Conditions: Late Onset Epilepsy; Stroke; Dementia
Sponsors: Lancashire Teaching Hospitals NHS Foundation Trust
Recruiting
-
Posted: February 16th, 2024, 3:00am GMT
Conditions: Cerebral Lymphoma
Interventions: Diagnostic Test: MRI imaging; Diagnostic Test: Cerebral biopsy
Sponsors: IRCCS San Raffaele
Recruiting
-
Posted: February 14th, 2024, 3:00am GMT
Conditions: Hereditary Hemorrhagic Telangiectasia; Arteriovenous Malformations; Telangiectasia; Epistaxis; GastroIntestinal Bleeding; Cerebral Arteriovenous Malformations; Vascular Malformation
Sponsors: Cure HHT; Augusta University; The Cleveland Clinic; Mayo Clinic; Massachusetts General Hospital; Columbia University; Oregon Health and Science University; University of California, Los Angeles; University of California, San Francisco; University of Colorado, Denver; University of North Carolina, Chapel Hill; University of Pennsylvania; University of Texas; University of Utah; Washington University School of Medicine; Yale University; Health Resources and Services Administration (HRSA); Children's Hospital of Philadelphia
Recruiting
-
Posted: February 14th, 2024, 3:00am GMT
Conditions: Brain Tumor
Interventions: Procedure: MRI scan
Sponsors: Nottingham University Hospitals NHS Trust
Completed
-
Posted: February 13th, 2024, 3:00am GMT
Conditions: Ornithine Transcarbamylase Deficiency; Ornithine Transcarbamylase Deficiency Disease; Ornithine Carbamoyltransferase Deficiency (Disorder); Urea Cycle Disorders, Inborn
Interventions: Genetic: ECUR-506
Sponsors: iECURE, Inc.
Recruiting
-
Posted: February 13th, 2024, 3:00am GMT
Conditions: Meningioma
Sponsors: Central Hospital, Nancy, France
Not yet recruiting
-
Posted: February 12th, 2024, 3:00am GMT
Conditions: Gastro-enteropancreatic Neuroendocrine Tumor; Acromegaly
Sponsors: Ipsen
Not yet recruiting
-
Posted: February 12th, 2024, 3:00am GMT
Conditions: Breast Cancer
Interventions: Drug: Dexmedetomidine; Drug: Liposomal bupivacaine
Sponsors: United States Naval Medical Center, Portsmouth
Not yet recruiting
-
Posted: February 9th, 2024, 3:00am GMT
Conditions: Head and Neck Squamous Cell Carcinoma; Malignant Head and Neck Tumors
Interventions: Drug: lithium-containing mouthwash; Drug: Plcacebo mouthwash; Drug: lithium-containing mouthwash
Sponsors: West China Hospital
Not yet recruiting
-
Posted: February 9th, 2024, 3:00am GMT
Conditions: Neurodevelopmental Disorders; Neurodegenerative Diseases; Brain Tumor; Multiple Sclerosis; Epilepsy
Interventions: Diagnostic Test: MRI exam with Magnetic Resonance Fingerprinting
Sponsors: IRCCS Fondazione Stella Maris; Azienda Ospedaliero, Universitaria Pisana
Completed
-
Posted: February 9th, 2024, 3:00am GMT
Conditions: Non Small Cell Lung Cancer
Interventions: Drug: Trastuzumab deruxtecan
Sponsors: Yonsei University
Not yet recruiting
-
Posted: February 9th, 2024, 3:00am GMT
Conditions: BRAF-positive Metastatic Melanoma
Sponsors: Novartis Pharmaceuticals
Completed
-
Posted: February 8th, 2024, 3:00am GMT
Conditions: Non Small Cell Lung Cancer; NSCLC; KRAS G12C
Interventions: Drug: Adagrasib; Radiation: Stereotactic Radiosurgery
Sponsors: Ryan Gentzler, MD; Mirati Therapeutics Inc.; University of Virginia
Not yet recruiting
-
Posted: February 8th, 2024, 3:00am GMT
Conditions: Systemic Lupus Erythematosus (SLE); Immune-Mediated Necrotizing Myopathy; Neuromyelitis Optica Spectrum Disorders; Multiple Sclerosis-Relapsing-Remitting
Interventions: Biological: CD20/BCMA-directed CAR-T cells
Sponsors: RenJi Hospital; AbelZeta Pharma Inc.
Recruiting
-
Posted: February 8th, 2024, 3:00am GMT
Conditions: Surgery; Anesthesia; Functional; Haemodynamic Instability
Interventions: Drug: NaCl 0.9%; Drug: Adjuvant lidocaine continous
Sponsors: Indonesia University
Completed
-
Posted: February 7th, 2024, 3:00am GMT
Conditions: Breast Cancer
Interventions: Diagnostic Test: Brain imaging; Diagnostic Test: Analysis of circulating tumor DNA; Behavioral: Testing Morbidities Index
Sponsors: Sunnybrook Health Sciences Centre; Princess Margaret Hospital, Canada; MOUNT SINAI HOSPITAL; Trillium Health Partners
Recruiting
-
Posted: February 7th, 2024, 3:00am GMT
Conditions: Alzheimer's Disease
Interventions: Dietary Supplement: Consumption of olive pomace olive oil by alzheimer's patients; Dietary Supplement: Consumption of high-oleic sunflower oil by alzheimer's patients
Sponsors: Spanish National Research Council
Recruiting
-
Posted: February 7th, 2024, 3:00am GMT
Conditions: Autoimmune Encephalitis Associated With Anti-CAPR2 Antibodies
Interventions: Other: Retrospective evaluation of specific brain MRI features
Sponsors: Hospices Civils de Lyon
Recruiting
-
Posted: February 6th, 2024, 3:00am GMT
Conditions: Medullary Thyroid Cancer; Medullary Carcinoma; Medullary Tumor; Medullary Neoplasms; Desmoplasia; Desmoplastic; Desmoplastic Reaction; Lymph Node Metastasis; Lymph Node Disease
Sponsors: Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Completed
-
Posted: February 6th, 2024, 3:00am GMT
Conditions: Giant Cell Arteritis; Temporal Arteritis; Clonal Hematopoiesis of Indeterminate Potential; Horton Disease; Systemic Vasculitis Primary
Interventions: Diagnostic Test: Temporal arterial biopsy; Diagnostic Test: Whole exome sequencing; Diagnostic Test: Single cell transcriptomics
Sponsors: ASST Fatebenefratelli Sacco
Not yet recruiting
-
Posted: February 5th, 2024, 3:00am GMT
Conditions: Stroke; High Blood Pressure
Interventions: Other: Mat Pilates
Sponsors: Rio de Janeiro State University; Postgraduate scholarship
Available
-
Posted: February 5th, 2024, 3:00am GMT
Conditions: SCLC,Extensive Stage; Brain Metastases
Interventions: Radiation: HA-WBRT plus SBRT
Sponsors: Fudan University
Recruiting
-
Posted: February 5th, 2024, 3:00am GMT
Conditions: Acute Ischemic Stroke
Interventions: Other: not have
Sponsors: Zhujiang Hospital
Recruiting
-
Posted: February 5th, 2024, 3:00am GMT
Conditions: Pain Cancer
Interventions: Device: Ultrasound-guided percutaneous neuromodulation (NMP); Drug: pharmacological treatment by Opioids
Sponsors: Universidad Europea de Canarias
Not yet recruiting
-
Posted: February 5th, 2024, 3:00am GMT
Conditions: Pain Cancer
Interventions: Device: Transcranial direct current stimulation (tDCS); Device: Ultrasound-guided percutaneous neuromodulation (NMP)
Sponsors: Universidad Europea de Canarias
Not yet recruiting
-
Posted: February 5th, 2024, 3:00am GMT
Conditions: Parkinson Disease; Epilepsy
Interventions: Procedure: High Resolution Electroencephalogram (EEG-HR); Procedure: Stereo-electro-encephalography (SEEG)
Sponsors: University Hospital, Bordeaux
Recruiting
-
Posted: February 2nd, 2024, 3:00am GMT
Conditions: Non-small Cell Lung Cancer; Brain Metastases; EGFR Gene Mutation
Interventions: Combination Product: Nitroglycerin
Sponsors: Instituto Nacional de Cancerologia de Mexico
Recruiting
-
Posted: February 2nd, 2024, 3:00am GMT
Conditions: Breast Cancer; Triple Negative Breast Cancer
Interventions: Radiation: Stereotactic Radiation; Drug: Zimberelimab; Drug: Sacituzumab govitecan
Sponsors: H. Lee Moffitt Cancer Center and Research Institute; Gilead Sciences
Not yet recruiting
-
Posted: February 1st, 2024, 3:00am GMT
Conditions: Obesity; Type2diabetes; Lipodystrophy; Infections; Obesity Associated Disorder
Interventions: Dietary Supplement: Mediterranean diet; Dietary Supplement: Melatonin supplementation
Sponsors: Federico II University; University of Roma La Sapienza; University of Pisa; Università degli Studi del Piemonte Orientale "Amedeo Avogadro"; University of Rome Foro Italico
Recruiting
-
Posted: January 31st, 2024, 3:00am GMT
Conditions: Breast Neoplasm Female
Interventions: Drug: Docetaxel; Drug: Carboplatin; Drug: Inetetamab; Drug: Pyrotinib
Sponsors: Wang Ouchen
Recruiting
-
Posted: January 31st, 2024, 3:00am GMT
Conditions: Pituitary Adenoma
Interventions: Procedure: surgery of pituitary adenomas
Sponsors: Beijing Tiantan Hospital
Active, not recruiting
-
Posted: January 31st, 2024, 3:00am GMT
Conditions: Intra-abdominal Cancer
Interventions: Drug: Hydrocodone; Drug: Tramadol; Drug: Oxycodone
Sponsors: M.D. Anderson Cancer Center
Recruiting
-
Posted: January 30th, 2024, 3:00am GMT
Conditions: Brain Metastases, Adult; Stereotactic Radiotherapy
Interventions: Radiation: iHD-SRT
Sponsors: Ruijin Hospital
Recruiting
-
Posted: January 30th, 2024, 3:00am GMT
Conditions: Stroke
Interventions: Device: Intravenous Laser Irradiation of Blood
Sponsors: Taipei Hospital, Ministry of Health and Welfare
Recruiting
-
Posted: January 29th, 2024, 3:00am GMT
Conditions: HER2-negative Breast Cancer; Leptomeningeal Metastasis
Interventions: Device: Ommaya reservoir; Drug: Systematic chemotherapy
Sponsors: Fudan University
Recruiting
-
Posted: January 26th, 2024, 3:00am GMT
Conditions: Pain, Postoperative; Pain, Acute; Opioid Consumption
Interventions: Procedure: Serratus posterior superior intercostal plane block
Sponsors: Zonguldak Bulent Ecevit University
Active, not recruiting
-
Posted: January 26th, 2024, 3:00am GMT
Conditions: Triple Negative Breast Cancer
Interventions: Diagnostic Test: ctDNA monitoring; Diagnostic Test: 68Ga-FAPI-46-PET-CT
Sponsors: Institut Curie; National Research Agency, France; Roche Pharma AG
Not yet recruiting
-
Posted: January 26th, 2024, 3:00am GMT
Conditions: Hereditary Tyrosinemia, Type I
Interventions: Drug: Nitisinone
Sponsors: Swedish Orphan Biovitrum
Recruiting
-
Posted: January 25th, 2024, 3:00am GMT
Conditions: Ischemic Stroke; Arterial Stiffness; Pulse Wave Velocity; Rehabilitation
Interventions: Other: Rehabilitation
Sponsors: Shin Kong Wu Ho-Su Memorial Hospital
Recruiting
-
Posted: January 25th, 2024, 3:00am GMT
Conditions: Dementia; Dementia Alzheimers; Parkinson Disease; Myocardial Infarction
Interventions: Other: dietary acrylamide exposure measured via biomarkers in blood (hemoglobin adducts of acrylamide and glycidamide)
Sponsors: Karolinska Institutet; Stockholm University
Recruiting
-
Posted: January 25th, 2024, 3:00am GMT
Conditions: Cutaneous Melanoma; Merkel Cell Carcinoma; Skin Squamous Cell Carcinoma
Interventions: Drug: Eutectic Mixture of Local Anesthetics; Drug: Placebo Administration; Other: Questionnaire Administration
Sponsors: Ohio State University Comprehensive Cancer Center
Recruiting
-
Posted: January 25th, 2024, 3:00am GMT
Conditions: Cerebral Adrenoleukodystrophy (CALD)
Interventions: Other: No Intervention
Sponsors: bluebird bio; Center for International Blood and Marrow Transplant Research
Recruiting
-
Posted: January 24th, 2024, 3:00am GMT
Conditions: Enhanced Recovery After Surgery; Pituitary Tumor; Postoperative Complications
Interventions: Diagnostic Test: Malnutrition Universal Screening Tool; Device: TIB Olfactory Test Device; Diagnostic Test: Apfel Score for Postoperative nausea and vomiting; Diagnostic Test: The American Society of Anesthesiologists (ASA) Physical Status Classification; Behavioral: Short Form-36; Behavioral: World Health Organization Quality of Life questionnaire (WHOQOL-BREF); Behavioral: BDI-II(Beck Depression Inventory-II); Behavioral: ERAS Patient Satisfaction Questionnaire(ERAS-PSQ); Behavioral: Quality of Recovery-40(QoR-40)
Sponsors: Chang Gung Memorial Hospital
Recruiting
-
Posted: January 24th, 2024, 3:00am GMT
Conditions: DIPG Brain Tumor; Diffuse Intrinsic Pontine Glioma
Interventions: Biological: B7H3 specific CAR T cell with IL-7Ra signaling domain
Sponsors: Chulalongkorn University; King Chulalongkorn Memorial Hospital
Not yet recruiting
-
Posted: January 23rd, 2024, 3:00am GMT
Conditions: Subarachnoid Hemorrhage, Spontaneous; Subarachnoid Hemorrhage, Aneurysmal
Interventions: Diagnostic Test: biomarkers
Sponsors: Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Recruiting
-
Posted: January 23rd, 2024, 3:00am GMT
Conditions: Glioblastoma Multiforme
Interventions: Drug: Haloperidol Tablets; Drug: Temozolomide
Sponsors: Southern Medical University, China
Not yet recruiting
-
Posted: January 22nd, 2024, 3:00am GMT
Conditions: Hemangioma, Cavernous, Central Nervous System
Sponsors: Beijing Tiantan Hospital; RenJi Hospital; Beijing Chao Yang Hospital; Beijing Friendship Hospital; Guangzhou Red Cross Hospital; Affiliated Hospital of Guangdong Medical University; Shanxi Provincipal People's Hospital; Qilu Hospital of Shandong University; Central South University; First Affiliated Hospital of Harbin Medical University
Recruiting
-
Posted: January 22nd, 2024, 3:00am GMT
Conditions: HER2-positive Breast Cancer; Advanced Breast Cancer
Interventions: Drug: Pyrotinib; Drug: Trastuzumab; Drug: Taxanes; Drug: Capecitabine
Sponsors: Hebei Medical University Fourth Hospital
Recruiting
-
Posted: January 22nd, 2024, 3:00am GMT
Conditions: Endometriosis
Interventions: Other: No Intervention
Sponsors: BC Women's Hospital & Health Centre; The Swedish Research Council
Active, not recruiting
-
Posted: January 19th, 2024, 3:00am GMT
Conditions: Analgesia; Surgery
Interventions: Drug: TAP Anesthesia; Drug: Surgeon-Initiated Local Anesthetic
Sponsors: University of Wisconsin, Madison
Recruiting
-
Posted: January 19th, 2024, 3:00am GMT
Conditions: Pancreatic Ductal Adenocarcinoma; Liver, Cancer of, Primary Resectable
Interventions: Drug: Ropivacaine 0.5%; Drug: Normal Saline
Sponsors: Sixth Affiliated Hospital, Sun Yat-sen University
Not yet recruiting
-
Posted: January 19th, 2024, 3:00am GMT
Conditions: Acute Lymphoblastic Leukemia, Adult B-Cell; Acute Lymphoblastic Leukemia, in Relapse; Non-Hodgkin Lymphoma, B-cell; Diffuse Large B Cell Lymphoma; Central Nervous System Lymphoma; Lymphoma, Follicular; MCL
Interventions: Biological: CD19/CD22-CAR T cells
Sponsors: Essen Biotech
Not yet recruiting
-
Posted: January 18th, 2024, 3:00am GMT
Conditions: AML; Pediatric AML
Interventions: Drug: ARM A: Active Comparator Drug; Drug: ARM B: Blocks Therapy Drug
Sponsors: Grupo Argentino de Tratamiento de la Leucemia Aguda
Completed
-
Posted: January 18th, 2024, 3:00am GMT
Conditions: Neurodegenerative Diseases; Brain Neoplasms; Neuroendocrine Tumors
Interventions: Diagnostic Test: Positron-Emission Tomography Imaging
Sponsors: Jagiellonian University; Medical University of Warsaw
Completed
-
Posted: January 18th, 2024, 3:00am GMT
Conditions: TNBC; Brain Metastasis
Interventions: Drug: SHR-A1921 + Bevacizumab
Sponsors: Fudan University
Not yet recruiting
-
Posted: January 17th, 2024, 3:00am GMT
Conditions: High-grade Glioma; Brain Metastases; Brain Metastases, Adult
Interventions: Diagnostic Test: 68Ga-PSMA-11 PET Scans
Sponsors: Memorial Sloan Kettering Cancer Center
Recruiting
-
Posted: January 17th, 2024, 3:00am GMT
Conditions: Childhood Cancer; Childhood Solid Tumor; Childhood Brain Tumor; Recurrent Cancer; Refractory Cancer
Interventions: Drug: Paxalisib, Irinotecan, Temozolomide; Drug: Pimasertib
Sponsors: Australian & New Zealand Children's Haematology/Oncology Group; Children's Cancer Institute Australia (CCIA); The Hospital for Sick Children; Medical Research Future Fund; Kazia Therapeutics Limited; Day One Biopharmaceuticals, Inc.; C17 Council
Not yet recruiting
-
Posted: January 15th, 2024, 3:00am GMT
Conditions: Dementia
Sponsors: KU Leuven; Odisee University College
Not yet recruiting
-
Posted: January 15th, 2024, 3:00am GMT
Conditions: Metastatic Appendiceal Adenocarcinoma; Intraperitoneal Paclitaxel
Interventions: Drug: Dexamethasone; Drug: Diphenhydramine; Drug: Famotidine; Drug: Paclitaxel
Sponsors: M.D. Anderson Cancer Center
Recruiting
-
Posted: January 12th, 2024, 3:00am GMT
Conditions: ALS; Amyotrophic Lateral Sclerosis; Alzheimer Disease; Alzheimer Disease, Early Onset; Alzheimer Disease, Late Onset; Batten Disease; Corticobasal Degeneration; Dementia; Frontotemporal Dementia; Huntington Disease; Lewy Body Disease; Multiple Sclerosis; Multiple System Atrophy; Parkinson Disease; Parkinson's Disease and Parkinsonism; Progressive Supranuclear Palsy; INAD; Diabetes; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetes Mellitus, Type 1; Macular Degeneration; Ovarian Cancer; Cervical Cancer; Uterine Cancer; Vaginal Cancer; Vulvar Cancer; PTSD; Post Traumatic Stress Disorder
Interventions: Other: Biological Sample Collection
Sponsors: New York Stem Cell Foundation Research Institute
Recruiting
-
Posted: January 12th, 2024, 3:00am GMT
Conditions: Spinal Cord; Metastatic Epidural; Spine Stereotactic
Interventions: Radiation: Stereotactic Radiosurgery
Sponsors: M.D. Anderson Cancer Center; Brainlab AG
Not yet recruiting
-
Posted: January 11th, 2024, 3:00am GMT
Conditions: Head and Neck Cancer
Interventions: Drug: 0.5% Lidocaine Hydrochloride; Drug: 0.9% Normal Saline
Sponsors: Sixth Affiliated Hospital, Sun Yat-sen University
Not yet recruiting
-
Posted: January 11th, 2024, 3:00am GMT
Conditions: Hormone Receptor Positive HER-2 Negative Breast Cancer; Advanced or Metastatic Breast Cancer; BRCA1 Mutation; BRCA2 Mutation; PALB2 Gene Mutation
Interventions: Drug: Niraparib + Elacestrant; Drug: Niraparib
Sponsors: German Breast Group; Stemline Therapeutics, Inc.; GlaxoSmithKline
Not yet recruiting
-
Posted: January 11th, 2024, 3:00am GMT
Conditions: Antipsychotics and Neuroleptics Toxicity
Interventions: Drug: Risperidone; Drug: Olanzapine; Drug: Quetiapine; Drug: Risperidone and Vitamin D and Vitamin E; Drug: Olanzapine and Vitamin D and Vitamin E; Drug: Quetiapine and Vitamin D and Vitamin E
Sponsors: Dr Rabia Arshad
Completed
-
Posted: January 10th, 2024, 3:00am GMT
Conditions: Dementia; Caregiver Burden; Quality of Life
Interventions: Dietary Supplement: Jing Si Herbal Tea; Dietary Supplement: Barley Tea
Sponsors: National Cheng Kung University; Buddhist Tzu Chi General Hospital; Tzu Chi University; E-DA Hospital
Not yet recruiting
-
Posted: January 10th, 2024, 3:00am GMT
Conditions: Misuse, Opioid
Interventions: Drug: Olanzapine; Drug: Olanzapine; Drug: Placebo
Sponsors: M.D. Anderson Cancer Center
Recruiting
-
Posted: January 10th, 2024, 3:00am GMT
Conditions: Acute Myeloid Leukemia, Adult; Myelodysplastic Syndromes, Adult
Interventions: Drug: Hydroxyurea, Hydroxycarbamide; Drug: Valproic acid; Drug: 6-Mercaptopurine (6-MP)
Sponsors: Haukeland University Hospital
Not yet recruiting
-
Posted: January 8th, 2024, 3:00am GMT
Conditions: Melanoma
Interventions: Drug: Defactinib; Drug: Avutometinib; Drug: Encorafenib
Sponsors: University of Utah; Verastem, Inc.
Recruiting
-
Posted: January 5th, 2024, 3:00am GMT
Conditions: Parkinson Disease; Prodromal Stage; Neurodegenerative Diseases; Parkinsonian Disorders; REM Sleep Behavior Disorder; Basal Ganglia Diseases; Central Nervous System Diseases; Synucleinopathies; Nervous System Diseases; Cerebral Disorder; Brain Diseases
Interventions: Behavioral: Increase of physical activity volume and intensity with the use of a motivational smartphone application
Sponsors: Radboud University Medical Center; Stichting ParkinsonNL; ZonMw: The Netherlands Organisation for Health Research and Development; Michael J. Fox Foundation for Parkinson's Research; PARKINSONS UK; Cure Parkinsons; Edmond J. Safra Foundation; Davis Phinney Foundation; Donders Centre for Cognitive Neuroimaging, Radboud University Nijmegen; Anne Wojcicki Foundation; Sleep Medicine Centre Kempenhaeghe; Sleep Medicine Centre SEIN; Queen Mary University of London; 23andMe, Inc.; Parkinsons Progression Markers Initiative (PPMI); Massachusetts General Hospital; Harvard School of Public Health (HSPH); IJsfontein B.V., Netherlands; Hoffmann-La Roche; Erasmus Medical Center; University of Illinois at Chicago; University of Rochester; University of Bristol; University of Plymouth; University of Luebeck; McGill University; University of Pittsburgh
Recruiting
-
Posted: January 5th, 2024, 3:00am GMT
Conditions: Brain Tumor
Interventions: Biological: Multi-tumor antigen specific cytotoxic T lymphocytes (TSA-T) directed against proteogenomically determined personalized tumor-specific antigens (TSA)
Sponsors: Children's National Research Institute
Not yet recruiting
-
Posted: January 4th, 2024, 3:00am GMT
Conditions: Lymphoma, Non-Hodgkin; Child, Only
Interventions: Other: intrathecal rituximab
Sponsors: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Completed
-
Posted: December 29th, 2023, 3:00am GMT
Conditions: Brain Tumor, Primary
Interventions: Other: Cognitive testing; Device: Resting State MRI/Precision functional mapping
Sponsors: Washington University School of Medicine
Not yet recruiting
-
Posted: December 28th, 2023, 3:00am GMT
Conditions: Anti-NMDA Receptor Encephalitis
Interventions: Behavioral: Remote cognitive rehabilitation program
Sponsors: Fundacion Clinic per a la Recerca Biomédica; Hospital Sant Joan de Deu
Recruiting
-
Posted: December 25th, 2023, 3:00am GMT
Conditions: General Anesthetic Drug Adverse Reaction
Interventions: Drug: remimazolam; Drug: propofol
Sponsors: Zhihong LU
Recruiting
-
Posted: December 22nd, 2023, 3:00am GMT
Conditions: Meningioma
Interventions: Diagnostic Test: PET CT with 18 FDG .
Sponsors: IRCCS San Raffaele
Completed
-
Posted: December 22nd, 2023, 3:00am GMT
Conditions: Neuromyelitis Optica Spectrum Disorder
Interventions: Other: Blood tests; Drug: Inebilizumab
Sponsors: Horizon Therapeutics Ireland DAC
Not yet recruiting
-
Posted: December 22nd, 2023, 3:00am GMT
Conditions: Brain Tumor; Brain Metastases; Brain Cancer; Metastatic Lung Cancer; Metastatic Breast Cancer; Metastatic Melanoma; Metastatic Colon Cancer; Metastatic Kidney Cancer
Interventions: Behavioral: CALM; Behavioral: Treatment as usual
Sponsors: Virginia Commonwealth University; United States Department of Defense
Recruiting
-
Posted: December 21st, 2023, 3:00am GMT
Conditions: Liver Cancer; Ciprofol
Interventions: Drug: Propofol; Drug: Ciprofol
Sponsors: Zhejiang Cancer Hospital
Recruiting
-
Posted: December 21st, 2023, 3:00am GMT
Conditions: Cholecystitis, Acute; Gallbladder Neoplasms; Acalculous Cholecystitis
Interventions: Drug: propofol group; Drug: remimazolam group
Sponsors: Yonsei University
Completed
-
Posted: December 20th, 2023, 3:00am GMT
Conditions: Recurrent Supratentorial Glioblastoma
Interventions: Drug: Lerapolturev; Drug: Lomustine Pill
Sponsors: Darell Bigner; Istari Oncology, Inc.
Not yet recruiting
-
Posted: December 20th, 2023, 3:00am GMT
Conditions: Cognitive Impairment, Mild; Cognitive Dysfunction; Amyloid Plaque; Neurodegenerative Disease, Hereditary; Inflammation, Brain
Interventions: Drug: Lenalidomide 10 mg
Sponsors: St. Joseph's Hospital and Medical Center, Phoenix; Texas Tech University
Not yet recruiting
-
Posted: February 28th, 2024, 3:00am GMT
Conditions: Glioblastoma; Cancer; Temozolomide
Interventions: Drug: 6-mercaptopurine
Sponsors: The First Affiliated Hospital with Nanjing Medical University
Recruiting
-
Posted: February 28th, 2024, 3:00am GMT
Conditions: Brain Tumor, Primary; Exercise
Interventions: Other: High-Intensity Interval Training (HIIT)
Sponsors: Amsterdam UMC, location VUmc
Recruiting
-
Posted: February 28th, 2024, 3:00am GMT
Conditions: Carcinoma, Non-Small-Cell Lung; Brain Metastases; Leptomeningeal Metastasis
Interventions: Drug: Lorlatinib
Sponsors: Guangdong Association of Clinical Trials
Not yet recruiting
-
Posted: February 28th, 2024, 3:00am GMT
Conditions: Glioblastoma; Glioblastoma Multiforme; Glioblastoma, IDH-wildtype; Glioblastoma Multiforme of Brain; Glioblastoma Multiforme, Adult; Recurrent Glioblastoma; Astrocytoma, Malignant; Astrocytoma of Brain
Interventions: Procedure: Re-resection; Drug: Temozolomide; Drug: Lomustine; Radiation: Re-irradiation; Procedure: Experimental therapy; Other: Best supportive care
Sponsors: Jasper Gerritsen; Haaglanden Medical Centre; Universitaire Ziekenhuizen KU Leuven; University Hospital Heidelberg; Technical University of Munich; Insel Gruppe AG, University Hospital Bern; Massachusetts General Hospital; University of California, San Francisco
Recruiting
-
Posted: February 28th, 2024, 3:00am GMT
Conditions: Brain Metastases, Adult
Interventions: Other: health services intervention
Sponsors: University of Vermont Medical Center
Recruiting
-
Posted: February 28th, 2024, 3:00am GMT
Conditions: Pituitary Neoplasms
Interventions: Device: Performing endoscopic transnasal skull base surgery with AR-integrated endoscope
Sponsors: The First Affiliated Hospital of Xiamen University
Not yet recruiting
-
Posted: February 28th, 2024, 3:00am GMT
Conditions: Acute Myocardial Infarction; Cancer
Interventions: Procedure: Revascularization
Sponsors: Samsung Medical Center; Chonnam National University
Active, not recruiting
-
Posted: February 26th, 2024, 3:00am GMT
Conditions: Mild Cognitive Impairment
Interventions: Dietary Supplement: Precision probiotics
Sponsors: National Yang Ming University; National Science and Technology Council; Far Eastern Memorial Hospital
Not yet recruiting
-
Posted: February 26th, 2024, 3:00am GMT
Conditions: Non-small Cell Lung Cancer
Interventions: Drug: Cadonilimab plus Pemetrexed and Anlotinib
Sponsors: Guangzhou University of Traditional Chinese Medicine; Akeso Pharmaceuticals, Inc.
Recruiting
-
Posted: February 22nd, 2024, 3:00am GMT
Conditions: Surgical Education
Interventions: Behavioral: Experimental Group - Verbal expert instructor feedback in AI's words; Behavioral: Experimental Group - Verbal expert instructor feedback in expert's own words
Sponsors: McGill University
Not yet recruiting
-
Posted: February 22nd, 2024, 3:00am GMT
Conditions: Glioblastoma, IDH-wildtype; Glioblastoma; Glioblastoma Multiforme of Brain; Astrocytoma, Malignant; Brain Neoplasms; Brain Neoplasms, Adult, Malignant; Brain Neoplasms, Adult; Recurrent Adult Brain Tumor; Recurrent Glioblastoma
Interventions: Procedure: Awake mapping under local anesthesia; Procedure: Asleep mapping under general anesthesia; Procedure: Resection under general anesthesia without mapping
Sponsors: Erasmus Medical Center; Haaglanden Medical Centre; Universitaire Ziekenhuizen KU Leuven; University Hospital Heidelberg; Technical University of Munich; Insel Gruppe AG, University Hospital Bern; Massachusetts General Hospital; University of California, San Francisco
Recruiting
-
Posted: February 21st, 2024, 3:00am GMT
Conditions: Glioblastoma Multiforme
Interventions: Device: NanoTherm therapy; Procedure: Glioma Resection; Radiation: radiotherapy according to Stupp protocol; Drug: chemotherapy according to Stupp protocol
Sponsors: Poznan University of Medical Sciences; MagForce USA
Recruiting
-
Posted: February 21st, 2024, 3:00am GMT
Conditions: Giant Cell Arteritis; Aortitis
Sponsors: GMIOFrance
Not yet recruiting
-
Posted: February 20th, 2024, 3:00am GMT
Conditions: Pituitary Tumor; Visual Fields Hemianopsia
Interventions: Diagnostic Test: SONDA
Sponsors: University Medical Center Groningen
Not yet recruiting
-
Posted: February 19th, 2024, 3:00am GMT
Conditions: Dementia; Death
Interventions: Other: There is no intervention. Exposures are predictor variables of mortality.
Sponsors: University of Toronto; Sunnybrook Research Institute; Ottawa Hospital Research Institute; ICES
Completed
-
Posted: February 19th, 2024, 3:00am GMT
Conditions: Depression
Interventions: Drug: ATP Group; Drug: Placebo Group
Sponsors: Nanfang Hospital, Southern Medical University
Recruiting
-
Posted: February 16th, 2024, 3:00am GMT
Conditions: Late Onset Epilepsy; Stroke; Dementia
Sponsors: Lancashire Teaching Hospitals NHS Foundation Trust
Recruiting
-
Posted: February 16th, 2024, 3:00am GMT
Conditions: Cerebral Lymphoma
Interventions: Diagnostic Test: MRI imaging; Diagnostic Test: Cerebral biopsy
Sponsors: IRCCS San Raffaele
Recruiting
-
Posted: February 15th, 2024, 3:00am GMT
Conditions: Anatomic Stage IV Breast Cancer AJCC v8; Estrogen Receptor-Positive Breast Carcinoma; Metastatic Breast Carcinoma
Interventions: Procedure: Biospecimen Collection; Procedure: Bone Scan; Procedure: Computed Tomography; Drug: F-18 16 Alpha-Fluoroestradiol; Procedure: Positron Emission Tomography; Other: Questionnaire Administration; Radiation: Stereotactic Body Radiation Therapy
Sponsors: City of Hope Medical Center; National Cancer Institute (NCI)
Not yet recruiting
-
Posted: February 14th, 2024, 3:00am GMT
Conditions: Glioma, Malignant
Interventions: Drug: Temodal; Drug: Niraparib
Sponsors: Armando Santoro, MD; Istituto Clinico Humanitas; GlaxoSmithKline
Not yet recruiting
-
Posted: February 14th, 2024, 3:00am GMT
Conditions: Hereditary Hemorrhagic Telangiectasia; Arteriovenous Malformations; Telangiectasia; Epistaxis; GastroIntestinal Bleeding; Cerebral Arteriovenous Malformations; Vascular Malformation
Sponsors: Cure HHT; Augusta University; The Cleveland Clinic; Mayo Clinic; Massachusetts General Hospital; Columbia University; Oregon Health and Science University; University of California, Los Angeles; University of California, San Francisco; University of Colorado, Denver; University of North Carolina, Chapel Hill; University of Pennsylvania; University of Texas; University of Utah; Washington University School of Medicine; Yale University; Health Resources and Services Administration (HRSA); Children's Hospital of Philadelphia
Recruiting
-
Posted: February 14th, 2024, 3:00am GMT
Conditions: Brain Tumor
Interventions: Procedure: MRI scan
Sponsors: Nottingham University Hospitals NHS Trust
Completed
-
Posted: February 13th, 2024, 3:00am GMT
Conditions: Ornithine Transcarbamylase Deficiency; Ornithine Transcarbamylase Deficiency Disease; Ornithine Carbamoyltransferase Deficiency (Disorder); Urea Cycle Disorders, Inborn
Interventions: Genetic: ECUR-506
Sponsors: iECURE, Inc.
Recruiting
-
Posted: February 12th, 2024, 3:00am GMT
Conditions: Recurrent Oligodendroglioma; Progressive Oligodendroglioma
Interventions: Biological: TTRNA-DC vaccines with GM-CSF; Biological: Autologous Hematopoietic Stem cells (HSCs); Biological: TTRNA-xALT; Drug: Td vaccine
Sponsors: University of Florida; Oligo Nation, Inc
Not yet recruiting
-
Posted: February 12th, 2024, 3:00am GMT
Conditions: Gastro-enteropancreatic Neuroendocrine Tumor; Acromegaly
Sponsors: Ipsen
Not yet recruiting
-
Posted: February 9th, 2024, 3:00am GMT
Conditions: Neurodevelopmental Disorders; Neurodegenerative Diseases; Brain Tumor; Multiple Sclerosis; Epilepsy
Interventions: Diagnostic Test: MRI exam with Magnetic Resonance Fingerprinting
Sponsors: IRCCS Fondazione Stella Maris; Azienda Ospedaliero, Universitaria Pisana
Completed
-
Posted: February 9th, 2024, 3:00am GMT
Conditions: Non Small Cell Lung Cancer
Interventions: Drug: Trastuzumab deruxtecan
Sponsors: Yonsei University
Not yet recruiting
-
Posted: February 8th, 2024, 3:00am GMT
Conditions: Non Small Cell Lung Cancer; NSCLC; KRAS G12C
Interventions: Drug: Adagrasib; Radiation: Stereotactic Radiosurgery
Sponsors: Ryan Gentzler, MD; Mirati Therapeutics Inc.; University of Virginia
Not yet recruiting
-
Posted: February 7th, 2024, 3:00am GMT
Conditions: Breast Cancer
Interventions: Diagnostic Test: Brain imaging; Diagnostic Test: Analysis of circulating tumor DNA; Behavioral: Testing Morbidities Index
Sponsors: Sunnybrook Health Sciences Centre; Princess Margaret Hospital, Canada; MOUNT SINAI HOSPITAL; Trillium Health Partners
Recruiting
-
Posted: February 7th, 2024, 3:00am GMT
Conditions: Alzheimer's Disease
Interventions: Dietary Supplement: Consumption of olive pomace olive oil by alzheimer's patients; Dietary Supplement: Consumption of high-oleic sunflower oil by alzheimer's patients
Sponsors: Spanish National Research Council
Recruiting
-
Posted: February 7th, 2024, 3:00am GMT
Conditions: NSCLC
Sponsors: Yuhan Corporation; The Korean Academy of Tuberculosis and Respiratory Diseases
Recruiting
-
Posted: February 7th, 2024, 3:00am GMT
Conditions: Healthy Adults; Adults With Stress-related Symptoms
Interventions: Behavioral: Seated rest; Behavioral: Exercise at moderate intensity; Behavioral: Exercise at vigorous intensity
Sponsors: The Swedish School of Sport and Health Sciences; The Knowledge Foundation; Avonova; SATS; Itrim
Not yet recruiting
-
Posted: February 7th, 2024, 3:00am GMT
Conditions: Autoimmune Encephalitis Associated With Anti-CAPR2 Antibodies
Interventions: Other: Retrospective evaluation of specific brain MRI features
Sponsors: Hospices Civils de Lyon
Recruiting
-
Posted: February 6th, 2024, 3:00am GMT
Conditions: Medullary Thyroid Cancer; Medullary Carcinoma; Medullary Tumor; Medullary Neoplasms; Desmoplasia; Desmoplastic; Desmoplastic Reaction; Lymph Node Metastasis; Lymph Node Disease
Sponsors: Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Completed
-
Posted: February 6th, 2024, 3:00am GMT
Conditions: Nasopharyngeal Carcinoma; Radiation-Induced Temporal Lobe Injury
Interventions: Radiation: intensity-modulated radiotherapy
Sponsors: Jiangsu Cancer Institute & Hospital
Completed
-
Posted: February 6th, 2024, 3:00am GMT
Conditions: Giant Cell Arteritis; Temporal Arteritis; Clonal Hematopoiesis of Indeterminate Potential; Horton Disease; Systemic Vasculitis Primary
Interventions: Diagnostic Test: Temporal arterial biopsy; Diagnostic Test: Whole exome sequencing; Diagnostic Test: Single cell transcriptomics
Sponsors: ASST Fatebenefratelli Sacco
Not yet recruiting
-
Posted: February 5th, 2024, 3:00am GMT
Conditions: Glioma; Astrocytoma; Anaplastic Astrocytoma; Oligodendroglioma; Glioblastoma Multiforme
Interventions: Diagnostic Test: PSMA PET-CT
Sponsors: All India Institute of Medical Sciences, Bhubaneswar
Not yet recruiting
-
Posted: February 5th, 2024, 3:00am GMT
Conditions: Stroke; High Blood Pressure
Interventions: Other: Mat Pilates
Sponsors: Rio de Janeiro State University; Postgraduate scholarship
Available
-
Posted: February 5th, 2024, 3:00am GMT
Conditions: SCLC,Extensive Stage; Brain Metastases
Interventions: Radiation: HA-WBRT plus SBRT
Sponsors: Fudan University
Recruiting
-
Posted: February 5th, 2024, 3:00am GMT
Conditions: Acute Ischemic Stroke
Interventions: Other: not have
Sponsors: Zhujiang Hospital
Recruiting
-
Posted: February 5th, 2024, 3:00am GMT
Conditions: Prostate Cancer; Prostatic Hyperplasia; Prostatic Neoplasms; Prostate Cancer Metastatic; Neuroendocrine Tumors; Neuroendocrine Carcinoma
Interventions: Diagnostic Test: J-PET scan
Sponsors: Jagiellonian University; University Hospital in Krakow
Recruiting
-
Posted: February 5th, 2024, 3:00am GMT
Conditions: Parkinson Disease; Epilepsy
Interventions: Procedure: High Resolution Electroencephalogram (EEG-HR); Procedure: Stereo-electro-encephalography (SEEG)
Sponsors: University Hospital, Bordeaux
Recruiting
-
Posted: February 2nd, 2024, 3:00am GMT
Conditions: Non-small Cell Lung Cancer; Brain Metastases; EGFR Gene Mutation
Interventions: Combination Product: Nitroglycerin
Sponsors: Instituto Nacional de Cancerologia de Mexico
Recruiting
-
Posted: February 2nd, 2024, 3:00am GMT
Conditions: Systemic Lupus Erythematosus
Interventions: Drug: Gusacitinib
Sponsors: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Not yet recruiting
-
Posted: February 2nd, 2024, 3:00am GMT
Conditions: Breast Cancer; Triple Negative Breast Cancer
Interventions: Radiation: Stereotactic Radiation; Drug: Zimberelimab; Drug: Sacituzumab govitecan
Sponsors: H. Lee Moffitt Cancer Center and Research Institute; Gilead Sciences
Not yet recruiting
-
Posted: February 2nd, 2024, 3:00am GMT
Conditions: Prostate Adenocarcinoma; Localized Prostate Carcinoma
Interventions: Procedure: Single-port extraperitoneal robotic-assisted radical prostatectomy with Vattikuti Institute Prostatectomy(VIP) techniques; Procedure: Multi-port transperitoneal robotic-assisted radical prostatectomy with bilateral intrafascial nerve-sparing techniques
Sponsors: Shanghai Changzheng Hospital; Shanghai Zhongshan Hospital; ShuGuang Hospital; The Third Affiliated Hospital of Naval Medical University; The First Affiliated Hospital of Guangzhou Medical University; Sir Run Run Shaw Hospital; Sichuan Provincial People's Hospital
Recruiting
-
Posted: February 1st, 2024, 3:00am GMT
Conditions: Hepatocellular Carcinoma; Liver Transplant; Complications
Interventions: Device: D-HOPE machine perfusion; Procedure: Liver transplantation
Sponsors: Azienda Ospedaliero-Universitaria di Modena
Recruiting
-
Posted: February 1st, 2024, 3:00am GMT
Conditions: Mild Cognitive Impairment
Interventions: Other: Thai dance with twenty-five squares (TDT); Other: Control (CON)
Sponsors: Chulalongkorn University
Recruiting
-
Posted: January 31st, 2024, 3:00am GMT
Conditions: Glioma
Interventions: Diagnostic Test: CXCR4
Sponsors: Xiao Chen
Recruiting
-
Posted: January 31st, 2024, 3:00am GMT
Conditions: Pituitary Adenoma
Interventions: Procedure: surgery of pituitary adenomas
Sponsors: Beijing Tiantan Hospital
Active, not recruiting
-
Posted: January 30th, 2024, 3:00am GMT
Conditions: Brain Metastases, Adult; Stereotactic Radiotherapy
Interventions: Radiation: iHD-SRT
Sponsors: Ruijin Hospital
Recruiting
-
Posted: January 30th, 2024, 3:00am GMT
Conditions: Stroke
Interventions: Device: Intravenous Laser Irradiation of Blood
Sponsors: Taipei Hospital, Ministry of Health and Welfare
Recruiting
-
Posted: January 29th, 2024, 3:00am GMT
Conditions: Brain Tumor; Bleeding
Interventions: Drug: TRANEXAMIC ACID 1 G in 10 mL INTRAVENOUS INJECTION, SOLUTION; Other: Placebo
Sponsors: Stephen Lownie; Dalhousie University
Recruiting
-
Posted: January 29th, 2024, 3:00am GMT
Conditions: Fertility Preservation
Interventions: Drug: Luveris
Sponsors: Ellen Greenblatt; EMD Serono
Not yet recruiting
-
Posted: January 26th, 2024, 3:00am GMT
Conditions: Pediatric Brain Tumor
Interventions: Diagnostic Test: 11C-MET-PET/RMN
Sponsors: IRCCS San Raffaele
Recruiting
-
Posted: January 26th, 2024, 3:00am GMT
Conditions: Hereditary Tyrosinemia, Type I
Interventions: Drug: Nitisinone
Sponsors: Swedish Orphan Biovitrum
Recruiting
-
Posted: January 26th, 2024, 3:00am GMT
Conditions: Wellness, Psychological; Well-Being, Psychological
Interventions: Dietary Supplement: Levagen+® Palmitoylethanolamide (PEA); Dietary Supplement: Placebo
Sponsors: University of Westminster; Gencor Pacific Group
Active, not recruiting
-
Posted: January 25th, 2024, 3:00am GMT
Conditions: Ischemic Stroke; Arterial Stiffness; Pulse Wave Velocity; Rehabilitation
Interventions: Other: Rehabilitation
Sponsors: Shin Kong Wu Ho-Su Memorial Hospital
Recruiting
-
Posted: January 25th, 2024, 3:00am GMT
Conditions: Dementia; Dementia Alzheimers; Parkinson Disease; Myocardial Infarction
Interventions: Other: dietary acrylamide exposure measured via biomarkers in blood (hemoglobin adducts of acrylamide and glycidamide)
Sponsors: Karolinska Institutet; Stockholm University
Recruiting
-
Posted: January 25th, 2024, 3:00am GMT
Conditions: Cognitive Decline; Cognitive Impairment
Interventions: Other: Walnuts; Other: Simply White Diary-free chocolate bar
Sponsors: Ohio State University; United States Department of Agriculture (USDA); The California Walnut Commission
Recruiting
-
Posted: January 25th, 2024, 3:00am GMT
Conditions: Cerebral Adrenoleukodystrophy (CALD)
Interventions: Other: No Intervention
Sponsors: bluebird bio; Center for International Blood and Marrow Transplant Research
Recruiting
-
Posted: January 24th, 2024, 3:00am GMT
Conditions: Neurofibromatosis 1; Nerve Sheath Neoplasms
Sponsors: National Cancer Institute (NCI)
Not yet recruiting
-
Posted: January 24th, 2024, 3:00am GMT
Conditions: Enhanced Recovery After Surgery; Pituitary Tumor; Postoperative Complications
Interventions: Diagnostic Test: Malnutrition Universal Screening Tool; Device: TIB Olfactory Test Device; Diagnostic Test: Apfel Score for Postoperative nausea and vomiting; Diagnostic Test: The American Society of Anesthesiologists (ASA) Physical Status Classification; Behavioral: Short Form-36; Behavioral: World Health Organization Quality of Life questionnaire (WHOQOL-BREF); Behavioral: BDI-II(Beck Depression Inventory-II); Behavioral: ERAS Patient Satisfaction Questionnaire(ERAS-PSQ); Behavioral: Quality of Recovery-40(QoR-40)
Sponsors: Chang Gung Memorial Hospital
Recruiting
-
Posted: January 24th, 2024, 3:00am GMT
Conditions: Glioblastoma
Interventions: Other: The samples described below will be collected:
Sponsors: Institut Claudius Regaud; NovoCure Ltd.
Not yet recruiting
-
Posted: January 24th, 2024, 3:00am GMT
Conditions: DIPG Brain Tumor; Diffuse Intrinsic Pontine Glioma
Interventions: Biological: B7H3 specific CAR T cell with IL-7Ra signaling domain
Sponsors: Chulalongkorn University; King Chulalongkorn Memorial Hospital
Not yet recruiting
-
Posted: January 23rd, 2024, 3:00am GMT
Conditions: Subarachnoid Hemorrhage, Spontaneous; Subarachnoid Hemorrhage, Aneurysmal
Interventions: Diagnostic Test: biomarkers
Sponsors: Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Recruiting
-
Posted: January 23rd, 2024, 3:00am GMT
Conditions: Breast Carcinoma
Interventions: Behavioral: Mindfulness Relaxation; Procedure: Functional Magnetic Resonance Imaging; Procedure: Biospecimen Collection; Other: Questionnaire Administration
Sponsors: Thomas Jefferson University
Recruiting
-
Posted: January 22nd, 2024, 3:00am GMT
Conditions: Hemangioma, Cavernous, Central Nervous System
Sponsors: Beijing Tiantan Hospital; RenJi Hospital; Beijing Chao Yang Hospital; Beijing Friendship Hospital; Guangzhou Red Cross Hospital; Affiliated Hospital of Guangdong Medical University; Shanxi Provincipal People's Hospital; Qilu Hospital of Shandong University; Central South University; First Affiliated Hospital of Harbin Medical University
Recruiting
-
Posted: January 19th, 2024, 3:00am GMT
Conditions: Coronary Heart Disease
Interventions: Behavioral: Two types of exercise interventions
Sponsors: Universidad de Granada; Instituto Mixto Universitario Deporte y Salud (iMUDS); Centro de Investigación Mente, Cerebro y Comportamiento (CIMCYC); University Hospital Virgen de las Nieves; Hospital Clinico Universitario San Cecilio; Centro de Investigación Biomédica en Red de la Fisiopatología de la Obesidad y Nutrición (CIBEROBN)
Enrolling by invitation
-
Posted: January 18th, 2024, 3:00am GMT
Conditions: Neurodegenerative Diseases; Brain Neoplasms; Neuroendocrine Tumors
Interventions: Diagnostic Test: Positron-Emission Tomography Imaging
Sponsors: Jagiellonian University; Medical University of Warsaw
Completed
-
Posted: January 18th, 2024, 3:00am GMT
Conditions: TNBC; Brain Metastasis
Interventions: Drug: SHR-A1921 + Bevacizumab
Sponsors: Fudan University
Not yet recruiting
-
Posted: January 18th, 2024, 3:00am GMT
Conditions: Locally Recurrent Head and Neck Squamous Cell Carcinoma; Metastatic Head and Neck Squamous Cell Carcinoma; Refractory Head and Neck Squamous Cell Carcinoma
Interventions: Drug: Losartan; Biological: Pembrolizumab; Radiation: Stereotactic Body Radiation Therapy
Sponsors: Shyam S.D. Rao; National Cancer Institute (NCI)
Recruiting
-
Posted: January 18th, 2024, 3:00am GMT
Conditions: Solid Tumor
Interventions: Drug: IPG1094
Sponsors: Nanjing Immunophage Biotech Co., Ltd
Not yet recruiting
-
Posted: January 17th, 2024, 3:00am GMT
Conditions: Frailty; Frail Elderly Syndrome; Frailty Syndrome; Aging
Interventions: Dietary Supplement: Nicotinamide Riboside (NR); Other: Placebo
Sponsors: Haukeland University Hospital
Not yet recruiting
-
Posted: January 17th, 2024, 3:00am GMT
Conditions: High-grade Glioma; Brain Metastases; Brain Metastases, Adult
Interventions: Diagnostic Test: 68Ga-PSMA-11 PET Scans
Sponsors: Memorial Sloan Kettering Cancer Center
Recruiting
-
Posted: January 17th, 2024, 3:00am GMT
Conditions: Childhood Cancer; Childhood Solid Tumor; Childhood Brain Tumor; Recurrent Cancer; Refractory Cancer
Interventions: Drug: Paxalisib, Irinotecan, Temozolomide; Drug: Pimasertib
Sponsors: Australian & New Zealand Children's Haematology/Oncology Group; Children's Cancer Institute Australia (CCIA); The Hospital for Sick Children; Medical Research Future Fund; Kazia Therapeutics Limited; Day One Biopharmaceuticals, Inc.; C17 Council
Not yet recruiting
-
Posted: January 15th, 2024, 3:00am GMT
Conditions: Biochemically Recurrent Prostate Carcinoma; Oligometastatic Prostate Carcinoma; Recurrent Prostate Adenocarcinoma; Stage IIB Prostate Cancer AJCC v8; Stage IIC Prostate Cancer AJCC v8; Stage III Prostate Cancer AJCC v8; Stage IV Prostate Cancer AJCC v8
Interventions: Drug: Antiandrogen Therapy; Procedure: Biospecimen Collection; Procedure: Bone Scan; Radiation: Hypofractionated Radiation Therapy; Procedure: Magnetic Resonance Imaging; Procedure: Positron Emission Tomography; Radiation: Stereotactic Body Radiation Therapy; Other: Survey Administration
Sponsors: Mayo Clinic
Recruiting
-
Posted: January 15th, 2024, 3:00am GMT
Conditions: Dementia
Sponsors: KU Leuven; Odisee University College
Not yet recruiting
-
Posted: January 15th, 2024, 3:00am GMT
Conditions: Irritable Bowel Syndrome
Interventions: Drug: TRYP-0082; Behavioral: Psychotherapy
Sponsors: TRYP Therapeutics
Recruiting
-
Posted: January 12th, 2024, 3:00am GMT
Conditions: ALS; Amyotrophic Lateral Sclerosis; Alzheimer Disease; Alzheimer Disease, Early Onset; Alzheimer Disease, Late Onset; Batten Disease; Corticobasal Degeneration; Dementia; Frontotemporal Dementia; Huntington Disease; Lewy Body Disease; Multiple Sclerosis; Multiple System Atrophy; Parkinson Disease; Parkinson's Disease and Parkinsonism; Progressive Supranuclear Palsy; INAD; Diabetes; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetes Mellitus, Type 1; Macular Degeneration; Ovarian Cancer; Cervical Cancer; Uterine Cancer; Vaginal Cancer; Vulvar Cancer; PTSD; Post Traumatic Stress Disorder
Interventions: Other: Biological Sample Collection
Sponsors: New York Stem Cell Foundation Research Institute
Recruiting
-
Posted: January 12th, 2024, 3:00am GMT
Conditions: Polycystic Ovary Syndrome
Interventions: Behavioral: Time-restricted eating
Sponsors: Joanna Bajerska
Recruiting
-
Posted: January 12th, 2024, 3:00am GMT
Conditions: Nervous System Diseases (C10 Unique ID D009422)
Sponsors: National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting
-
Posted: January 12th, 2024, 3:00am GMT
Conditions: Cancer
Interventions: Behavioral: resistance exercise and walking
Sponsors: Taipei Medical University
Recruiting
-
Posted: January 11th, 2024, 3:00am GMT
Conditions: Metastasis; Predictive Cancer Model
Sponsors: Fudan University
Recruiting
-
Posted: January 10th, 2024, 3:00am GMT
Conditions: Brain Malignancies; Pseudoprogression
Interventions: Procedure: MRI Scan; Procedure: CT Scan; Procedure: Biopsy
Sponsors: M.D. Anderson Cancer Center
Not yet recruiting
-
Posted: January 10th, 2024, 3:00am GMT
Conditions: Fear; Anxiety; Breast Cancer; Lung Cancer; Prostate Cancer; Head and Neck Cancer; Brain Tumor
Interventions: Other: Questionnaire: SPIRIT; Other: Questionnaire: HADS; Other: Questionnaire: QSC-R23; Other: General questions; Other: Clinical data collected
Sponsors: Maastricht Radiation Oncology
Recruiting
-
Posted: January 10th, 2024, 3:00am GMT
Conditions: Dementia; Caregiver Burden; Quality of Life
Interventions: Dietary Supplement: Jing Si Herbal Tea; Dietary Supplement: Barley Tea
Sponsors: National Cheng Kung University; Buddhist Tzu Chi General Hospital; Tzu Chi University; E-DA Hospital
Not yet recruiting
-
Posted: January 10th, 2024, 3:00am GMT
Conditions: Glioma
Interventions: Other: Survival state
Sponsors: Tang-Du Hospital
Completed
-
Posted: January 9th, 2024, 3:00am GMT
Conditions: Glioma, Malignant
Interventions: Drug: Rivaroxaban 10 MG; Drug: Placebo
Sponsors: Nanfang Hospital, Southern Medical University
Recruiting
-
Posted: January 8th, 2024, 3:00am GMT
Conditions: Melanoma
Interventions: Drug: Defactinib; Drug: Avutometinib; Drug: Encorafenib
Sponsors: University of Utah; Verastem, Inc.
Recruiting
-
Posted: January 5th, 2024, 3:00am GMT
Conditions: Parkinson Disease; Prodromal Stage; Neurodegenerative Diseases; Parkinsonian Disorders; REM Sleep Behavior Disorder; Basal Ganglia Diseases; Central Nervous System Diseases; Synucleinopathies; Nervous System Diseases; Cerebral Disorder; Brain Diseases
Interventions: Behavioral: Increase of physical activity volume and intensity with the use of a motivational smartphone application
Sponsors: Radboud University Medical Center; Stichting ParkinsonNL; ZonMw: The Netherlands Organisation for Health Research and Development; Michael J. Fox Foundation for Parkinson's Research; PARKINSONS UK; Cure Parkinsons; Edmond J. Safra Foundation; Davis Phinney Foundation; Donders Centre for Cognitive Neuroimaging, Radboud University Nijmegen; Anne Wojcicki Foundation; Sleep Medicine Centre Kempenhaeghe; Sleep Medicine Centre SEIN; Queen Mary University of London; 23andMe, Inc.; Parkinsons Progression Markers Initiative (PPMI); Massachusetts General Hospital; Harvard School of Public Health (HSPH); IJsfontein B.V., Netherlands; Hoffmann-La Roche; Erasmus Medical Center; University of Illinois at Chicago; University of Rochester; University of Bristol; University of Plymouth; University of Luebeck; McGill University; University of Pittsburgh
Recruiting
-
Posted: January 5th, 2024, 3:00am GMT
Conditions: Brain Tumor
Interventions: Biological: Multi-tumor antigen specific cytotoxic T lymphocytes (TSA-T) directed against proteogenomically determined personalized tumor-specific antigens (TSA)
Sponsors: Children's National Research Institute
Not yet recruiting
-
Posted: January 5th, 2024, 3:00am GMT
Conditions: Recurrent Malignant Glioma; Glioblastoma Multiforme of Brain; Gliosarcoma of Brain; Anaplastic Astrocytoma of Brain
Interventions: Drug: C134 Re-Administration
Sponsors: University of Alabama at Birmingham
Not yet recruiting
-
Posted: January 4th, 2024, 3:00am GMT
Conditions: Esophageal Squamous Cell Carcinoma; Oligometastatic Disease; Radiotherapy
Interventions: Combination Product: PD-1 inhibitor+/- chemotherapy combined with local therapy; Drug: PD-1 inhibitor+/- chemotherapy alone
Sponsors: Fudan University
Recruiting
-
Posted: January 4th, 2024, 3:00am GMT
Conditions: Hypogonadism; Malignant Testicular Germ Cell Tumor
Interventions: Procedure: 7 Tesla Magnetic Resonance Imaging; Procedure: Biospecimen Collection; Procedure: Cognitive Assessment
Sponsors: University of Southern California; National Cancer Institute (NCI)
Recruiting
-
Posted: January 4th, 2024, 3:00am GMT
Conditions: HDL; Coronary Heart Disease
Sponsors: Beijing Tsinghua Chang Gung Hospital; Guangdong Guosheng Medical Technology
Recruiting
-
Posted: January 3rd, 2024, 3:00am GMT
Conditions: Small Cell Lung Cancer Extensive Stage
Interventions: Radiation: thoracic radiotherapy
Sponsors: Fudan University
Recruiting
-
Posted: January 1st, 2024, 3:00am GMT
Conditions: Glioblastoma Multiforme of Brain
Interventions: Drug: Cisplatin Plus Temozolomide; Drug: Temozolomide
Sponsors: Zhongnan Hospital
Not yet recruiting
-
Posted: December 29th, 2023, 3:00am GMT
Conditions: Brain Tumor, Primary
Interventions: Other: Cognitive testing; Device: Resting State MRI/Precision functional mapping
Sponsors: Washington University School of Medicine
Not yet recruiting
-
Posted: December 28th, 2023, 3:00am GMT
Conditions: Glioblastoma
Interventions: Diagnostic Test: Extended MRI
Sponsors: Erasmus Medical Center
Recruiting
-
Posted: March 23rd, 2022, 2:00am GMT
Conditions: Primary Liver Cancer; Hepatocellular Carcinoma; Intrahepatic Cholangiocarcinoma; Combined Hepatocellular-cholangiocarcinoma
Interventions: Other: Observation
Sponsors: Geneplus-Beijing Co. Ltd.; Eastern Hepatobiliary Surgery Hospital
Withdrawn
-
Posted: March 18th, 2022, 2:00am GMT
Conditions: Metastatic Colorectal Cancer (Mcrc); Intrahepatic Cholangiocarcinoma (Icc); Colorectal Cancer; Colorectal Neoplasms; Cholangiocarcinoma; Intrahepatic Bile Duct Cancer; Bile Duct Cancer; Bile Duct Neoplasms
Interventions: Drug: Floxuridine; Drug: 5-Fluorouracil; Drug: Irinotecan; Device: Intera 3000 Hepatic Artery Infusion Pump (HAIP); Drug: Oxaliplatin; Drug: Leucovorin; Drug: M9241; Drug: Gemcitabine; Drug: Dexamethasone
Sponsors: National Cancer Institute (NCI)
Recruiting
-
Posted: March 17th, 2022, 2:00am GMT
Conditions: Distal Bile Duct Adenocarcinoma; Gallbladder Carcinoma; Intrahepatic Cholangiocarcinoma; Metastatic Malignant Neoplasm in the Peritoneum; Stage IV Distal Bile Duct Cancer AJCC v8; Stage IV Intrahepatic Bile Duct Cancer AJCC v8; Stage IV Intrahepatic Cholangiocarcinoma AJCC v8; Stage IVB Gallbladder Cancer AJCC v8
Interventions: Drug: Cisplatin; Drug: Gemcitabine; Drug: Nab-paclitaxel; Other: Quality-of-Life Assessment; Other: Questionnaire Administration
Sponsors: City of Hope Medical Center; National Cancer Institute (NCI)
Recruiting
-
Posted: March 11th, 2022, 3:00am GMT
Conditions: Locally Advanced Solid Tumor
Interventions: Drug: TNG908
Sponsors: Tango Therapeutics, Inc.
Recruiting
-
Posted: February 22nd, 2022, 3:00am GMT
Conditions: Pancreatic Cancer; Pancreas Cancer; Ampullary Cancer; Pancreas Neuroendocrine Tumor; Pancreatitis; Distal Extrahepatic Cholangiocarcinoma; Duodenal Cancer
Interventions: Drug: Placebo; Drug: Pantoprazole
Sponsors: Washington University School of Medicine
Active, not recruiting
-
Posted: February 16th, 2022, 3:00am GMT
Conditions: Solid Tumor, Adult; Intrahepatic Cholangiocarcinoma; Urothelial Carcinoma
Interventions: Drug: KIN-3248
Sponsors: Kinnate Biopharma
Active, not recruiting
-
Posted: February 14th, 2022, 3:00am GMT
Conditions: Biliary Tract Cancer (CCA); Intrahepatic Cholangiocarcinoma; Hilar Cholangiocarcinoma; Distal Cholangiocarcinoma; Gall Bladder Carcinoma
Interventions: Drug: Durvalumab; Drug: Tremelimumab; Drug: Capecitabine
Sponsors: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Active, not recruiting
-
Posted: February 11th, 2022, 3:00am GMT
Conditions: Intrahepatic Cholangiocarcinoma
Interventions: Combination Product: DEB-TACE combined with Surufatinib and Camrelizumab
Sponsors: Tongji Hospital
Recruiting
-
Posted: February 4th, 2022, 3:00am GMT
Conditions: Hepatocellular Carcinoma; Intrahepatic Cholangiocarcinoma
Interventions: Drug: VG161; Drug: Nivolumab Injection [Opdivo]
Sponsors: Virogin Biotech Canada Ltd
Recruiting
-
Posted: February 2nd, 2022, 3:00am GMT
Conditions: Hepatocellular Carcinoma; Intrahepatic Cholangiocarcinoma
Interventions: Drug: SD-101; Biological: Pembrolizumab; Biological: Nivolumab; Biological: Ipilimumab
Sponsors: TriSalus Life Sciences, Inc.
Active, not recruiting
-
Posted: February 1st, 2022, 3:00am GMT
Conditions: Rare Malignant Neoplasm
Interventions: Other: Genomic sequence
Sponsors: National Cancer Center, Japan
Recruiting
-
Posted: January 31st, 2022, 3:00am GMT
Conditions: Pancreatic Cancer; Breast Cancer; Gastric Cancer; Non-small Cell Lung Cancer; Cervical Cancer; Endocervical Cancer; Squamous Cell Carcinoma of Head and Neck; Bladder Urothelial Cancer; Colorectal Carcinoma; Esophageal Cancer; Ovarian Cancer; Renal Cell Carcinoma; Prostate Cancer; Melanoma; Mesothelioma; Cholangiocarcinoma
Interventions: Drug: NGM831; Drug: NGM831 plus pembrolizumab (KEYTRUDA®); Drug: NGM831 and NGM438 plus pembrolizumab (KEYTRUDA®)
Sponsors: NGM Biopharmaceuticals, Inc; Merck Sharp & Dohme LLC
Recruiting
-
Posted: January 27th, 2022, 3:00am GMT
Conditions: Combined Hepatocellular Carcinoma and Cholangiocarcinoma; Stage III Liver Cancer; Stage IV Liver Cancer
Interventions: Biological: Atezolizumab; Biological: Bevacizumab; Procedure: Biospecimen Collection; Drug: Cisplatin; Procedure: Computed Tomography; Procedure: Conventional Magnetic Resonance Imaging; Drug: Gemcitabine Hydrochloride
Sponsors: National Cancer Institute (NCI)
Recruiting
-
Posted: January 27th, 2022, 3:00am GMT
Conditions: Biliary Stones; Cholangiocarcinoma, Intrahepatic; Biliary Stricture; Cholelithiasis; Choledocholithiasis
Interventions: Procedure: Percutaneous cholangiopancreatoscopy
Sponsors: Johns Hopkins University
Recruiting
-
Posted: January 18th, 2022, 3:00am GMT
Conditions: Ovarian Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Triple Negative Breast Neoplasms; HER2 Negative Breast Neoplasms; Hormone Receptor Positive Breast Neoplasms; Endometrial Neoplasms; Carcinoma, Non-Small-Cell Lung; Cholangiocarcinoma; Gallbladder Carcinoma; Adenoid Cystic Carcinoma
Interventions: Drug: SGN-B7H4V
Sponsors: Seagen Inc.
Recruiting
-
Posted: January 11th, 2022, 3:00am GMT
Conditions: Gynecologic Cancer; Gynecologic Neoplasms; Peritoneal Carcinomatosis; Peritoneal Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Colorectal Cancer; Colorectal Neoplasms; Appendiceal Cancer; Appendiceal Neoplasms
Interventions: Drug: Paclitaxel; Drug: Nilotinib
Sponsors: National Cancer Institute (NCI)
Recruiting
-
Posted: January 11th, 2022, 3:00am GMT
Conditions: Cholangiocarcinoma; Pancreatic Cancer; Sclerosing Cholangitis
Interventions: Procedure: Endoscopic retrograde Cholangio- pancreatography; Procedure: Endoscopic ultrasound
Sponsors: Region Stockholm; Karolinska Institutet
Recruiting
-
Posted: December 28th, 2021, 3:00am GMT
Conditions: Advanced Biliary Tract Cancer
Interventions: Drug: Lenvatinib Pill,Paclitaxel
Sponsors: National Health Research Institutes, Taiwan; National Cheng-Kung University Hospital; National Taiwan University Hospital; Kaohsiung Medical University Chung-Ho Memorial Hospital; Taipei Veterans General Hospital, Taiwan; Chang Gung Memorial Hospital; China Medical University, Taiwan
Recruiting
-
Posted: November 24th, 2021, 3:00am GMT
Conditions: Immune System
Interventions: Other: blood samples
Sponsors: Servier
Terminated
-
Posted: November 17th, 2021, 3:00am GMT
Conditions: Cholangiocarcinoma, Intrahepatic
Interventions: Drug: Recombinant Human Adenovirus Type 5; Drug: HAIC of FOLFOX
Sponsors: Beijing Tsinghua Chang Gung Hospital
Recruiting
-
Posted: October 1st, 2021, 2:00am GMT
Conditions: Hepatocellular Carcinoma; Hepatocellular Cancer; Hepatitis B; Cirrhosis; Liver Cancer
Interventions: Device: Study CT/MRI Imaging; Device: Standard of Care CT/MRI Imaging; Diagnostic Test: Oncoguard™ Liver Test
Sponsors: Exact Sciences Corporation
Recruiting
-
Posted: September 10th, 2021, 2:00am GMT
Conditions: Cholangiocarcinoma,Adult
Interventions: Drug: 3D185
Sponsors: 3D Medicines (Beijing) Co., Ltd.
Not yet recruiting
-
Posted: August 27th, 2021, 2:00am GMT
Conditions: Perihilar Cholangiocarcinoma
Interventions: Drug: oxaliplatin and 5-fluorouracil; Procedure: Biliary Drainage; Other: Best Supportive Care; Procedure: External biliary drainage
Sponsors: Peking University
Recruiting
-
Posted: August 16th, 2021, 2:00am GMT
Conditions: Uterine Cervical Neoplasms; Endometrial Neoplasms; Squamous Cell Carcinoma of Head and Neck; Gallbladder Neoplasms; Cholangiocarcinoma; Esophageal Neoplasms; Triple Negative Breast Neoplasms; Hepatocellular Carcinoma; Urinary Bladder Neoplasms; Ovarian Neoplasms; Stomach Neoplasms
Interventions: Biological: Pembrolizumab/Vibostolimab Co-Formulation; Biological: Pembrolizumab; Drug: Lenvatinib; Drug: 5-Fluorouracil; Drug: Cisplatin; Drug: Paclitaxel; Drug: Gemcitabine; Drug: Carboplatin; Drug: Docetaxel; Drug: Bevacizumab; Drug: Capecitabine; Drug: Oxaliplatin
Sponsors: Merck Sharp & Dohme LLC
Recruiting
-
Posted: August 6th, 2021, 2:00am GMT
Conditions: Perihilar Cholangiocarcinoma; Klatskin Tumor; Bile Duct Cancer
Interventions: Procedure: Liver transplant
Sponsors: Oslo University Hospital
Recruiting
-
Posted: August 4th, 2021, 2:00am GMT
Conditions: Cholangiocarcinoma
Interventions: Drug: Novel combination of chemotherapy and immunotherapy
Sponsors: University of Alabama at Birmingham
Active, not recruiting
-
Posted: August 2nd, 2021, 2:00am GMT
Conditions: Stage III Breast Cancer; Stage IV Breast Cancer; Stage III Lung Cancer; Stage IV Lung Cancer; AML; Multiple Myeloma in Relapse; Carcinoma; Carcinoma, Pancreatic; Carcinoma of Lung; Carcinoma, Non-Small-Cell Lung; Carcinoma Breast; Carcinoma Prostate; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Carcinoma, Neuroendocrine; Carcinoma, Small Cell Lung; Carcinoma, Ovarian; Carcinoma Bladder; Carcinoma of Esophagus; Carcinoma Cervix; Carcinoma, Thymic; Carcinoma, Ductal; Carcinoma of the Head and Neck; Carcinoma of the Lip; Carcinoma of the Oral Cavity; Carcinoma of Unknown Primary; Carcinoma of the Skin; Carcinoma of the Anus; Carcinoma of the Larynx; Carcinoma of the Penis; Carcinoma of the Oropharynx; Carcinoma of the Appendix; Carcinoma of the Paranasal Sinus; Carcinoma of the Vulva; Malignant Pleural Effusion; Malignant Ascites; Mesothelioma; Cholangiocarcinoma
Sponsors: Travera Inc
Not yet recruiting
-
Posted: July 22nd, 2021, 2:00am GMT
Conditions: Solid Tumors, KRAS Mutation
Interventions: Drug: BI 1823911; Drug: BI 1701963; Drug: Midazolam
Sponsors: Boehringer Ingelheim
Active, not recruiting
-
Posted: July 21st, 2021, 2:00am GMT
Conditions: Advanced Biliary Tract Cancer; Neuroendocrine Tumors; Female Reproductive System Neoplasm; MSI-H Solid Malignant Tumor
Interventions: Drug: Ipilimumab; Drug: Nivolumab
Sponsors: Olivia Newton-John Cancer Research Institute; Bristol-Myers Squibb
Active, not recruiting
-
Posted: June 28th, 2021, 2:00am GMT
Conditions: Metastatic Distal Bile Duct Adenocarcinoma; Metastatic Gallbladder Carcinoma; Metastatic Intrahepatic Cholangiocarcinoma; Recurrent Distal Bile Duct Adenocarcinoma; Recurrent Gallbladder Carcinoma; Recurrent Intrahepatic Cholangiocarcinoma; Stage IV Distal Bile Duct Cancer AJCC v8; Stage IV Gallbladder Cancer AJCC v8; Stage IV Intrahepatic Cholangiocarcinoma AJCC v8; Unresectable Liver and Intrahepatic Bile Duct Carcinoma
Interventions: Biological: Atezolizumab; Procedure: Biopsy; Procedure: Biospecimen Collection; Drug: Cobimetinib; Procedure: Computed Tomography; Procedure: Magnetic Resonance Imaging; Drug: Varlilumab
Sponsors: National Cancer Institute (NCI)
Active, not recruiting
-
Posted: June 23rd, 2021, 2:00am GMT
Conditions: Biliary Tract Cancer
Sponsors: GERCOR - Multidisciplinary Oncology Cooperative Group
Recruiting
-
Posted: June 18th, 2021, 2:00am GMT
Conditions: Metastatic Cancer; Foregut Carcinoid Tumor; Gastric Adenocarcinoma; Gallbladder Adenocarcinoma; Liver Cancer; GI Cancer; GI Carcinoma; Lung Cancer
Interventions: Drug: Standard of Care Chemotherapy; Procedure: Video-Assisted Thoracic Surgery (VATS); Procedure: Lobectomy; Radiation: Consolidative Radiation; Radiation: Ablation Treatment; Procedure: Resection or Excision; Procedure: Peritonectomy; Other: Transarterial Radioembolization
Sponsors: University of Chicago
Not yet recruiting
-
Posted: June 11th, 2021, 2:00am GMT
Conditions: Biliary Tract Carcinoma
Interventions: Biological: Pembrolizumab; Drug: Gemcitabine; Drug: Cisplatin; Drug: Placebo
Sponsors: Merck Sharp & Dohme LLC
Active, not recruiting
-
Posted: June 9th, 2021, 2:00am GMT
Conditions: Cholangiocarcinoma; FGFR2 Fusion; FGFR2 Gene Mutation; FGFR1 Alteration; FGFR3 Alteration
Interventions: Drug: TT-00420
Sponsors: TransThera Sciences (Nanjing), Inc.
Active, not recruiting
-
Posted: June 1st, 2021, 2:00am GMT
Conditions: Advanced Solid Tumours
Interventions: Drug: RXC004; Drug: RXC004; Drug: RXC004; Biological: Denosumab; Biological: pembrolizumab
Sponsors: Redx Pharma Plc; Merck Sharp & Dohme LLC
Completed
-
Posted: May 18th, 2021, 2:00am GMT
Conditions: Intrahepatic Cholangiocarcinoma
Interventions: Drug: Gemcitabine; Drug: Oxaliplatin; Drug: Dexamethasone; Drug: Floxuridine (FUDR); Device: Implanted Medical Device
Sponsors: Memorial Sloan Kettering Cancer Center
Recruiting
-
Posted: May 4th, 2021, 2:00am GMT
Conditions: Biliary Tract Cancer; Cholangiocarcinoma; Gallbladder Cancer
Interventions: Drug: nab-paclitaxel plus gemcitabine-cisplatin
Sponsors: CHA University; Dong-A Pharmaceutical
Recruiting
-
Posted: April 21st, 2021, 2:00am GMT
Conditions: Minimal Residual Disease; KRAS G12D; KRAS G12R; NRAS G12D; NRAS G12R; Pancreatic Ductal Adenocarcinoma; Colorectal Cancer; Non-small Cell Lung Cancer; Ovarian Cancer; Cholangiocarcinoma; Bile Duct Cancer; Gallbladder Carcinoma
Interventions: Drug: ELI-002 2P
Sponsors: Elicio Therapeutics
Active, not recruiting
-
Posted: March 16th, 2021, 2:00am GMT
Conditions: Unresectable Hilar Cholangiocarcinoma
Interventions: Procedure: REMS+TAI; Procedure: SEMS+TAI
Sponsors: Zhongda Hospital
Completed
-
Posted: February 21st, 2021, 3:00am GMT
Conditions: Isocitrate Dehydrogenase Gene Mutation
Interventions: Drug: HMPL-306
Sponsors: Hutchmed
Active, not recruiting
-
Posted: February 15th, 2021, 3:00am GMT
Conditions: Primary Sclerosing Cholangitis; PSC; Cholangiocarcinoma
Sponsors: Mayo Clinic; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting
-
Posted: January 13th, 2021, 3:00am GMT
Conditions: Locally Advanced Intrahepatic Cholangiocarcinoma; Metastatic Intrahepatic Cholangiocarcinoma; Stage III Intrahepatic Cholangiocarcinoma AJCC v8; Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8; Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8; Stage IV Intrahepatic Cholangiocarcinoma AJCC v8
Interventions: Drug: Bintrafusp Alfa; Procedure: Biopsy; Radiation: Hypofractionated Radiation Therapy
Sponsors: M.D. Anderson Cancer Center
Active, not recruiting
-
Posted: December 21st, 2020, 3:00am GMT
Conditions: Hepatocellular Carcinoma; Liver Metastases; Cholangiocarcinoma
Interventions: Drug: STP705
Sponsors: Sirnaomics; Translational Drug Development
Completed
-
Posted: December 17th, 2020, 3:00am GMT
Conditions: Metastatic Cancer; Solid Tumor
Interventions: Drug: Sym021; Drug: Sym024
Sponsors: Symphogen A/S
Active, not recruiting
-
Posted: December 14th, 2020, 3:00am GMT
Conditions: Metastatic Cancer; Solid Tumor; Pancreatic Cancer; Urothelial Carcinoma; Head and Neck Cancer; Colorectal Cancer
Interventions: Drug: LYT-200; Drug: Tislelizumab; Drug: Gemcitabine/nab-paclitaxel
Sponsors: PureTech
Recruiting
-
Posted: December 9th, 2020, 3:00am GMT
Conditions: HER2-positive; Adenocarcinoma; Bile Duct Cancer; Biliary Tract Cancer; Bladder Cancer; Breast Cancer; Breast Neoplasm; Carcinoma, Ductal; Carcinoma, Hepatocellular; Cancer; Lung Cancer, Non-Small-Cell; Carcinoma, Ovarian Epithelial; Carcinoma, Small Cell; Carcinoma, Squamous; Carcinoma, Transitional Cell; Colorectal Cancer; Esophagogastric Junction Neoplasms; Inflammatory Breast Cancer; Stomach Neoplasms; Malignant Neoplasms; Ovarian Neoplasms; Pancreatic Cancer; HER2-positive Solid Tumors; HER2-positive Breast Cancer; HER2-positive Gastric Cancer; HER-2 Protein Overexpression; HER-2 Gene Amplification; Prostate Cancer; Head and Neck Cancer; Endometrial Cancer; Lung Cancer, Small Cell
Interventions: Biological: CT-0508; Biological: Pembrolizumab
Sponsors: Carisma Therapeutics Inc
Active, not recruiting
-
Posted: September 23rd, 2020, 2:00am GMT
Conditions: Biliary Tract Cancer; Cholangiocarcinoma; Gallbladder Cancer; Intrahepatic Cholangiocarcinoma; Perihilar Cholangiocarcinoma; Extrahepatic Cholangiocarcinoma; Hilar Cholangiocarcinoma; Distal Bile Duct Cancer
Interventions: Diagnostic Test: Multi-Platform Profiling with Organoid Drug Sensitivity Screening and ctDNA Monitoring
Sponsors: University of Washington; Natera, Inc.; SEngine Precision Medicine, Inc.
Recruiting
-
Posted: September 16th, 2020, 2:00am GMT
Conditions: Advanced Biliary Tract Carcinoma
Interventions: Drug: Pembrolizumab Injection [Keytruda]; Drug: Lenvatinib Mesylate
Sponsors: Shanghai Jiahui International Hospital; Shanghai Zhongshan Hospital
Recruiting
-
Posted: August 25th, 2020, 2:00am GMT
Conditions: FGFR2 Amplification; FGFR2 Gene Mutation; FGFR2 Gene Fusion/Rearrangement; FGFR2 Gene Translocation; FGFR2 Gene Activation; Intrahepatic Cholangiocarcinoma; Cholangiocarcinoma; Other Solid Tumors, Adult
Interventions: Drug: RLY-4008
Sponsors: Relay Therapeutics, Inc.
Active, not recruiting
-
Posted: August 11th, 2020, 2:00am GMT
Conditions: Advanced Cholangiocarcinoma
Interventions: Drug: TAS-120
Sponsors: Taiho Oncology, Inc.
Approved for marketing
-
Posted: July 30th, 2020, 2:00am GMT
Conditions: Advanced Bile Duct Carcinoma; Advanced Breast Carcinoma; Advanced Cervical Carcinoma; Advanced Endometrial Carcinoma; Advanced Esophageal Carcinoma; Advanced Gastric Carcinoma; Advanced Head and Neck Carcinoma; Advanced Lung Non-Small Cell Carcinoma; Advanced Lung Small Cell Carcinoma; Advanced Malignant Solid Neoplasm; Advanced Ovarian Carcinoma; Advanced Penile Carcinoma; Advanced Pleural Malignant Mesothelioma; Advanced Urothelial Carcinoma; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Clinical Stage III Gastric Cancer AJCC v8; Clinical Stage IV Gastric Cancer AJCC v8; Stage III Cervical Cancer AJCC v8; Stage III Distal Bile Duct Cancer AJCC v8; Stage III Intrahepatic Bile Duct Cancer AJCC v8; Stage III Lung Cancer AJCC v8; Stage III Ovarian Cancer AJCC v8; Stage III Penile Cancer AJCC v8; Stage III Pleural Malignant Mesothelioma AJCC v8; Stage IV Cervical Cancer AJCC v8; Stage IV Distal Bile Duct Cancer AJCC v8; Stage IV Intrahepatic Bile Duct Cancer AJCC v8; Stage IV Lung Cancer AJCC v8; Stage IV Ovarian Cancer AJCC v8; Stage IV Penile Cancer AJCC v8; Stage IV Pleural Malignant Mesothelioma AJCC v8; Triple-Negative Breast Carcinoma; Unresectable Urothelial Carcinoma
Interventions: Drug: Cisplatin; Drug: Elimusertib; Drug: Gemcitabine Hydrochloride
Sponsors: National Cancer Institute (NCI)
Active, not recruiting
-
Posted: June 12th, 2020, 2:00am GMT
Conditions: Colorectal Carcinoma; Gastric Adenocarcinoma; GEJ Adenocarcinoma; Esophageal Adenocarcinoma; Cholangiocarcinoma; Gallbladder Carcinoma
Interventions: Drug: tucatinib; Drug: trastuzumab; Drug: oxaliplatin; Drug: leucovorin; Drug: fluorouracil; Drug: capecitabine; Drug: pembrolizumab
Sponsors: Seagen Inc.
Recruiting
-
Posted: June 1st, 2020, 2:00am GMT
Conditions: Metastatic and Locally Advanced NRG1-rearranged Malignancies
Interventions: Drug: Afatinib 40 MG
Sponsors: German Cancer Research Center; German Consortium for Translational Cancer Research
Completed
-
Posted: March 24th, 2020, 2:00am GMT
Conditions: Biliary Tract Cancer
Interventions: Other: Tumour and germline molecular profiling
Sponsors: McGill University Health Centre/Research Institute of the McGill University Health Centre; Cancer Research Society
Recruiting
-
Posted: March 13th, 2020, 2:00am GMT
Conditions: Biliary Tract Neoplasms; Gallbladder Cancer; Cholangiocarcinoma
Interventions: Drug: Durvalumab + Gem/Cis; Drug: Gem/Cis
Sponsors: Asan Medical Center; Samsung Medical Center
Active, not recruiting
-
Posted: March 10th, 2020, 2:00am GMT
Conditions: Unresectable Intrahepatic Cholangiocarcinoma
Interventions: Drug: Durvalumab; Drug: SNDX-6352
Sponsors: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Syndax Pharmaceuticals; AstraZeneca
Completed
-
Posted: March 6th, 2020, 3:00am GMT
Conditions: Bile Duct Cancer; Chemotherapy Effect
Interventions: Drug: AZD6738; Drug: Durvalumab; Drug: Olaparib
Sponsors: Seoul National University Hospital
Active, not recruiting
-
Posted: February 5th, 2020, 3:00am GMT
Conditions: Liver and Intrahepatic Bile Duct Carcinoma; Stage III Intrahepatic Cholangiocarcinoma AJCC v8; Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8; Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8; Stage IV Intrahepatic Cholangiocarcinoma AJCC v8; Unresectable Intrahepatic Cholangiocarcinoma
Interventions: Drug: Dexamethasone; Drug: Floxuridine; Device: Implanted Medical Device; Drug: Irinotecan; Drug: Leucovorin; Drug: Oxaliplatin; Other: Quality-of-Life Assessment
Sponsors: OHSU Knight Cancer Institute; Oregon Health and Science University
Active, not recruiting
-
Posted: January 27th, 2020, 3:00am GMT
Conditions: Radiotherapy
Interventions: Radiation: Adaptative MR-Guided Stereotactic Body Radiotherapy
Sponsors: Centre Georges Francois Leclerc
Active, not recruiting
-
Posted: December 18th, 2019, 3:00am GMT
Conditions: Biliary Tract Cancer
Interventions: Drug: CPI 613; Drug: Gemcitabine; Drug: Cisplatin
Sponsors: University of Michigan Rogel Cancer Center
Active, not recruiting
-
Posted: December 9th, 2019, 3:00am GMT
Conditions: Advanced Solid Tumor; BRAF V600 Mutation
Interventions: Drug: ABM-1310; Drug: Cobimetinib
Sponsors: ABM Therapeutics Corporation
Active, not recruiting
-
Posted: December 6th, 2019, 3:00am GMT
Conditions: Advanced or Metastatic Solid Tumor; Advanced or Metastatic Gastric or Gastroesophageal Cancer; Myeloid or Lymphoid Neoplasms (MLN)
Interventions: Drug: Futibatinib
Sponsors: Taiho Oncology, Inc.
Active, not recruiting
-
Posted: November 25th, 2019, 3:00am GMT
Conditions: Metastatic Cholangiocarcinoma; Metastatic Hepatocellular Carcinoma; Stage III Hepatocellular Carcinoma AJCC v8; Stage III Intrahepatic Cholangiocarcinoma AJCC v8; Stage IIIA Hepatocellular Carcinoma AJCC v8; Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8; Stage IIIB Hepatocellular Carcinoma AJCC v8; Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8; Stage IV Hepatocellular Carcinoma AJCC v8; Stage IV Intrahepatic Cholangiocarcinoma AJCC v8; Stage IVA Hepatocellular Carcinoma AJCC v8; Stage IVB Hepatocellular Carcinoma AJCC v8; Unresectable Cholangiocarcinoma; Unresectable Hepatocellular Carcinoma; Unresectable Intrahepatic Cholangiocarcinoma
Interventions: Drug: Carboplatin; Drug: Paclitaxel; Drug: Pevonedistat
Sponsors: National Cancer Institute (NCI)
Active, not recruiting
-
Posted: November 15th, 2019, 3:00am GMT
Conditions: Advanced Colorectal Carcinoma; Metastatic Colorectal Carcinoma; Stage IV Colorectal Cancer AJCC v8; Stage IVA Colorectal Cancer AJCC v8; Stage IVB Colorectal Cancer AJCC v8; Stage IVC Colorectal Cancer AJCC v8; Stage II Colon Cancer; Stage II Rectal Cancer; Stage III Colon Cancer; Stage III Rectal Cancer; Esophageal Cancer; Pancreatic Cancer; Bile Duct Cancer; Gastric Cancer; Gall Bladder Cancer; Small Bowel Adenocarcinoma
Interventions: Biological: Bevacizumab; Drug: Dasatinib; Drug: Fluorouracil; Drug: Leucovorin; Drug: Leucovorin Calcium; Drug: Oxaliplatin; Other: Quality-of-Life Assessment
Sponsors: Anne Noonan
Active, not recruiting
-
Posted: November 8th, 2019, 3:00am GMT
Conditions: Advanced Solid Tumors; NSCLC; Bladder Cancer; HNSCC; Renal Cancer; Melanoma; Anal Cancer; Colorectal Cancer; Cholangiocarcinoma; Gastric Cancer; Hepatocellular Carcinoma; Merkel Cell Carcinoma; Cervical Cancer
Interventions: Drug: Continue PD-1/PD-L1 Inhibitors treatment; Other: Discontinue PD-1/PD-L1-1 inhibitor
Sponsors: Jason J. Luke, MD
Recruiting
-
Posted: November 5th, 2019, 3:00am GMT
Conditions: Squamous Cell Carcinoma of the Head and Neck; Renal Cell Carcinoma; Ovarian Cancer; Gastric Cancer; Esophageal Cancer; Lung Squamous Cell Carcinoma; Pancreatic Cancer; Bile Duct Cancer; Endometrial Cancer; Melanoma Cancer; Urothelial Cancer
Interventions: Drug: PF-06940434; Drug: PF-06801591
Sponsors: Pfizer
Active, not recruiting
-
Posted: November 4th, 2019, 3:00am GMT
Conditions: Gastric Cancer; Bladder Cancer; Squamous Non-small Cell Lung Cancer; Cholangiocarcinoma; Sarcoma; Endometrial Cancer; Other Solid Tumours
Interventions: Drug: CPL304110
Sponsors: Celon Pharma SA; National Center for Research and Development, Poland
Recruiting
-
Posted: October 30th, 2019, 2:00am GMT
Conditions: Hepatocellular Carcinoma; Liver Cancer; Cholangiocarcinoma
Sponsors: National Cancer Institute (NCI)
Recruiting
-
Posted: October 24th, 2019, 2:00am GMT
Conditions: Gastrointestinal Neoplasms; Cholangiocarcinoma; Pancreatic Neoplasms
Interventions: Drug: BI 905711
Sponsors: Boehringer Ingelheim
Completed
-
Posted: September 26th, 2019, 2:00am GMT
Conditions: Pancreas Cancer; Pancreatic Cancer; Pancreas Neoplasm; Pancreas Cyst; Pancreatic Precancerous Condition; Familial Pancreatic Cancer; Hereditary Cancer; Bile Duct Cancer; Ampullary Cancer; Duodenal Cancer; Gallbladder Cancer
Sponsors: George Zogopoulos
Recruiting
-
Posted: September 24th, 2019, 2:00am GMT
Conditions: NRG1 Fusion; Pancreatic Cancer; Non Small Cell Lung Cancer; Solid Tumor, Unspecified, Adult; Prostate Cancer; Head and Neck Cancer; Colorectal Cancer; Breast Cancer; Cholangiocarcinoma; Renal Cell Carcinoma; Unknown Primary Tumors
Interventions: Drug: MCLA-128
Sponsors: Merus N.V.
Available
-
Posted: September 18th, 2019, 2:00am GMT
Conditions: Advanced Cholangiocarcinoma; FGFR2 Gene Rearrangements
Interventions: Drug: TAS-120; Drug: Cisplatin/Gemcitabine
Sponsors: Taiho Oncology, Inc.
Active, not recruiting
-
Posted: August 28th, 2019, 2:00am GMT
Conditions: Hepatocellular Carcinoma
Interventions: Device: TheraSphere
Sponsors: Boston Scientific Corporation; Biocompatibles UK Ltd
Active, not recruiting
-
Posted: August 28th, 2019, 2:00am GMT
Conditions: Cholangiocarcinoma; Gallbladder Carcinoma; Malignant Solid Neoplasm; Stage III Gallbladder Cancer AJCC v8; Stage III Hilar Cholangiocarcinoma AJCC v8; Stage III Intrahepatic Cholangiocarcinoma AJCC v8; Stage IV Gallbladder Cancer AJCC v8; Stage IV Hilar Cholangiocarcinoma AJCC v8; Stage IV Intrahepatic Cholangiocarcinoma AJCC v8
Interventions: Drug: Avelumab; Procedure: Biopsy; Procedure: Biospecimen Collection; Procedure: Computed Tomography; Radiation: Hypofractionated Radiation Therapy; Drug: Peposertib
Sponsors: National Cancer Institute (NCI)
Recruiting
-
Posted: August 16th, 2019, 2:00am GMT
Conditions: Cholangiocarcinoma
Interventions: Combination Product: Combination of Lonsurf® and Irinotecan
Sponsors: Heinrich-Heine University, Duesseldorf; Servier
Completed
-
Posted: July 1st, 2019, 2:00am GMT
Conditions: Biliary Tract Carcinoma
Interventions: Biological: Pembrolizumab; Drug: Gemcitabine; Drug: Cisplatin; Drug: Placebo
Sponsors: Merck Sharp & Dohme LLC
Active, not recruiting
-
Posted: June 19th, 2019, 2:00am GMT
Conditions: Glioma; Cholangiocarcinoma; Solid Tumor; IDH Mutation
Interventions: Drug: Olaparib; Drug: Durvalumab
Sponsors: University Health Network, Toronto
Recruiting
-
Posted: May 8th, 2019, 2:00am GMT
Conditions: Stage III Hepatocellular Carcinoma AJCC v8; Stage III Intrahepatic Cholangiocarcinoma AJCC v8; Stage IV Hepatocellular Carcinoma AJCC v8; Stage IV Intrahepatic Cholangiocarcinoma AJCC v8; Unresectable Hepatocellular Carcinoma; Unresectable Intrahepatic Cholangiocarcinoma
Interventions: Biological: Atezolizumab; Biological: Bevacizumab; Radiation: External Beam Radiation Therapy; Procedure: Pheresis; Biological: Pneumococcal 13-valent Conjugate Vaccine; Biological: Therapeutic Autologous Dendritic Cells
Sponsors: Mayo Clinic; National Cancer Institute (NCI)
Recruiting
-
Posted: April 29th, 2019, 2:00am GMT
Conditions: HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer
Interventions: Drug: ZW25 (Zanidatamab); Drug: Capecitabine; Drug: Cisplatin; Drug: Fluorouracil; Drug: Leucovorin; Drug: Oxaliplatin; Drug: Bevacizumab; Drug: Gemcitabine
Sponsors: Jazz Pharmaceuticals
Active, not recruiting
-
Posted: April 23rd, 2019, 2:00am GMT
Conditions: Metastatic Breast Carcinoma; Locally Advanced Breast Cancer; Cancer of Pancreas; Solid Tumor With Intermediate or High HER2 Expression; Salivary Gland Cancer; Gastric Cancer; Endometrial Cancer; Uterine Cancer; Non Small Cell Lung Cancer; Biliary Tract Cancer; Cholangiocarcinoma; Colorectal Cancer; Urothelial Carcinoma; Prostate Cancer
Interventions: Drug: 68GaNOTA-Anti-HER2 VHH1
Sponsors: Universitair Ziekenhuis Brussel; Kom Op Tegen Kanker; Agentschap voor Innovatie door Wetenschap en Technologie, Project Toegepast Biomedisch onderzoek met een primair Maatschappelijke finaliteit.
Recruiting
-
Posted: April 9th, 2019, 2:00am GMT
Conditions: Mesothelioma; Mesothelioma, Malignant; Mesothelioma; Pleura; Mesotheliomas Pleural; Mesothelioma Peritoneum; Cholangiocarcinoma; Cholangiocarcinoma Recurrent; Ovarian Cancer; Non Small Cell Lung Cancer; Non Small Cell Lung Cancer Metastatic; High Grade Ovarian Serous Adenocarcinoma
Interventions: Biological: gavo-cel; Drug: fludarabine; Drug: cyclophosphamide; Drug: Nivolumab; Drug: Ipilimumab
Sponsors: TCR2 Therapeutics; Bristol-Myers Squibb
Active, not recruiting
-
Posted: March 18th, 2019, 2:00am GMT
Conditions: Malignant Solid Neoplasm; Refractory Cholangiocarcinoma; Refractory Malignant Solid Neoplasm
Interventions: Procedure: Biopsy; Procedure: Biospecimen Collection; Procedure: Bone Marrow Aspiration; Procedure: Bone Marrow Biopsy; Drug: Ceralasertib; Procedure: Computed Tomography; Procedure: Magnetic Resonance Imaging; Drug: Olaparib
Sponsors: National Cancer Institute (NCI)
Suspended
-
Posted: January 29th, 2019, 3:00am GMT
Conditions: HER2-expressing Cancers
Interventions: Drug: ZW49
Sponsors: Zymeworks Inc.
Active, not recruiting
-
Posted: September 11th, 2018, 2:00am GMT
Conditions: Advanced or Metastatic Solid Tumors; Lung Cancer; Breast Cancer; Head and Neck Squamous Cell Carcinoma; Endometrial Cancer; Melanoma; CRC; Urothelial Carcinoma; Cholangiocarcinoma
Interventions: Drug: NC318
Sponsors: NextCure, Inc.
Completed
-
Posted: September 4th, 2018, 2:00am GMT
Conditions: Unresectable Cholangiocarcinoma; Metastatic Cholangiocarcinoma
Interventions: Drug: Pemigatinib; Drug: Gemcitabine; Drug: Cisplatin
Sponsors: Incyte Corporation
Recruiting
-
Posted: March 2nd, 2018, 3:00am GMT
Conditions: Cancer, Metastatic; Cancer; Cancer of Pancreas; Cancer of Liver; Cancer of Stomach; Cancer Liver; Cancer of Rectum; Cancer of Kidney; Cancer of Esophagus; Cancer of Cervix; Cancer of Colon; Cancer of Larynx; Cancer, Lung; Cancer, Breast; Cancer, Advanced; Cancer Prostate; Cancer of Neck; Cancer of Skin; Neuroendocrine Tumors; Carcinoma; Mismatch Repair Deficiency; BRCA Gene Rearrangement; Non Hodgkin Lymphoma; Leukemia; Non Small Cell Lung Cancer; Cholangiocarcinoma; Glioblastoma; Central Nervous System Tumor; Melanoma; Urothelial Carcinoma; Bladder Cancer; Ovarian Cancer; Endometrial Cancer; Testicular Cancer; Breast Cancer; COVID; Myelofibrosis; Myeloproliferative Neoplasm; Myeloproliferative Disorders; Follicular Lymphoma; Mantle Cell Lymphoma; Marginal Zone Lymphoma; Myelodysplastic Syndromes
Interventions: Other: Clinical Trial Matching
Sponsors: Massive Bio, Inc.
Recruiting
-
Posted: February 26th, 2018, 3:00am GMT
Conditions: Primary Sclerosing Cholangitis; Primary Biliary Cirrhosis; Cholangiocarcinoma; Liver Cancer
Sponsors: Mayo Clinic
Recruiting
-
Posted: December 11th, 2017, 3:00am GMT
Conditions: Colorectal Adenocarcinoma; Gastric Adenocarcinoma; Metastatic Pancreatic Adenocarcinoma; Non-Resectable Cholangiocarcinoma; Stage IV Colorectal Cancer; Stage IV Gastric Cancer; Stage IV Pancreatic Cancer; Stage IVA Colorectal Cancer; Stage IVB Colorectal Cancer; Stage III Colorectal Cancer; Stage III Gastric Cancer; Stage III Pancreatic Cancer; Unresectable Digestive System Adenocarcinoma; Unresectable Pancreatic Carcinoma
Interventions: Drug: Nanoliposomal Irinotecan; Drug: Trifluridine and Tipiracil Hydrochloride
Sponsors: Emory University; Taiho Oncology, Inc.; Ipsen
Recruiting
-
Posted: December 6th, 2017, 3:00am GMT
Conditions: Cholangiocarcinoma Non-resectable; Non-metastatic
Interventions: Drug: Gemcitabine-Oxaliplatin Regimen; Procedure: Hepatic intra arterial chemotherapy
Sponsors: University Hospital, Montpellier; Federation Francophone de Cancerologie Digestive
Recruiting
-
Posted: November 6th, 2017, 3:00am GMT
Conditions: Melanoma; Non-small Cell Lung Cancer; Breast Cancer; Gastric Cancer; Renal Cell Carcinoma; Ovarian Cancer; Cholangiocarcinoma; Bladder Urothelial Carcinoma; Pancreatic Adenocarcinoma; Colorectal Cancer; Esophageal Cancer; Hepatic Cancer; Head and Neck Cancer; Primary Peritoneal Cancer; Fallopian Tube Cancer; Other Solid Tumors; Diffuse Large B-cell Lymphoma (DLBCL); Mantle Cell Lymphoma; Indolent B-cell Lymphomas; Non-Hodgkin Lymphoma; Follicular Lymphoma; Lymphoplasmacytic Lymphoma; Waldenstrom's Disease; Marginal Zone Lymphoma; Mucosa Associated Lymphoid Tissue; Small Lymphocytic Leukemia
Interventions: Drug: CDX-1140; Drug: CDX-301; Drug: pembrolizumab; Drug: Chemotherapy
Sponsors: Celldex Therapeutics; Merck Sharp & Dohme LLC
Completed
-
Posted: August 22nd, 2017, 2:00am GMT
Conditions: Extrahepatic Bile Duct Adenocarcinoma, Biliary Type; Gallbladder Adenocarcinoma, Biliary Type; Metastatic Pancreatic Adenocarcinoma; Recurrent Cholangiocarcinoma; Recurrent Gallbladder Carcinoma; Recurrent Hepatocellular Carcinoma; Recurrent Intrahepatic Cholangiocarcinoma; Recurrent Pancreatic Carcinoma; Stage III Gallbladder Cancer AJCC V7; Stage III Hepatocellular Carcinoma AJCC v7; Stage III Intrahepatic Cholangiocarcinoma AJCC v7; Stage III Pancreatic Cancer AJCC v6 and v7; Stage IIIA Gallbladder Cancer AJCC v7; Stage IIIA Hepatocellular Carcinoma AJCC v7; Stage IIIB Gallbladder Cancer AJCC v7; Stage IIIB Hepatocellular Carcinoma AJCC v7; Stage IIIC Hepatocellular Carcinoma AJCC v7; Stage IV Gallbladder Cancer AJCC v7; Stage IV Hepatocellular Carcinoma AJCC v7; Stage IV Pancreatic Cancer AJCC v6 and v7; Stage IVA Gallbladder Cancer AJCC v7; Stage IVA Hepatocellular Carcinoma AJCC v7; Stage IVA Intrahepatic Cholangiocarcinoma AJCC v7; Stage IVB Gallbladder Cancer AJCC v7; Stage IVB Hepatocellular Carcinoma AJCC v7; Stage IVB Intrahepatic Cholangiocarcinoma AJCC v7; Unresectable Gallbladder Carcinoma; Unresectable Pancreatic Carcinoma
Interventions: Biological: Durvalumab; Drug: Guadecitabine
Sponsors: University of Southern California; National Cancer Institute (NCI); Van Andel Research Institute
Active, not recruiting
-
Posted: July 26th, 2017, 2:00am GMT
Conditions: Intrahepatic Cholangiocarcinoma; Combined Hepatocellular and Cholangiocarcinoma
Interventions: Drug: derazantinib
Sponsors: Basilea Pharmaceutica
Completed
-
Posted: July 17th, 2017, 2:00am GMT
Conditions: Advanced Solid Tumors; Hematologic Neoplasms; Ovarian Cancer; HER2-positive Advanced Solid Tumors; Non Small Cell Lung Cancer; Small-cell Lung Cancer; Squamous Cell Carcinoma of Head and Neck; Cholangiocarcinoma; Cervical Cancer; TNBC - Triple-Negative Breast Cancer
Interventions: Biological: tebotelimab 1 mg; Biological: tebotelimab 3 mg; Biological: tebotelimab 10 mg; Biological: tebotelimab 30 mg; Biological: tebotelimab 120 mg; Biological: tebotelimab 300 mg; Biological: tebotelimab 400 mg; Biological: tebotelimab 600 mg; Biological: tebotelimab 800 mg; Biological: tebotelimab 1200 mg; Biological: margetuximab
Sponsors: MacroGenics
Completed
-
Posted: July 11th, 2017, 2:00am GMT
Conditions: Advanced Malignant Solid Neoplasm; Glioblastoma; Recurrent Cholangiocarcinoma; Recurrent Glioma; Recurrent Malignant Solid Neoplasm; WHO Grade 2 Glioma; WHO Grade 3 Glioma
Interventions: Procedure: Biopsy; Procedure: Biospecimen Collection; Procedure: Computed Tomography; Procedure: Magnetic Resonance Imaging; Drug: Olaparib
Sponsors: National Cancer Institute (NCI)
Active, not recruiting
-
Posted: April 7th, 2017, 2:00am GMT
Conditions: Cholangitis
Interventions: Procedure: Injection of 37℃ contrast agent
Sponsors: Hepatopancreatobiliary Surgery Institute of Gansu Province
Not yet recruiting
-
Posted: September 28th, 2016, 2:00am GMT
Conditions: Hepatocellular Carcinoma; Cholangiocarcinoma
Sponsors: Mayo Clinic
Recruiting
-
Posted: September 20th, 2016, 2:00am GMT
Conditions: Hepatocellular Carcinoma; Biliary Tract Cancer; Cirrhosis; Liver Diseases
Interventions: Other: Blood samples
Sponsors: Mayo Clinic
Active, not recruiting
-
Posted: August 29th, 2016, 2:00am GMT
Conditions: Hepatocellular Carcinoma; Intrahepatic Cholangiocarcinoma; Stage IV Liver Cancer; Stage IVA Liver Cancer; Stage IVB Liver Cancer; Vascular Thrombosis
Interventions: Procedure: Computed Tomography; Procedure: Single Photon Emission Computed Tomography; Drug: Technetium Tc-99m Sulfur Colloid
Sponsors: University of Washington
Recruiting
-
Posted: August 19th, 2016, 2:00am GMT
Conditions: Pancreatic Cancer; Lymphadenopathy; Cholangiocarcinoma
Interventions: Device: 22G SharkCore™ needle; Device: 22G BNX EUS-FNA Needle
Sponsors: Thomas Jefferson University
Terminated
-
Posted: July 15th, 2016, 2:00am GMT
Conditions: Acinar Cell Carcinoma; Adenoid Cystic Carcinoma; Adrenal Cortical Carcinoma; Adrenal Gland Pheochromocytoma; Anal Canal Neuroendocrine Carcinoma; Anal Canal Undifferentiated Carcinoma; Angiosarcoma; Apocrine Neoplasm; Appendix Mucinous Adenocarcinoma; Bartholin Gland Transitional Cell Carcinoma; Basal Cell Carcinoma; Bladder Adenocarcinoma; Breast Metaplastic Carcinoma; Cervical Adenocarcinoma; Cholangiocarcinoma; Chordoma; Colorectal Squamous Cell Carcinoma; Desmoid Fibromatosis; Endometrial Transitional Cell Carcinoma; Endometrioid Adenocarcinoma; Esophageal Neuroendocrine Carcinoma; Esophageal Undifferentiated Carcinoma; Extrahepatic Bile Duct Carcinoma; Extramammary Paget Disease; Fallopian Tube Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Fibromyxoid Tumor; Gallbladder Carcinoma; Gastric Neuroendocrine Carcinoma; Gastric Squamous Cell Carcinoma; Gastric Undifferentiated Carcinoma; Gastrointestinal Stromal Tumor; Gestational Trophoblastic Tumor; Giant Cell Carcinoma; Human Papillomavirus-Independent Cervical Adenocarcinoma, Clear Cell-Type; Intestinal Neuroendocrine Carcinoma; Intrahepatic Cholangiocarcinoma; Lung Neuroendocrine Tumor; Lung Sarcomatoid Carcinoma; Major Salivary Gland Carcinoma; Malignant Odontogenic Neoplasm; Malignant Peripheral Nerve Sheath Tumor; Malignant Solid Neoplasm; Malignant Testicular Sex Cord-Stromal Tumor; Metastatic Malignant Neoplasm of Unknown Primary; Metastatic Pituitary Neuroendocrine Tumor; Minimally Invasive Lung Adenocarcinoma; Mixed Mesodermal (Mullerian) Tumor; Mucinous Adenocarcinoma; Mucinous Cystadenocarcinoma; Nasal Cavity Adenocarcinoma; Nasal Cavity Carcinoma; Nasopharyngeal Carcinoma; Nasopharyngeal Low Grade Papillary Adenocarcinoma; Nasopharyngeal Undifferentiated Carcinoma; Oral Cavity Carcinoma; Oropharyngeal Undifferentiated Carcinoma; Ovarian Adenocarcinoma; Ovarian Germ Cell Tumor; Ovarian Mucinous Adenocarcinoma; Ovarian Squamous Cell Carcinoma; Ovarian Transitional Cell Carcinoma; Pancreatic Acinar Cell Carcinoma; Pancreatic Neuroendocrine Carcinoma; Paraganglioma; Paranasal Sinus Adenocarcinoma; Paranasal Sinus Carcinoma; Parathyroid Gland Carcinoma; PEComa; Penile Squamous Cell Carcinoma; Peritoneal Mesothelial Neoplasm; Placental Choriocarcinoma; Primary Peritoneal High Grade Serous Adenocarcinoma; Pseudomyxoma Peritonei; Rare Disorder; Scrotal Squamous Cell Carcinoma; Seminal Vesicle Adenocarcinoma; Seminoma; Serous Cystadenocarcinoma; Small Intestinal Adenocarcinoma; Small Intestinal Squamous Cell Carcinoma; Spindle Cell Neoplasm; Teratoma With Somatic-Type Malignancy; Testicular Non-Seminomatous Germ Cell Tumor; Thyroid Gland Carcinoma; Tracheal Carcinoma; Transitional Cell Carcinoma; Ureter Adenocarcinoma; Ureter Squamous Cell Carcinoma; Urethral Adenocarcinoma; Urethral Squamous Cell Carcinoma; Vaginal Adenocarcinoma; Vaginal Squamous Cell Carcinoma, Not Otherwise Specified; Vulvar Carcinoma
Interventions: Procedure: Biospecimen Collection; Procedure: Computed Tomography; Procedure: Echocardiography; Biological: Ipilimumab; Procedure: Magnetic Resonance Imaging; Biological: Nivolumab
Sponsors: National Cancer Institute (NCI)
Active, not recruiting
-
Posted: September 30th, 2022, 2:00am GMT
Conditions: Gastric Outlet Obstruction
Interventions: Procedure: Surgical gastrojejunostomy (SGJ); Procedure: Endoscopic gastrojejunostomy (EGJ)
Sponsors: Northwell Health
Recruiting
-
Posted: September 22nd, 2022, 2:00am GMT
Conditions: Hilar Cholangiocarcinoma
Interventions: Drug: Photosensitizer; Procedure: Radiofrequency ablation (RFA)
Sponsors: University of Leipzig; Zentrum für Klinische Studien Leipzig
Recruiting
-
Posted: September 8th, 2022, 2:00am GMT
Conditions: Advanced Cholangiocarcinoma
Interventions: Drug: Lenvatinib, tislelizumab, gemcitabine and cisplatin; Drug: gemcitabine and cisplatin
Sponsors: Second Affiliated Hospital, School of Medicine, Zhejiang University
Recruiting
-
Posted: August 26th, 2022, 2:00am GMT
Conditions: Pancreas Adenocarcinoma; Cholangiocarcinoma
Interventions: Drug: CRGD-ZW800-1; Device: Intraoperative near-infrared fluorescence imaging
Sponsors: Leiden University Medical Center
Recruiting
-
Posted: August 25th, 2022, 2:00am GMT
Conditions: Resectable Intrahepatic Cholangiocarcinoma; Stage 0 Intrahepatic Cholangiocarcinoma AJCC v8; Stage I Intrahepatic Cholangiocarcinoma AJCC v8; Stage II Intrahepatic Cholangiocarcinoma AJCC v8; Stage III Intrahepatic Cholangiocarcinoma AJCC v8
Interventions: Drug: Cisplatin; Drug: Gemcitabine Hydrochloride; Drug: Infigratinib Phosphate; Drug: Nab-paclitaxel
Sponsors: Emory University; National Cancer Institute (NCI)
Withdrawn
-
Posted: August 23rd, 2022, 2:00am GMT
Conditions: Pancreatic Neoplasms; Solid Tumors; Biliary Tract Cancer; Lung Neoplasms; Bladder Cancer
Interventions: Drug: brigimadlin
Sponsors: Boehringer Ingelheim
Recruiting
-
Posted: August 18th, 2022, 2:00am GMT
Conditions: Biliary Tract Cancer; Cholangiocarcinoma; Gall Bladder Cancer; Ampullary Cancer
Interventions: Drug: CTX-009; Drug: Paclitaxel
Sponsors: Compass Therapeutics
Recruiting
-
Posted: July 18th, 2022, 2:00am GMT
Conditions: Pleural Effusion, Malignant; Ascites, Malignant; Carcinoma; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Carcinoma, Renal; Carcinoma, Small Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Neuroendocrine; Carcinoma, Thymic; Carcinoma, Pancreatic; Carcinoma Breast; Carcinoma, Ovarian; Carcinoma Bladder; Carcinoma of Unknown Primary; Carcinoma of the Head and Neck; Carcinoma of the Oropharynx; Carcinoma of the Larynx; Carcinoma of the Bladder; Carcinoma of Esophagus; Carcinoma of the Nasopharynx; Carcinoma of the Penis; Carcinoma of the Cervix; Carcinoma of the Anus; Carcinoma of the Vulva; Carcinoma of the Appendix; Carcinoma of the Oral Cavity; Cholangiocarcinoma; Melanoma; Mesothelioma; Pancreatic Cancer
Sponsors: Travera Inc; xCures
Recruiting
-
Posted: July 11th, 2022, 2:00am GMT
Conditions: Mesothelioma; Mesotheliomas Pleural; Mesothelioma, Malignant; Mesothelioma Peritoneum; Ovarian Cancer; Ovarian Serous Adenocarcinoma; Pancreatic Cancer; Pancreatic Adenocarcinoma; Colorectal Cancer; Triple Negative Breast Cancer; TNBC - Triple-Negative Breast Cancer; Ovarian Adenocarcinoma; Pancreatic Neoplasms; Colorectal Neoplasms; Ovarian Neoplasms; Cholangiocarcinoma; Non Small Cell Lung Cancer
Interventions: Biological: TC-510; Drug: Fludarabine; Drug: Cyclophosphamide
Sponsors: TCR2 Therapeutics
Active, not recruiting
-
Posted: June 23rd, 2022, 2:00am GMT
Conditions: Biliary Disease; Pancreatic Disease; Choledocholithiasis; Biliary Obstruction; Biliary Tract Neoplasms; Pancreatic Neoplasms
Interventions: Device: Duodenoscope with single-use distal cover; Device: Conventional duodenoscope
Sponsors: Stanford University
Recruiting
-
Posted: June 16th, 2022, 2:00am GMT
Conditions: Intrahepatic Cholangiocarcinoma
Interventions: Drug: Induction Chemotherapy Triplet Therapy; Radiation: Concurrent Y-90 treatment; Drug: Consolidation Doublet Therapy:
Sponsors: Inova Health Care Services
Not yet recruiting
-
Posted: June 9th, 2022, 2:00am GMT
Conditions: Gastrointestinal Cancer; Cholangiocarcinoma; Liver Cancer; Colorectal Adenocarcinoma; Pancreatic Cancer; Gastric Cancer; Esophageal Adenocarcinoma; Gastroesophageal Junction
Interventions: Drug: Cabotamig (ARB202)
Sponsors: Arbele Pty Ltd
Recruiting
-
Posted: April 14th, 2022, 2:00am GMT
Conditions: Intrahepatic Cholangiocarcinoma
Interventions: Drug: Perflutren Protein-Type A Microspheres; Procedure: Contrast-Enhanced Ultrasound
Sponsors: Thomas Jefferson University
Recruiting
-
Posted: April 13th, 2022, 2:00am GMT
Conditions: Solid Tumors
Interventions: Drug: Bemarituzumab
Sponsors: Amgen
Recruiting
-
Posted: April 11th, 2022, 2:00am GMT
Conditions: Cholangiocarcinoma; Liver Fluke-Related Cholangiocarcinoma; Opisthorchiasis
Interventions: Behavioral: eCHEC program
Sponsors: McMaster University; Khon Kaen University; Global Alliance for Chronic Diseases (GACD); Canadian Institutes of Health Research (CIHR)
Not yet recruiting
-
Posted: April 5th, 2022, 2:00am GMT
Conditions: Pancreatic Cancer; Breast Cancer; Gastric Cancer; Non Small Cell Lung Cancer; Cervical Cancer; Endocervical Cancer; Squamous Cell Carcinoma of Head and Neck; Bladder Urothelial Cancer; Colorectal Cancer; Esophageal Cancer; Ovarian Cancer; Renal Cell Carcinoma; Prostate Cancer; Melanoma; Mesothelioma; Cholangiocarcinoma
Interventions: Drug: NGM438; Drug: Pembrolizumab (KEYTRUDA ®)
Sponsors: NGM Biopharmaceuticals, Inc; Merck Sharp & Dohme LLC
Active, not recruiting
-
Posted: March 23rd, 2022, 2:00am GMT
Conditions: Primary Liver Cancer; Hepatocellular Carcinoma; Intrahepatic Cholangiocarcinoma; Combined Hepatocellular-cholangiocarcinoma
Interventions: Other: Observation
Sponsors: Geneplus-Beijing Co. Ltd.; Eastern Hepatobiliary Surgery Hospital
Withdrawn
-
Posted: March 18th, 2022, 2:00am GMT
Conditions: Metastatic Colorectal Cancer (Mcrc); Intrahepatic Cholangiocarcinoma (Icc); Colorectal Cancer; Colorectal Neoplasms; Cholangiocarcinoma; Intrahepatic Bile Duct Cancer; Bile Duct Cancer; Bile Duct Neoplasms
Interventions: Drug: Floxuridine; Drug: 5-Fluorouracil; Drug: Irinotecan; Device: Intera 3000 Hepatic Artery Infusion Pump (HAIP); Drug: Oxaliplatin; Drug: Leucovorin; Drug: M9241; Drug: Gemcitabine; Drug: Dexamethasone
Sponsors: National Cancer Institute (NCI)
Recruiting
-
Posted: March 17th, 2022, 2:00am GMT
Conditions: Distal Bile Duct Adenocarcinoma; Gallbladder Carcinoma; Intrahepatic Cholangiocarcinoma; Metastatic Malignant Neoplasm in the Peritoneum; Stage IV Distal Bile Duct Cancer AJCC v8; Stage IV Intrahepatic Bile Duct Cancer AJCC v8; Stage IV Intrahepatic Cholangiocarcinoma AJCC v8; Stage IVB Gallbladder Cancer AJCC v8
Interventions: Drug: Cisplatin; Drug: Gemcitabine; Drug: Nab-paclitaxel; Other: Quality-of-Life Assessment; Other: Questionnaire Administration
Sponsors: City of Hope Medical Center; National Cancer Institute (NCI)
Recruiting
-
Posted: March 11th, 2022, 3:00am GMT
Conditions: Locally Advanced Solid Tumor
Interventions: Drug: TNG908
Sponsors: Tango Therapeutics, Inc.
Recruiting
-
Posted: February 22nd, 2022, 3:00am GMT
Conditions: Pancreatic Cancer; Pancreas Cancer; Ampullary Cancer; Pancreas Neuroendocrine Tumor; Pancreatitis; Distal Extrahepatic Cholangiocarcinoma; Duodenal Cancer
Interventions: Drug: Placebo; Drug: Pantoprazole
Sponsors: Washington University School of Medicine
Active, not recruiting
-
Posted: February 16th, 2022, 3:00am GMT
Conditions: Solid Tumor, Adult; Intrahepatic Cholangiocarcinoma; Urothelial Carcinoma
Interventions: Drug: KIN-3248
Sponsors: Kinnate Biopharma
Active, not recruiting
-
Posted: February 15th, 2022, 3:00am GMT
Conditions: Primary Biliary Cholangitis
Interventions: Drug: Bezafibrate 100 mg; Drug: Bezafibrate 200 mg; Drug: Obeticholic Acid 5 mg; Drug: Obeticholic Acid placebo; Drug: Bezafibrate Placebo
Sponsors: Intercept Pharmaceuticals
Active, not recruiting
-
Posted: February 14th, 2022, 3:00am GMT
Conditions: Biliary Tract Cancer (CCA); Intrahepatic Cholangiocarcinoma; Hilar Cholangiocarcinoma; Distal Cholangiocarcinoma; Gall Bladder Carcinoma
Interventions: Drug: Durvalumab; Drug: Tremelimumab; Drug: Capecitabine
Sponsors: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Active, not recruiting
-
Posted: February 11th, 2022, 3:00am GMT
Conditions: Intrahepatic Cholangiocarcinoma
Interventions: Combination Product: DEB-TACE combined with Surufatinib and Camrelizumab
Sponsors: Tongji Hospital
Recruiting
-
Posted: February 4th, 2022, 3:00am GMT
Conditions: Hepatocellular Carcinoma; Intrahepatic Cholangiocarcinoma
Interventions: Drug: VG161; Drug: Nivolumab Injection [Opdivo]
Sponsors: Virogin Biotech Canada Ltd
Recruiting
-
Posted: February 2nd, 2022, 3:00am GMT
Conditions: Hepatocellular Carcinoma; Intrahepatic Cholangiocarcinoma
Interventions: Drug: SD-101; Biological: Pembrolizumab; Biological: Nivolumab; Biological: Ipilimumab
Sponsors: TriSalus Life Sciences, Inc.
Active, not recruiting
-
Posted: February 1st, 2022, 3:00am GMT
Conditions: Rare Malignant Neoplasm
Interventions: Other: Genomic sequence
Sponsors: National Cancer Center, Japan
Recruiting
-
Posted: January 31st, 2022, 3:00am GMT
Conditions: Pancreatic Cancer; Breast Cancer; Gastric Cancer; Non-small Cell Lung Cancer; Cervical Cancer; Endocervical Cancer; Squamous Cell Carcinoma of Head and Neck; Bladder Urothelial Cancer; Colorectal Carcinoma; Esophageal Cancer; Ovarian Cancer; Renal Cell Carcinoma; Prostate Cancer; Melanoma; Mesothelioma; Cholangiocarcinoma
Interventions: Drug: NGM831; Drug: NGM831 plus pembrolizumab (KEYTRUDA®); Drug: NGM831 and NGM438 plus pembrolizumab (KEYTRUDA®)
Sponsors: NGM Biopharmaceuticals, Inc; Merck Sharp & Dohme LLC
Recruiting
-
Posted: January 27th, 2022, 3:00am GMT
Conditions: Combined Hepatocellular Carcinoma and Cholangiocarcinoma; Stage III Liver Cancer; Stage IV Liver Cancer
Interventions: Biological: Atezolizumab; Biological: Bevacizumab; Procedure: Biospecimen Collection; Drug: Cisplatin; Procedure: Computed Tomography; Procedure: Conventional Magnetic Resonance Imaging; Drug: Gemcitabine Hydrochloride
Sponsors: National Cancer Institute (NCI)
Recruiting
-
Posted: January 27th, 2022, 3:00am GMT
Conditions: Biliary Stones; Cholangiocarcinoma, Intrahepatic; Biliary Stricture; Cholelithiasis; Choledocholithiasis
Interventions: Procedure: Percutaneous cholangiopancreatoscopy
Sponsors: Johns Hopkins University
Recruiting
-
Posted: January 20th, 2022, 3:00am GMT
Conditions: Solid Tumors With PTCH1 Loss-of-function Mutations
Interventions: Drug: ENV-101 (taladegib)
Sponsors: Endeavor Biomedicines, Inc.
Active, not recruiting
-
Posted: January 18th, 2022, 3:00am GMT
Conditions: Ovarian Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Triple Negative Breast Neoplasms; HER2 Negative Breast Neoplasms; Hormone Receptor Positive Breast Neoplasms; Endometrial Neoplasms; Carcinoma, Non-Small-Cell Lung; Cholangiocarcinoma; Gallbladder Carcinoma; Adenoid Cystic Carcinoma
Interventions: Drug: SGN-B7H4V
Sponsors: Seagen Inc.
Recruiting
-
Posted: January 11th, 2022, 3:00am GMT
Conditions: Gynecologic Cancer; Gynecologic Neoplasms; Peritoneal Carcinomatosis; Peritoneal Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Colorectal Cancer; Colorectal Neoplasms; Appendiceal Cancer; Appendiceal Neoplasms
Interventions: Drug: Paclitaxel; Drug: Nilotinib
Sponsors: National Cancer Institute (NCI)
Recruiting
-
Posted: January 11th, 2022, 3:00am GMT
Conditions: Cholangiocarcinoma; Pancreatic Cancer; Sclerosing Cholangitis
Interventions: Procedure: Endoscopic retrograde Cholangio- pancreatography; Procedure: Endoscopic ultrasound
Sponsors: Region Stockholm; Karolinska Institutet
Recruiting
-
Posted: December 28th, 2021, 3:00am GMT
Conditions: Advanced Biliary Tract Cancer
Interventions: Drug: Lenvatinib Pill,Paclitaxel
Sponsors: National Health Research Institutes, Taiwan; National Cheng-Kung University Hospital; National Taiwan University Hospital; Kaohsiung Medical University Chung-Ho Memorial Hospital; Taipei Veterans General Hospital, Taiwan; Chang Gung Memorial Hospital; China Medical University, Taiwan
Recruiting
-
Posted: November 24th, 2021, 3:00am GMT
Conditions: Immune System
Interventions: Other: blood samples
Sponsors: Servier
Terminated
-
Posted: November 17th, 2021, 3:00am GMT
Conditions: Cholangiocarcinoma, Intrahepatic
Interventions: Drug: Recombinant Human Adenovirus Type 5; Drug: HAIC of FOLFOX
Sponsors: Beijing Tsinghua Chang Gung Hospital
Recruiting
-
Posted: October 1st, 2021, 2:00am GMT
Conditions: Hepatocellular Carcinoma; Hepatocellular Cancer; Hepatitis B; Cirrhosis; Liver Cancer
Interventions: Device: Study CT/MRI Imaging; Device: Standard of Care CT/MRI Imaging; Diagnostic Test: Oncoguard™ Liver Test
Sponsors: Exact Sciences Corporation
Recruiting
-
Posted: September 13th, 2021, 2:00am GMT
Conditions: Cancer of Pancreas; Cancer of Stomach; Cancer of Esophagus; Cancer of Liver; Cancer
Interventions: Other: wet heparinzed suction; Other: Microsieve; Other: No heparin flush; Other: No microsieve
Sponsors: H. Lee Moffitt Cancer Center and Research Institute
Not yet recruiting
-
Posted: September 10th, 2021, 2:00am GMT
Conditions: Cholangiocarcinoma,Adult
Interventions: Drug: 3D185
Sponsors: 3D Medicines (Beijing) Co., Ltd.
Not yet recruiting
-
Posted: August 27th, 2021, 2:00am GMT
Conditions: Perihilar Cholangiocarcinoma
Interventions: Drug: oxaliplatin and 5-fluorouracil; Procedure: Biliary Drainage; Other: Best Supportive Care; Procedure: External biliary drainage
Sponsors: Peking University
Recruiting
-
Posted: August 16th, 2021, 2:00am GMT
Conditions: Uterine Cervical Neoplasms; Endometrial Neoplasms; Squamous Cell Carcinoma of Head and Neck; Gallbladder Neoplasms; Cholangiocarcinoma; Esophageal Neoplasms; Triple Negative Breast Neoplasms; Hepatocellular Carcinoma; Urinary Bladder Neoplasms; Ovarian Neoplasms; Stomach Neoplasms
Interventions: Biological: Pembrolizumab/Vibostolimab Co-Formulation; Biological: Pembrolizumab; Drug: Lenvatinib; Drug: 5-Fluorouracil; Drug: Cisplatin; Drug: Paclitaxel; Drug: Gemcitabine; Drug: Carboplatin; Drug: Docetaxel; Drug: Bevacizumab; Drug: Capecitabine; Drug: Oxaliplatin
Sponsors: Merck Sharp & Dohme LLC
Recruiting
-
Posted: August 6th, 2021, 2:00am GMT
Conditions: Perihilar Cholangiocarcinoma; Klatskin Tumor; Bile Duct Cancer
Interventions: Procedure: Liver transplant
Sponsors: Oslo University Hospital
Recruiting
-
Posted: August 4th, 2021, 2:00am GMT
Conditions: Cholangiocarcinoma
Interventions: Drug: Novel combination of chemotherapy and immunotherapy
Sponsors: University of Alabama at Birmingham
Active, not recruiting
-
Posted: August 2nd, 2021, 2:00am GMT
Conditions: Stage III Breast Cancer; Stage IV Breast Cancer; Stage III Lung Cancer; Stage IV Lung Cancer; AML; Multiple Myeloma in Relapse; Carcinoma; Carcinoma, Pancreatic; Carcinoma of Lung; Carcinoma, Non-Small-Cell Lung; Carcinoma Breast; Carcinoma Prostate; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Carcinoma, Neuroendocrine; Carcinoma, Small Cell Lung; Carcinoma, Ovarian; Carcinoma Bladder; Carcinoma of Esophagus; Carcinoma Cervix; Carcinoma, Thymic; Carcinoma, Ductal; Carcinoma of the Head and Neck; Carcinoma of the Lip; Carcinoma of the Oral Cavity; Carcinoma of Unknown Primary; Carcinoma of the Skin; Carcinoma of the Anus; Carcinoma of the Larynx; Carcinoma of the Penis; Carcinoma of the Oropharynx; Carcinoma of the Appendix; Carcinoma of the Paranasal Sinus; Carcinoma of the Vulva; Malignant Pleural Effusion; Malignant Ascites; Mesothelioma; Cholangiocarcinoma
Sponsors: Travera Inc
Not yet recruiting
-
Posted: July 29th, 2021, 2:00am GMT
Conditions: Liver and Intrahepatic Bile Duct Neoplasm; Metastatic Malignant Neoplasm in the Liver; Primary Malignant Liver Neoplasm
Interventions: Other: Quality-of-Life Assessment; Procedure: Surgical Procedure; Procedure: Surgical Procedure
Sponsors: M.D. Anderson Cancer Center
Recruiting
-
Posted: July 22nd, 2021, 2:00am GMT
Conditions: Solid Tumors, KRAS Mutation
Interventions: Drug: BI 1823911; Drug: BI 1701963; Drug: Midazolam
Sponsors: Boehringer Ingelheim
Active, not recruiting
-
Posted: July 21st, 2021, 2:00am GMT
Conditions: Advanced Biliary Tract Cancer; Neuroendocrine Tumors; Female Reproductive System Neoplasm; MSI-H Solid Malignant Tumor
Interventions: Drug: Ipilimumab; Drug: Nivolumab
Sponsors: Olivia Newton-John Cancer Research Institute; Bristol-Myers Squibb
Active, not recruiting
-
Posted: July 9th, 2021, 2:00am GMT
Conditions: Breast Carcinoma; Colon Carcinoma; Invasive Carcinoma; Kidney Carcinoma; Liver and Intrahepatic Bile Duct Carcinoma; Malignant Solid Neoplasm; Multiple Myeloma; Prostate Carcinoma
Interventions: Procedure: Biospecimen Collection; Other: Laboratory Biomarker Analysis
Sponsors: National Cancer Institute (NCI)
Suspended
-
Posted: June 28th, 2021, 2:00am GMT
Conditions: Metastatic Distal Bile Duct Adenocarcinoma; Metastatic Gallbladder Carcinoma; Metastatic Intrahepatic Cholangiocarcinoma; Recurrent Distal Bile Duct Adenocarcinoma; Recurrent Gallbladder Carcinoma; Recurrent Intrahepatic Cholangiocarcinoma; Stage IV Distal Bile Duct Cancer AJCC v8; Stage IV Gallbladder Cancer AJCC v8; Stage IV Intrahepatic Cholangiocarcinoma AJCC v8; Unresectable Liver and Intrahepatic Bile Duct Carcinoma
Interventions: Biological: Atezolizumab; Procedure: Biopsy; Procedure: Biospecimen Collection; Drug: Cobimetinib; Procedure: Computed Tomography; Procedure: Magnetic Resonance Imaging; Drug: Varlilumab
Sponsors: National Cancer Institute (NCI)
Active, not recruiting
-
Posted: June 23rd, 2021, 2:00am GMT
Conditions: Biliary Tract Cancer
Sponsors: GERCOR - Multidisciplinary Oncology Cooperative Group
Recruiting
-
Posted: June 18th, 2021, 2:00am GMT
Conditions: Metastatic Cancer; Foregut Carcinoid Tumor; Gastric Adenocarcinoma; Gallbladder Adenocarcinoma; Liver Cancer; GI Cancer; GI Carcinoma; Lung Cancer
Interventions: Drug: Standard of Care Chemotherapy; Procedure: Video-Assisted Thoracic Surgery (VATS); Procedure: Lobectomy; Radiation: Consolidative Radiation; Radiation: Ablation Treatment; Procedure: Resection or Excision; Procedure: Peritonectomy; Other: Transarterial Radioembolization
Sponsors: University of Chicago
Not yet recruiting
-
Posted: June 18th, 2021, 2:00am GMT
Conditions: Appendix Carcinoma by AJCC V8 Stage; Colorectal Carcinoma by AJCC V8 Stage; Digestive System Neoplasm; Esophageal Carcinoma by AJCC V8 Stage; Gastric Carcinoma by AJCC V8 Stage; Liver and Intrahepatic Bile Duct Carcinoma; Peritoneal Carcinomatosis
Interventions: Procedure: Biospecimen Collection - blood and tissue sample collection; Other: Electronic Health Record Review
Sponsors: Rutgers, The State University of New Jersey; National Cancer Institute (NCI)
Recruiting
-
Posted: June 11th, 2021, 2:00am GMT
Conditions: Biliary Tract Carcinoma
Interventions: Biological: Pembrolizumab; Drug: Gemcitabine; Drug: Cisplatin; Drug: Placebo
Sponsors: Merck Sharp & Dohme LLC
Active, not recruiting
-
Posted: June 9th, 2021, 2:00am GMT
Conditions: Cholangiocarcinoma; FGFR2 Fusion; FGFR2 Gene Mutation; FGFR1 Alteration; FGFR3 Alteration
Interventions: Drug: TT-00420
Sponsors: TransThera Sciences (Nanjing), Inc.
Active, not recruiting
-
Posted: June 3rd, 2021, 2:00am GMT
Conditions: Adenocarcinoma of the Pancreas
Interventions: Drug: Hydroxychloroquine sulfate
Sponsors: West Virginia University
Recruiting
-
Posted: June 1st, 2021, 2:00am GMT
Conditions: Advanced Solid Tumours
Interventions: Drug: RXC004; Drug: RXC004; Drug: RXC004; Biological: Denosumab; Biological: pembrolizumab
Sponsors: Redx Pharma Plc; Merck Sharp & Dohme LLC
Completed
-
Posted: May 18th, 2021, 2:00am GMT
Conditions: Intrahepatic Cholangiocarcinoma
Interventions: Drug: Gemcitabine; Drug: Oxaliplatin; Drug: Dexamethasone; Drug: Floxuridine (FUDR); Device: Implanted Medical Device
Sponsors: Memorial Sloan Kettering Cancer Center
Recruiting
-
Posted: May 4th, 2021, 2:00am GMT
Conditions: Biliary Tract Cancer; Cholangiocarcinoma; Gallbladder Cancer
Interventions: Drug: nab-paclitaxel plus gemcitabine-cisplatin
Sponsors: CHA University; Dong-A Pharmaceutical
Recruiting
-
Posted: April 21st, 2021, 2:00am GMT
Conditions: Minimal Residual Disease; KRAS G12D; KRAS G12R; NRAS G12D; NRAS G12R; Pancreatic Ductal Adenocarcinoma; Colorectal Cancer; Non-small Cell Lung Cancer; Ovarian Cancer; Cholangiocarcinoma; Bile Duct Cancer; Gallbladder Carcinoma
Interventions: Drug: ELI-002 2P
Sponsors: Elicio Therapeutics
Active, not recruiting
-
Posted: March 16th, 2021, 2:00am GMT
Conditions: Unresectable Hilar Cholangiocarcinoma
Interventions: Procedure: REMS+TAI; Procedure: SEMS+TAI
Sponsors: Zhongda Hospital
Completed
-
Posted: February 21st, 2021, 3:00am GMT
Conditions: Isocitrate Dehydrogenase Gene Mutation
Interventions: Drug: HMPL-306
Sponsors: Hutchmed
Active, not recruiting
-
Posted: February 15th, 2021, 3:00am GMT
Conditions: Primary Sclerosing Cholangitis; PSC; Cholangiocarcinoma
Sponsors: Mayo Clinic; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting
-
Posted: February 5th, 2021, 3:00am GMT
Conditions: Bile Duct Carcinoma; Gallbladder Carcinoma; Pancreatic Ductal Adenocarcinoma
Interventions: Procedure: Endoscopic Retrograde Cholangiopancreatography; Procedure: Endoscopic Retrograde Cholangiopancreatography
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Completed
-
Posted: January 13th, 2021, 3:00am GMT
Conditions: Locally Advanced Intrahepatic Cholangiocarcinoma; Metastatic Intrahepatic Cholangiocarcinoma; Stage III Intrahepatic Cholangiocarcinoma AJCC v8; Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8; Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8; Stage IV Intrahepatic Cholangiocarcinoma AJCC v8
Interventions: Drug: Bintrafusp Alfa; Procedure: Biopsy; Radiation: Hypofractionated Radiation Therapy
Sponsors: M.D. Anderson Cancer Center
Active, not recruiting
-
Posted: December 22nd, 2020, 3:00am GMT
Conditions: Colorectal Liver Metastasis
Interventions: Procedure: Resection of colorectal liver metastases
Sponsors: Technische Universität Dresden; KKS Dresden; German Cancer Research Center
Recruiting
-
Posted: December 21st, 2020, 3:00am GMT
Conditions: Hepatocellular Carcinoma; Liver Metastases; Cholangiocarcinoma
Interventions: Drug: STP705
Sponsors: Sirnaomics; Translational Drug Development
Completed
-
Posted: December 17th, 2020, 3:00am GMT
Conditions: Metastatic Cancer; Solid Tumor
Interventions: Drug: Sym021; Drug: Sym024
Sponsors: Symphogen A/S
Active, not recruiting
-
Posted: December 17th, 2020, 3:00am GMT
Conditions: Cancer
Interventions: Drug: JTX-8064; Drug: pimivalimab
Sponsors: Jounce Therapeutics, Inc.
Completed
-
Posted: December 14th, 2020, 3:00am GMT
Conditions: Metastatic Cancer; Solid Tumor; Pancreatic Cancer; Urothelial Carcinoma; Head and Neck Cancer; Colorectal Cancer
Interventions: Drug: LYT-200; Drug: Tislelizumab; Drug: Gemcitabine/nab-paclitaxel
Sponsors: PureTech
Recruiting
-
Posted: December 9th, 2020, 3:00am GMT
Conditions: HER2-positive; Adenocarcinoma; Bile Duct Cancer; Biliary Tract Cancer; Bladder Cancer; Breast Cancer; Breast Neoplasm; Carcinoma, Ductal; Carcinoma, Hepatocellular; Cancer; Lung Cancer, Non-Small-Cell; Carcinoma, Ovarian Epithelial; Carcinoma, Small Cell; Carcinoma, Squamous; Carcinoma, Transitional Cell; Colorectal Cancer; Esophagogastric Junction Neoplasms; Inflammatory Breast Cancer; Stomach Neoplasms; Malignant Neoplasms; Ovarian Neoplasms; Pancreatic Cancer; HER2-positive Solid Tumors; HER2-positive Breast Cancer; HER2-positive Gastric Cancer; HER-2 Protein Overexpression; HER-2 Gene Amplification; Prostate Cancer; Head and Neck Cancer; Endometrial Cancer; Lung Cancer, Small Cell
Interventions: Biological: CT-0508; Biological: Pembrolizumab
Sponsors: Carisma Therapeutics Inc
Active, not recruiting
-
Posted: November 24th, 2020, 3:00am GMT
Conditions: Metastatic Cancer; Solid Tumor
Interventions: Drug: Sym021; Drug: Sym022; Drug: Sym023; Drug: Irinotecan Hydrochloride
Sponsors: Symphogen A/S
Active, not recruiting
-
Posted: November 18th, 2020, 3:00am GMT
Conditions: Acute Cholecystitis; Colorectal Cancer; Diverticulitis, Colonic; Obesity, Morbid; Inflammatory Bowel Diseases
Interventions: Device: ActivSight
Sponsors: Activ Surgical; The University of Texas Health Science Center, Houston; University at Buffalo; Ohio State University
Enrolling by invitation
-
Posted: September 16th, 2020, 2:00am GMT
Conditions: Advanced Biliary Tract Carcinoma
Interventions: Drug: Pembrolizumab Injection [Keytruda]; Drug: Lenvatinib Mesylate
Sponsors: Shanghai Jiahui International Hospital; Shanghai Zhongshan Hospital
Recruiting
-
Posted: August 26th, 2020, 2:00am GMT
Conditions: Primary Biliary Cirrhosis
Interventions: Drug: Elafibranor 80mg; Drug: Placebo
Sponsors: Ipsen
Active, not recruiting
-
Posted: August 25th, 2020, 2:00am GMT
Conditions: FGFR2 Amplification; FGFR2 Gene Mutation; FGFR2 Gene Fusion/Rearrangement; FGFR2 Gene Translocation; FGFR2 Gene Activation; Intrahepatic Cholangiocarcinoma; Cholangiocarcinoma; Other Solid Tumors, Adult
Interventions: Drug: RLY-4008
Sponsors: Relay Therapeutics, Inc.
Active, not recruiting
-
Posted: August 11th, 2020, 2:00am GMT
Conditions: Advanced Cholangiocarcinoma
Interventions: Drug: TAS-120
Sponsors: Taiho Oncology, Inc.
Approved for marketing
-
Posted: August 10th, 2020, 2:00am GMT
Conditions: Appendix Carcinoma; Colon Carcinoma; Esophageal Carcinoma; Gastric Carcinoma; Liver and Intrahepatic Bile Duct Carcinoma; Malignant Digestive System Neoplasm; Pancreatic Carcinoma; Rectal Carcinoma; Small Intestinal Carcinoma; Anal Carcinoma; Digestive System Carcinoma; Digestive System Neuroendocrine Tumor; Pancreatic Neuroendocrine Tumor
Interventions: Procedure: Acupuncture Therapy; Procedure: Acupressure Therapy; Procedure: Oral Cryotherapy; Other: Questionnaire Administration; Other: Quality-of-Life Assessment
Sponsors: University of Washington; National Cancer Institute (NCI); The Safeway Foundation
Active, not recruiting
-
Posted: July 30th, 2020, 2:00am GMT
Conditions: Advanced Bile Duct Carcinoma; Advanced Breast Carcinoma; Advanced Cervical Carcinoma; Advanced Endometrial Carcinoma; Advanced Esophageal Carcinoma; Advanced Gastric Carcinoma; Advanced Head and Neck Carcinoma; Advanced Lung Non-Small Cell Carcinoma; Advanced Lung Small Cell Carcinoma; Advanced Malignant Solid Neoplasm; Advanced Ovarian Carcinoma; Advanced Penile Carcinoma; Advanced Pleural Malignant Mesothelioma; Advanced Urothelial Carcinoma; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Clinical Stage III Gastric Cancer AJCC v8; Clinical Stage IV Gastric Cancer AJCC v8; Stage III Cervical Cancer AJCC v8; Stage III Distal Bile Duct Cancer AJCC v8; Stage III Intrahepatic Bile Duct Cancer AJCC v8; Stage III Lung Cancer AJCC v8; Stage III Ovarian Cancer AJCC v8; Stage III Penile Cancer AJCC v8; Stage III Pleural Malignant Mesothelioma AJCC v8; Stage IV Cervical Cancer AJCC v8; Stage IV Distal Bile Duct Cancer AJCC v8; Stage IV Intrahepatic Bile Duct Cancer AJCC v8; Stage IV Lung Cancer AJCC v8; Stage IV Ovarian Cancer AJCC v8; Stage IV Penile Cancer AJCC v8; Stage IV Pleural Malignant Mesothelioma AJCC v8; Triple-Negative Breast Carcinoma; Unresectable Urothelial Carcinoma
Interventions: Drug: Cisplatin; Drug: Elimusertib; Drug: Gemcitabine Hydrochloride
Sponsors: National Cancer Institute (NCI)
Active, not recruiting
-
Posted: June 12th, 2020, 2:00am GMT
Conditions: Colorectal Carcinoma; Gastric Adenocarcinoma; GEJ Adenocarcinoma; Esophageal Adenocarcinoma; Cholangiocarcinoma; Gallbladder Carcinoma
Interventions: Drug: tucatinib; Drug: trastuzumab; Drug: oxaliplatin; Drug: leucovorin; Drug: fluorouracil; Drug: capecitabine; Drug: pembrolizumab
Sponsors: Seagen Inc.
Recruiting
-
Posted: June 1st, 2020, 2:00am GMT
Conditions: Metastatic and Locally Advanced NRG1-rearranged Malignancies
Interventions: Drug: Afatinib 40 MG
Sponsors: German Cancer Research Center; German Consortium for Translational Cancer Research
Completed
-
Posted: March 24th, 2020, 2:00am GMT
Conditions: Biliary Tract Cancer
Interventions: Other: Tumour and germline molecular profiling
Sponsors: McGill University Health Centre/Research Institute of the McGill University Health Centre; Cancer Research Society
Recruiting
-
Posted: March 13th, 2020, 2:00am GMT
Conditions: Biliary Tract Neoplasms; Gallbladder Cancer; Cholangiocarcinoma
Interventions: Drug: Durvalumab + Gem/Cis; Drug: Gem/Cis
Sponsors: Asan Medical Center; Samsung Medical Center
Active, not recruiting
-
Posted: March 10th, 2020, 2:00am GMT
Conditions: Unresectable Intrahepatic Cholangiocarcinoma
Interventions: Drug: Durvalumab; Drug: SNDX-6352
Sponsors: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Syndax Pharmaceuticals; AstraZeneca
Completed
-
Posted: March 6th, 2020, 3:00am GMT
Conditions: Bile Duct Cancer; Chemotherapy Effect
Interventions: Drug: AZD6738; Drug: Durvalumab; Drug: Olaparib
Sponsors: Seoul National University Hospital
Active, not recruiting
-
Posted: February 5th, 2020, 3:00am GMT
Conditions: Liver and Intrahepatic Bile Duct Carcinoma; Stage III Intrahepatic Cholangiocarcinoma AJCC v8; Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8; Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8; Stage IV Intrahepatic Cholangiocarcinoma AJCC v8; Unresectable Intrahepatic Cholangiocarcinoma
Interventions: Drug: Dexamethasone; Drug: Floxuridine; Device: Implanted Medical Device; Drug: Irinotecan; Drug: Leucovorin; Drug: Oxaliplatin; Other: Quality-of-Life Assessment
Sponsors: OHSU Knight Cancer Institute; Oregon Health and Science University
Active, not recruiting
-
Posted: January 27th, 2020, 3:00am GMT
Conditions: Radiotherapy
Interventions: Radiation: Adaptative MR-Guided Stereotactic Body Radiotherapy
Sponsors: Centre Georges Francois Leclerc
Active, not recruiting
-
Posted: December 18th, 2019, 3:00am GMT
Conditions: Biliary Tract Cancer
Interventions: Drug: CPI 613; Drug: Gemcitabine; Drug: Cisplatin
Sponsors: University of Michigan Rogel Cancer Center
Active, not recruiting
-
Posted: December 9th, 2019, 3:00am GMT
Conditions: Advanced Solid Tumor; BRAF V600 Mutation
Interventions: Drug: ABM-1310; Drug: Cobimetinib
Sponsors: ABM Therapeutics Corporation
Active, not recruiting
-
Posted: December 6th, 2019, 3:00am GMT
Conditions: Advanced or Metastatic Solid Tumor; Advanced or Metastatic Gastric or Gastroesophageal Cancer; Myeloid or Lymphoid Neoplasms (MLN)
Interventions: Drug: Futibatinib
Sponsors: Taiho Oncology, Inc.
Active, not recruiting
-
Posted: November 25th, 2019, 3:00am GMT
Conditions: Metastatic Cholangiocarcinoma; Metastatic Hepatocellular Carcinoma; Stage III Hepatocellular Carcinoma AJCC v8; Stage III Intrahepatic Cholangiocarcinoma AJCC v8; Stage IIIA Hepatocellular Carcinoma AJCC v8; Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8; Stage IIIB Hepatocellular Carcinoma AJCC v8; Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8; Stage IV Hepatocellular Carcinoma AJCC v8; Stage IV Intrahepatic Cholangiocarcinoma AJCC v8; Stage IVA Hepatocellular Carcinoma AJCC v8; Stage IVB Hepatocellular Carcinoma AJCC v8; Unresectable Cholangiocarcinoma; Unresectable Hepatocellular Carcinoma; Unresectable Intrahepatic Cholangiocarcinoma
Interventions: Drug: Carboplatin; Drug: Paclitaxel; Drug: Pevonedistat
Sponsors: National Cancer Institute (NCI)
Active, not recruiting
-
Posted: November 21st, 2019, 3:00am GMT
Conditions: Pancreaticoduodenectomy
Interventions: Procedure: robotic pancreaticoduodenectomy
Sponsors: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Recruiting
-
Posted: November 15th, 2019, 3:00am GMT
Conditions: Advanced Colorectal Carcinoma; Metastatic Colorectal Carcinoma; Stage IV Colorectal Cancer AJCC v8; Stage IVA Colorectal Cancer AJCC v8; Stage IVB Colorectal Cancer AJCC v8; Stage IVC Colorectal Cancer AJCC v8; Stage II Colon Cancer; Stage II Rectal Cancer; Stage III Colon Cancer; Stage III Rectal Cancer; Esophageal Cancer; Pancreatic Cancer; Bile Duct Cancer; Gastric Cancer; Gall Bladder Cancer; Small Bowel Adenocarcinoma
Interventions: Biological: Bevacizumab; Drug: Dasatinib; Drug: Fluorouracil; Drug: Leucovorin; Drug: Leucovorin Calcium; Drug: Oxaliplatin; Other: Quality-of-Life Assessment
Sponsors: Anne Noonan
Active, not recruiting
-
Posted: November 8th, 2019, 3:00am GMT
Conditions: Advanced Solid Tumors; NSCLC; Bladder Cancer; HNSCC; Renal Cancer; Melanoma; Anal Cancer; Colorectal Cancer; Cholangiocarcinoma; Gastric Cancer; Hepatocellular Carcinoma; Merkel Cell Carcinoma; Cervical Cancer
Interventions: Drug: Continue PD-1/PD-L1 Inhibitors treatment; Other: Discontinue PD-1/PD-L1-1 inhibitor
Sponsors: Jason J. Luke, MD
Recruiting
-
Posted: November 5th, 2019, 3:00am GMT
Conditions: Squamous Cell Carcinoma of the Head and Neck; Renal Cell Carcinoma; Ovarian Cancer; Gastric Cancer; Esophageal Cancer; Lung Squamous Cell Carcinoma; Pancreatic Cancer; Bile Duct Cancer; Endometrial Cancer; Melanoma Cancer; Urothelial Cancer
Interventions: Drug: PF-06940434; Drug: PF-06801591
Sponsors: Pfizer
Active, not recruiting
-
Posted: November 4th, 2019, 3:00am GMT
Conditions: Gastric Cancer; Bladder Cancer; Squamous Non-small Cell Lung Cancer; Cholangiocarcinoma; Sarcoma; Endometrial Cancer; Other Solid Tumours
Interventions: Drug: CPL304110
Sponsors: Celon Pharma SA; National Center for Research and Development, Poland
Recruiting
-
Posted: October 30th, 2019, 2:00am GMT
Conditions: Hepatocellular Carcinoma; Liver Cancer; Cholangiocarcinoma
Sponsors: National Cancer Institute (NCI)
Recruiting
-
Posted: October 24th, 2019, 2:00am GMT
Conditions: Gastrointestinal Neoplasms; Cholangiocarcinoma; Pancreatic Neoplasms
Interventions: Drug: BI 905711
Sponsors: Boehringer Ingelheim
Completed
-
Posted: September 26th, 2019, 2:00am GMT
Conditions: Pancreas Cancer; Pancreatic Cancer; Pancreas Neoplasm; Pancreas Cyst; Pancreatic Precancerous Condition; Familial Pancreatic Cancer; Hereditary Cancer; Bile Duct Cancer; Ampullary Cancer; Duodenal Cancer; Gallbladder Cancer
Sponsors: George Zogopoulos
Recruiting